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Abstract and Lay Summary 
Abstract 
There has been a global rise in obesity in the last three decades, and at present 
one in five women are obese at antenatal booking. Maternal obesity is associated 
with an increased risk of adverse pregnancy outcomes, including increased fetal 
size and prolonged pregnancy. In the longer-term, offspring of obese are at 
increased risk of premature death from a cardiovascular event in their adulthood. 
One mechanism that has been linked to these outcomes is fetal exposure to 
glucocorticoids in utero.  
During normal pregnancy, the maternal hypothalamic pituitary adrenal (HPA) 
axis undergoes major changes, resulting in exponentially increasing levels of the 
major circulating glucocorticoid cortisol, and other HPA axis hormones, such as 
corticotrophin releasing hormone (CRH). Cortisol and CRH are vital for normal 
fetal growth and length of gestation, but in excess they are associated with fetal 
growth restriction and preterm labour.  
In non-pregnant obesity, it is thought that the HPA axis is dysregulated, although 
evidence is inconclusive. Little is known about the effects of maternal obesity in 
pregnancy on the HPA axis. The work in this Thesis used clinical studies to test 
the hypothesis that the HPA axis is dysregulated in obese pregnant women with 
altered release, clearance and placental metabolism of cortisol. Associations with 
clinical outcomes related to fetal size and length of gestation were also studied.  
The HPA axis activity during pregnancy was investigated in a prospective case-
control study cohort. Fasting serum cortisol levels were measured at 16, 28 and 
36 weeks of gestation (obese n=276, lean n=135). In a subset (obese n=20, lean 
n=20), corticosteroid binding globulin (CBG), CRH, estrogens and progesterone 
were measured. Salivary cortisol was measured in samples collected at bedtime, 
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waking and 30 minutes after waking at 16 weeks. Urinary glucocorticoid 
metabolites were measured at 19 weeks and 36 weeks (obese n=6, lean n=5) and 
non-pregnant (obese n=7, lean n=7) subjects. All circulating hormone levels rose 
similarly in obese and lean during pregnancy, but were significantly lower in 
obese women. The diurnal rhythm of cortisol was maintained. Urinary 
glucocorticoids increased with gestation in lean, but not in obese, indicating a 
lesser activation of the HPA axis in obese compared with lean pregnancy. These 
findings associated with increased birthweight and longer gestation in obese 
pregnancy, suggesting that decreased HPA axis activity may underlie these obese 
related adverse pregnancy outcomes.  
Whether or not lower glucocorticoids in obese pregnancies are maintained at 
delivery was investigated by measuring active glucocorticoids (cortisol and 
corticosterone) and their inactive versions (cortisone and 11-
dehydrocorticosterone, respectively) from matched maternal and cord plasma 
samples (n=259, BMI 18 – 55 kg/m2). Active glucocorticoids were significantly 
higher in maternal than cord blood, and inactive versions were significantly 
higher in cord than maternal blood. Increased maternal BMI associated with 
lower maternal cortisol, corticosterone and 11-dehydrocorticosterone. Despite 
significant correlations between maternal and cord blood glucocorticoid levels, 
increased maternal BMI did not associate with lower cord blood glucocorticoids. 
This suggests that conditions at delivery may overcome any potential negative 
effects of low maternal glucocorticoids on the fetus in the short-term. However, 
it may not preclude the longer-term effects of fetal exposure to lower 
glucocorticoid levels during obese pregnancy, and offspring follow-up studies 
are required.  
Potential mechanisms leading to altered HPA axis activity in obese pregnancy 
were explored by studying the pulsatile release and placental metabolism of 
glucocorticoid hormones. Glucocorticoid pulsatility is thought to be important 
for transcriptional regulation of glucocorticoid responsive genes, and disruptions 
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to pulsatility have been reported in some disease processes. Glucocorticoids were 
measured in 10-minute serum sampling between 08.00h-11.00h and 16.00h-
19.00h. Peripheral tissue cortisol was measured from 20-minute sampling of 
interstitial fluid, over 24-hours, at 16-24 weeks and 30-36 weeks (obese n=7, 
lean n=8), and non-pregnant controls (obese n=4, lean n=3). Total circulating 
serum cortisol levels were higher in pregnancy than non-pregnancy in lean and 
obese, and increased significantly with advancing gestation in lean but not in 
obese. Pulsatility of cortisol was demonstrated in interstitial fluid in both non-
pregnancy and pregnancy. In obese pregnancy, interstitial fluid pulse frequency 
was lower with advancing gestation. This may be a novel mechanism underlying 
the observed decreased HPA axis activity in obese pregnancy.  
Placental cortisol metabolism and transport was studied using an ex vivo 
placental perfusion model, perfused with a deuterium-labelled cortisol tracer 
combined with computational modeling. The findings challenge the concept that 
maternal cortisol diffuses freely across the placenta, but confirmed that 11β-
HSD2 acts as major ‘barrier’ to cortisol transfer to the fetus, protecting the fetus 
from the high maternal circulating cortisol levels. In addition we showed 
preliminary evidence of local cortisol production within the placenta. The model 
is able to predict maternal-fetal cortisol transfer and can now be used in future 
experimental design. 
In conclusion, in obese pregnancy, lower maternal cortisol and urinary clearance 
suggested reduced HPA axis activity. Altered glucocorticoid pulsatility may 
underlie this change. Future studies of placental cortisol metabolism in maternal 
obesity could be conducted using an ex vivo perfusion model. The lower HPA 





There has been a global rise in obesity in the last three decades, and one in five 
women are obese at the time of their first antenatal appointment. Obesity during 
pregnancy is associated with increased birthweight of the baby, and a higher 
chance that the pregnancy will continue beyond the estimated due date. 
Offspring of women who were obese during pregnancy are also more likely to 
die at a younger age in their adulthood, as a result of heart disease. One 
mechanism that has been linked to these outcomes is exposure of the developing 
baby to ‘stress hormones’ during pregnancy.  
During normal pregnancy, the ‘hypothalamic pituitary adrenal axis’, which is a 
family of naturally occurring ‘stress hormones’ undergoes major changes, and 
the result of this is that the levels of stress hormones such as cortisol are much 
higher. Cortisol is important for normal growth of the baby during pregnancy, 
and for the length of the pregnancy. However, in pregnancies where cortisol 
levels are abnormally high, the overall growth of the baby can be restricted, and 
labour may occur prematurely.  
In non-pregnant obese women, it is thought that cortisol levels become 
imbalanced. However, it is not known whether cortisol levels are affected by 
obesity during pregnancy. The work in this thesis aimed to study whether or not 
cortisol levels are altered in obese pregnancy, and to identify potential reasons 
for any alterations. These included studying the release (in blood) and clearance 
(in urine) of cortisol, and studying how the placenta processes cortisol.  
Cortisol measured from blood samples from 276 obese and 135 normal weight 
women at 16, 28 and 36 weeks of pregnancy, showed that levels increased as 
pregnancy progressed, and were lower in obese than normal weight pregnant 
women. Urine samples showed that the breakdown products of cortisol increased 
as pregnancy progressed in normal weight women, but not in obese women. This 
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suggested that the lower levels of cortisol in blood could not be explained by 
higher breakdown and clearance in the urine. These results were also linked to 
increased offspring birthweight and longer length of pregnancy, suggesting that 
lower levels of cortisol in obese pregnant women may be linked to these 
pregnancy outcomes.  
Blood samples obtained from pregnant women and their babies (via the umbilical 
cord) at the time of delivery, showed that cortisol levels were lower in obese than 
normal weight women, but there were no differences in the samples collected 
from the umbilical cord. This suggests that the ‘stressful’ conditions at delivery 
may overcome any potential effect of the mother being obese at the time of 
delivery. However, it may not negate the longer-term effects of the developing 
baby being exposed to lower levels of stress hormones during pregnancy, so 
longer-term studies of the offspring are required.  
Cortisol is released in pulses, and these pulses are important for maintaining 
normal genetic processes. In order to investigate the effect of obesity on the 
pulsatile release of cortisol, frequent samples of blood and peripheral tissue 
stress hormone levels were collected at 16-24 weeks and 30-36 weeks of 
pregnancy, in obese and lean pregnant, and non-pregnant women. Pulses were 
detected in the peripheral tissue fluid and occurred less frequently in obese than 
normal weight pregnant women. Less frequently occurring cortisol pulses may 
be an underlying reason for the lower levels of stress hormones demonstrated in 
obese pregnant women. The way the placenta processes cortisol was investigated 
by pumping solutions with different concentrations of cortisol through a piece of 
placenta, within 30-mintues of delivery of the baby. The results challenged a 
previously held thought that cortisol can pass freely through the placenta, and 
confirmed that an enzyme within the placenta acts as a major ‘barrier’ to prevent 
the developing baby from being exposed to abnormally high levels of cortisol. 
These experiments also showed preliminary evidence that the placenta can 
produce cortisol. This model could be used for future experiments to study 
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cortisol transport between the mother and baby and how the placenta processes 
cortisol. In conclusion, in obese pregnant women, lower levels of cortisol in 
blood and urine suggest that the activity of stress hormones are reduced 
compared with normal weight pregnant women. An altered pattern of cortisol 
pulses may underlie this change. Future studies of the way the placenta processes 
cortisol could be conducted using the experiments we used. Lower activity of 
stress hormones in obese pregnancy represents a novel underlying pathway for 
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1.1 Obesity in Pregnancy 
1.1.1 Global Incidence 
Obesity is defined as ‘abnormal or excessive fat accumulation that may impair 
health’ by the World Health Organisation (WHO). Body mass index (BMI) is a 
crude population measure of obesity that is an index of weight-for-height. In 
adults, overweight is defined as a BMI of ≥ 25 kg/m2, and obesity is defined as a 
BMI ≥ 30 kg/m2.  
During the last three decades there has been a global rise in the incidence of 
obesity. The number of overweight and obese individuals worldwide increased 
from 857 million in 1980, to 2.1 billion in 2013 (Ng et al., 2014). Between 1975 
and 2014, the age-standardised prevalence of obesity in men increased from 
3.2% to 10.8%, and increased from 6.4% to 14.9% in women (Risk Factor 
Collaboration, 2016).  If these trends continue, it is estimated that by 2025, the 
global obesity prevalence will be 18% in men and 21% in women (Risk Factor 
Collaboration, 2016). In 2015 the Scottish Health Survey reported that 65% 
adults aged 16-64 were overweight, and 29% were obese (Rose, 2015).  
As the prevalence of obesity increases, so does the number of women of 
reproductive age who are becoming overweight and obese (Linne, 2004). In 2009 
maternal obesity was reported to affect at least 20% of pregnancies in the United 
States (Chu et al., 2009). In 2010 a national audit of obesity during pregnancy 
was conducted across the UK by the Centre for Maternal and Child Enquiries 
(CMACE) from 1 March – 30 April 2009; this reported that at least 5% of 
pregnant women in the UK are severely obese (BMI > 35 kg/m2) (CMACE, 
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2010). Recent national statistics from the UK suggest that similar rates of 
maternal obesity are persisting. The Health and Social Care Information Centre 
(HSIC) reviewed data from the first antenatal appointment of 33,950 pregnancies 
in England in September 2015, and reported that 23% were obese at antenatal 
booking (HSIC, 2015). In Scotland, the Information Services Division (ISD) 
reported that 22.2% of women delivering in Scottish hospitals in 2016 were 
obese at the time of antenatal booking (ISD, 2016). This significantly high 
proportion of women who are obese means there is an equally high proportion of 
offspring who have been exposed to the obesogenic environment in utero.  
 
1.1.2 Risks of Maternal Obesity in Pregnancy  
Maternal obesity is associated with an increased risk of adverse outcomes for 
both the mother and the baby, including maternal, fetal and neonatal mortality. In 
the most recent confidential enquiry into maternal deaths in the United Kingdom 
(MBRACE-UK, 2016), 65 women (33%) who died had a BMI > 30 kg/m2. 
Adverse pregnancy outcomes and short-term neonatal complications associated 
with maternal obesity have been well described (Galliano and Bellver, 2013, 
Vasudevan et al., 2011, Sebire et al., 2001, Dinatale et al., 2010) and it is 
recognised that obese pregnant women should receive consultant-led, multi-
disciplinary care (Ghaffari et al., 2015). A recent study examining pregnancy 
outcomes of obese women in NHS Lothian found that women who attended a 
specialist high-risk clinic for women with BMI > 40 kg/m2, were less likely to 
have a stillbirth or a low birthweight baby (Denison et al., 2017) 
Obese women are more likely to experience infertility (Mitchell and Fantasia, 
2016) and those who do become pregnant are at increased risk of miscarriage 
from both spontaneous (Boots and Stephenson, 2011) and assisted conception 
(Metwally et al., 2008). Obesity has also been identified as an independent risk 
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factor for recurrent, unexplained miscarriage (Lashen et al., 2004), with up to 
73% increased risk of another miscarriage (Lo et al., 2012).  
Obese women are at increased risk of major antenatal complications, including 
gestational diabetes (Leddy et al., 2008, Denison et al., 2014), gestational 
hypertensive disorders (Leddy et al., 2008, Denison et al., 2014), and 
thromboembolic disease (Larsen et al., 2007, Jacobsen et al., 2008). Minor 
complications are also more prevalent during pregnancy in the obese population. 
These include respiratory tract and chest infections, gastro-oesophageal reflux, 
carpal tunnel syndrome and symphysis pubis dysfunction (SPD) (Denison et al., 
2009).  
Later in pregnancy, obese women are at increased risk of having a prolonged or 
post-dates pregnancy (Denison et al., 2008, Heslehurst et al., 2017), which 
increases the need for induction of labour and increases the risk of stillbirth 
(Flenady et al., 2011, Leddy et al., 2008). Operative or instrumental deliveries 
are more prevalent in obese women (Hollowell et al., 2013). The risk of 
Caesarean section due to previous Caesarean delivery, failure to progress in 
labour, failed induction of labour or fetal distress is higher in obese compared 
with normal weight women (Fernandez Alba et al., 2017), and the risk increases 
progressively with increasing maternal BMI. Obese patients undergoing 
Caesarean delivery have an increased risk of surgical complications, including 
wound dehiscence, infectious morbidity and hospital readmission (Owen and 
Andrews, 1994, Vermillion et al., 2000, Stamilio and Scifres, 2014). Maternal 
obesity may reduce surgical exposure, increase the duration of operation, 





1.1.3 Short-Term Offspring Outcomes  
Offspring of obese women are at increased risk of congenital malformations 
(Stothard et al., 2009). Potential mechanisms may include deficiencies in 
nutrients such as folic acid, chronic hypoxia, and metabolic changes including 
maternal hyperglycaemia, increased insulin resistance, and increased circulating 
levels of triglycerides and uric acid (Stirrat and Reynolds, 2014). Relative 
difficulties with antenatal detection may also contribute to the apparent increase 
in congenital abnormalities. Ultrasound scanning of obese pregnant women may 
lead to suboptimal visualisation of fetal anatomy (Hendler et al., 2005), lower 
detection rates of structural abnormalities, and therefore an increased prevalence 
at birth.  
Maternal obesity is associated with up to a 72% increased risk of having a large 
for gestational age (LGA) baby, independent of co-existent diabetes (Ehrenberg 
et al., 2004). In addition to being born LGA, anthropometric measurements of 
neonates born to obese women demonstrate they are more likely to have a 
significantly higher fat mass and a higher percentage of body fat (Sewell et al., 
2006). LGA infants are predisposed to a variety of obstetric and neonatal 
complications due to potential difficulties during labour and delivery, such as 
shoulder dystocia and brachial plexus injury (Walsh et al., 2011).  
In the neonatal period, macrosomic infants (often defined as birthweight ≥ 4000 
g at ≥ 37 weeks gestation) are more likely to have electrolyte and metabolic 
disturbances, such as hypoglycaemia, hyperbilirubinamia and hypomagnesemia 
(Nold and Georgieff, 2004). In the long-term, infants that are at the highest end 
of the distribution for weight or BMI are at greater risk of being obese in 
childhood, adolescence, and early adulthood (Boney et al., 2005), and are at risk 
of cardiovascular and metabolic complications later in life (Hermann et al., 2010, 
Ornoy, 2011). Potentially modifiable predictors of birthweight include maternal 
weight, gestational weight gain, gestational age at birth, and maternal glucose 
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metabolism. An interesting paradox exists, with some reports suggesting that 
offspring of obese women are also at increased risk of intrauterine growth 
restriction (unrelated to pre-eclampsia) (Rajasingam et al., 2009). Mechanisms 
underlying these findings are not known but may be related to poor placental 
function.  
Babies of obese mothers have up to a 31% increased risk of have a low Apgar 
score at birth (defined as Agar Score < 7 at 1 minute) (Kalk et al., 2009). 
Offspring from overweight or obese mothers appear to be at up to 38% increased 
risk of being admitted to the neonatal unit (Kinnunen et al.) at birth than 
offspring of mothers with a normal BMI (Minsart et al., 2013). Higher rates of 
admission for treatment of neonatal hypoglycaemia have been reported in 
offspring from obese mothers (Kalk et al., 2009). 
 
1.1.4 Long-Term Offspring Outcomes 
The ‘Barker hypothesis’ states that environmental influences acting in fetal life 
are reflected in impaired growth and developments which permanently affect 
structure and metabolism, leading to increased risk of metabolic disease later in 
life (Barker, 1998). This theory stimulated interest in the fetal origins of adult 
disorders, which then expanded and coalesced with the formation of an 
international society for the Developmental Origins of Health and Disease 
(DOHaD). The original Barker hypothesis has mainly focussed on under-
nutrition in the pregnant mother. However, during obese pregnancy, it has been 
suggested that the increased nutrient supply may lead to a response by the fetus 
to ‘program’ its organs and tissues in a way that translates to long-term 
alterations to their function (Lucas, 1991). This has been termed the 
‘developmental over-nutrition’ hypothesis (Taylor and Poston, 2007). There is a 
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growing body of evidence that there is a long-term relationship between maternal 
obesity and cardio-metabolic health in adulthood for the offspring.  
Offspring of obese have an increased risk of both childhood and adulthood 
obesity (Drake and Reynolds, 2010, Catalano et al., 2009), and this appears to be 
independent of maternal diabetes (Sewell et al., 2006). Both macrosomia and 
excessive gestational weight gain during pregnancy are strong predictors of 
higher BMI at one year of age, and BMI at one year of age is predictive of 
weight at five-eight years of age (Lindberg et al., 2012). A sibling study using a 
cohort of mothers who underwent surgical interventions for obesity found that 
offspring born before surgical intervention had significantly higher bodyweights 
at 12 years and at 21-25 years, than offspring born after surgery (Barisione et al., 
2012).  
There is increasing evidence to support a link between maternal obesity, 
offspring obesity and cardiometabolic risk factors (Drake and Reynolds, 2010). 
Maternal obesity has been associated with offspring insulin resistance in 
newborn babies (Catalano et al., 2009), at 11 years (Boney et al., 2005) and at 
age 20 years (Mingrone et al., 2008).  Maternal obesity has been shown to be 
independently correlated with higher systolic and diastolic blood pressure in 
offspring at 17 years (Laor et al., 1997) and at age 32 years (Hochner et al., 
2012). In the same cohort, maternal BMI was also significantly associated with 
lower high density lipoproteins at age 32 years (Hochner et al., 2012). These 
associations were significant when separated from ‘shared environment’ and 
‘postnatal lifestyle’ factors. This would support a programming influence of 
maternal obesity of offspring obesity.  
Recent evidence has suggested that these associations may translate into 
increased risk of cardiovascular disease and death for the offspring. A study 
investigating the relationship between maternal obesity and premature adults 
mortality in 37,709 offspring from obese mothers (Reynolds et al., 2013), found 
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offspring of obese mothers had a 40% increased risk of premature death from all 
causes, and at 29% increased risk of death due to cardiovascular disease. The risk 
was independent of socioeconomic status. Only 4% of mothers in this study were 
obese, far fewer than current obesity levels, thus these findings are alarming.  
Offspring of obese women are also thought to be at increased risk of asthma 
(Harpsoe et al., 2013), neurodevelopmental disorders such as autism spectrum 
disorders and developmental delay (Krakowiak et al., 2012). Observational 
evidence suggests that increased maternal BMI is an independent rick factor for 
schizophrenia in offspring, when controlling for other potentially confounding 
maternal characteristics (Schaefer et al., 2000).  
The effects of the positive feedback loop of adiposity from obese mothers to the 
child may increase the risk of some cancers for the offspring (Simmen and 
Simmen, 2011) with which birth weight is positively associated (Andersson et 
al., 2001, Ahlgren et al., 2007).  
 
1.2 The Hypothalamic Pituitary Adrenal Axis 
1.2.1 Glucocorticoids 
Glucocorticoids are vital for life, and are involved in regulating or supporting 
cardiovascular, metabolic, immune, and homeostatic functions. Cortisol is the 
major circulating glucocorticoid hormone in humans. There is also an increasing 
interest in the potential physiological roles of glucocorticoid hormone 
corticosterone, which comprises 5-10% of total plasma glucocorticoids (Nixon et 
al., 2016). These glucocorticoid hormones are synthesised in the zona fasciculata 
of the adrenal cortex, under the regulation of the hypothalamic-pituitary-adrenal 
(HPA) axis (Figure 1-1). Glucocorticoid synthesis is initiated by transport of 
cholesterol into the inner mitochondrial membrane by the steroidogenic acute 
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regulatory protein (StAR) (Stocco and Clark, 1996). Following a series of 
enzyme catalysed conversion steps, glucocorticoids are formed (Bush, 1953, 
Hum and Miller, 1993). Secretion of glucocorticoids is regulated by 
adrenocorticotrophic hormone (ACTH), secreted by the pituitary gland, and 
ACTH is under the control of corticotrophin releasing hormone (CRH), secreted 
from the paraventricular nucleus of the hypothalamus (Vale et al., 1981). The 
HPA axis is a series of feedback interactions between the paraventricular nucleus 
of the hypothalamus, the anterior pituitary gland and the adrenal cortex. CRH is 
released from the hypothalamus in response to stress, illness, physical activity, 
levels of circulating cortisol in the bloodstream, and also by the sleep-wake 
‘circadian rhythm’ cycle.  
 
Figure 1-1. The Hypothalamic Pituitary Adrenal Axis in Humans 
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Glucocorticoids bind to glucocorticoid and mineralocorticoid receptors (GR and 
MR, respectively) (Bamberger et al., 1996). These receptors are activated upon 
ligand binding and the receptor-ligand complex translocates to the nucleus, 
where it binds to glucocorticoid response elements in the promoter region of 
target genes, and can then influence gene transcription. Glucocorticoids can also 
exert non-genomic effects by direct actions on membrane lipid and cytoplasmic 
proteins via membrane-located receptors (Haller et al., 2008). GR is expressed 
from mid-gestation onwards in fetal tissues, the placenta and fetal membranes 
(Cole et al., 1995); and animal studies suggest that MR is more limited and tends 
to be present later in gestation (Brown et al., 1996b). 
The majority of cortisol metabolism takes place in the liver by A-ring reductase 
enzymes. Additional metabolism occurs by enzymes 5α-reductase in fat, and by 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the distal nephron of 
the kidney (Chapman et al., 2013), which converts active cortisol into cortisone 
(its inactive version). Cortisol can also be regenerated from cortisone by enzyme 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The extent of 
regeneration of cortisol from cortisone by 11β-HSD1 in liver or fat influences 
the metabolic clearance rate (Phillipov et al., 1996).  Free cortisol and 
metabolites of cortisol (glucocorticoid metabolites; Figure 1-2) are excreted in 




Figure 1-2. The Metabolism of Cortisol by 11beta-hydroxysteroid 
dehydrogenase (11β-HSD2) and 5α- and 5β-reductase.  




1.2.1.1 Circadian Rhythm of Cortisol 
Circadian rhythms are 24-hour cycles in bodily processes that allow organisms to 
anticipate and prepare for changing environmental factors such as light and dark 
or seasonal changes. Such rhythms exist in all organisms, and can affect 
biochemistry, physiology, endocrinology and behavioural (Panda et al., 2002).  
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The HPA axis is under circadian regulation, which in humans is characterised by 
peak levels of cortisol early in the morning at the end of the ‘resting’ overnight 
period, in preparation for the increased metabolic demands of the active day time 
phase (Young et al., 2004). Nocturnal animals such as rodents exhibit a peak in 
corticosterone levels (corticosterone is the major circulating glucocorticoid in 
rodents) towards the end of the afternoon, when the dark cycle begins (Gong et 
al., 2015). This daily rhythm arises from a genetically operated ‘biological clock’ 
(Dunlap, 1999, Reppert, 1998). In mammals, the suprachiasmatic nucleus (SCN) 
of the anterior hypothalamus functions as the master circadian pacemaker, 
driving the rhythmic secretion of hormones (Stratmann and Schibler, 2006). 
Daily cyclic variations in glucocorticoid hormone concentrations are thought to 
be fundamental for the overall maintenance of physiology and well being (Young 
et al., 2004, Lightman and Conway-Campbell, 2010). The circadian rhythm of 
the HPA axis develops sometime after birth and can be detected as early as one 
month of age in humans (Ivars et al., 2015). 
 
1.2.1.2 Ultradian Rhythm of Cortisol 
Knowledge and understanding of basal circadian rhythmicity has been advanced 
with the development of automated sampling devices (Jasper and Engeland, 
1991, Windle et al., 1998b, Tapp et al., 1984, Cook, 2001, Weitzman et al., 1971, 
Henley et al., 2009a). These facilitate frequent sampling without repeated 
insertion of needles, which would mount a stress response. Furthermore, the 
development of intra-tissue microdialysis sampling for use in animals (Droste et 
al., 2008) and humans (Bhake et al., 2013), and mathematical algorithms for 
analysis (Veldhuis et al., 1989, Merriam and Wachter, 1982), which accounts for 
secretory dynamics, have facilitated a more in depth study of HPA axis activity. 
Together these advances have contributed to the discovery that underlying the 
circadian release of glucocorticoids are discrete pulses of HPA axis hormones, 
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forming a rapid and dynamic ‘ultradian rhythm’ (Veldhuis et al., 1989). This is a 
recurrent cycle of hormone oscillations in blood and target tissues occurring 
approximately hourly (Veldhuis et al., 1989, Follenius et al., 1987, Jasper and 
Engeland, 1991), repeated throughout a 24-hour circadian day (Spiga et al., 
2014). This type of pattern was previously interpreted as ‘noise’ in the system, 
because it was particularly difficult to study basal, unstressed conditions. The 
‘amplitude’ and ‘frequency’ of these oscillations, or pulses, increase during the 
circadian peak of secretion (Veldhuis et al., 1989). Intracranial microdialysis 
studies in animals have demonstrated that ultradian pulses of corticosterone are 
synchronised in plasma and in the brain (Droste et al., 2008). The pulsatile 
pattern of glucocorticoids has been described in a number of species. These 
include rat (Atkinson et al., 2006, Jasper and Engeland, 1991, Windle et al., 
1998a), rhesus monkey (Sarnyai et al., 1995, Tapp et al., 1984), Syrian hamster 
(Loudon et al., 1994, Lucas et al., 1999), horse (Cudd et al., 1995), sheep (Engler 
et al., 1989), goat (Carnes et al., 1992) and humans (Hellman et al., 1970, 
Veldhuis et al., 1990, Weitzman et al., 1971). 
Until recently, it had been assumed that glucocorticoid pulses originated from a 
‘pulse generator’ such as the SCN (Ixart et al., 1991). This theory worked on the 
assumption that the pulsatile characteristics of CRH (Ixart et al., 1991, Caraty et 
al., 1988, Ixart et al., 1993) would drive ACTH release (Carnes et al., 1988), that 
would in turn cause glucocorticoid pulsatility, thus resulting in the ultradian 
rhythm. However, studies in rodents have revealed a mismatch in pulse 
frequency; CRH was found to have three pulses per hour (Ixart et al., 1991) 
compared to hourly pulses of ACTH (Carnes et al., 1986) and corticosterone 
(Windle et al., 1998b). In sheep, the pulsatility of both ACTH and 
glucocorticoids have been shown to continue even after disconnection of the 
hypothalamus from the pituitary gland (Engler et al., 1990), which supports a sub 
hypothalamic origin. Further still, in SCN-lesioned rodents, the ultradian rhythm 
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of corticosterone has been shown to persist despite a loss in circadian 
rhythmicity (Waite et al., 2012). 
Walker et al., (Walker et al., 2012) demonstrated that pulsatile release of CRH is 
not needed for ultradian of the pituitary-adrenal system to continue, and 
supported that hypothesis that glucocorticoid inhibition at the anterior pituitary 
plays a key role in regulating the ultradian rhythm of glucocorticoid release. 
Their model of sub-hypothalamic origin of pituitary-adrenal ultradian pulses was 
tested in vivo by measuring ACTH and corticosterone in freely behaving rats 
under different rates of constant CRH infusions at the circadian trough when 
endogenous CRH drive was very low and there was minimal secretion of 
endogenous ACTH and corticosterone. As predicted by a mathematical model 
(Walker et al., 2010), the constant infusion of CRH did induce ultradian release 
of both ACTH and corticosterone with consistent pulse amplitude and frequency 
for the duration of the infusion, and the ACTH pulses preceding corticosterone 
pulses. High levels of CRH infusion disrupted the pattern leading to large pulses 
of ACTH and corticosterone, followed by a subsequent dampening of 
corticosterone pulses. These data confirmed that ultradian oscillations of the 
pituitary-adrenal system are a result of the feedforward:feedback relationship of 
ACTH with the adrenal cortex and endogenous glucocorticoids on the pituitary 
corticotrophs (Walker et al., 2010, Walker et al., 2012). Whether pulsatility of 
hypothalamic CRH secretion could impact on this sub-hypothalamic system is as 
yet unknown. 
As previously described (Droste et al., 2008), ultradian glucocorticoid pulses in 
plasma are paralleled in brain tissue. This would suggest that the local neuronal 
target environments where GR and MR are found, are not in constant 
equilibrium. On the contrary, it would appear that they are exposed to a rapidly 
changing concentration of their ligand, glucocorticoids (de Kloet and 
Sarabdjitsingh, 2008). This has been confirmed in both in vitro and in vivo 
animal models, where it has been shown that pulses of tissue corticosterone are 
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paralleled by pulses of GR binding and gene transcription. Studies in cultured 
cells and in animal models have confirmed that oscillations in glucocorticoids 
induce a phenomenon known as ‘gene pulsing’ (Stavreva et al., 2009, Conway-
Campbell et al., 2010). During periods of low hormone concentration such as 
during the nadir of the circadian rhythm, GR is thought to be present in the 
cytoplasmic compartment where ligand binding occurs. When glucocorticoid 
levels rise during an endogenous pulse, glucocorticoids bind to and activate GR, 
which then translocate into the cell nucleus. After interacting with glucocorticoid 
response elements (GRE), the complex binds to DNA to initiate transcription.  
After withdrawal of the ligand, GR has been shown to remain in the nucleus for 
several hours (Stavreva et al., 2015, Stavreva et al., 2004, Yang et al., 1997, 
Carrigan et al., 2007), and while unliganded, GR does not associate with 
chromatin (Stavreva et al., 2009). After a fresh pulse of glucocorticoid, there was 
a re-activation of GR within the nuclear compartment and re-association of GR 
with the chromatin template (Stavreva et al., 2009). 
In contrast to pulsatile presentation of glucocorticoids and pulsatile response of 
gene transcription, constant presentation of glucocorticoids is associated with a 
change in genomic responses in a brain-area and cell-type specific fashion 
(Conway-Campbell et al., 2010, Stavreva et al., 2015), where transcription levels 
of many glucocorticoid responsive genes continue to rise (Stavreva et al., 2009). 
This suggests that it is ultradian rhythm rather than the absolute level of 
glucocorticoids present that are necessary to maintain transcriptional efficiency 
in target tissues (Stavreva et al., 2009). Interestingly, only endogenous (as 
opposed to exogenous) glucocorticoids led to the pulsatile GR activation profiles 
(Stavreva et al., 2009). Therapeutically, patients are typically treated with 
glucocorticoid replacement therapy administered in two or three divided doses 
each day, in an attempt to mimic circadian cortisol rhythm. One limitation of this 
is that the morning peaks occur later than they wake up, such that their circadian 
curve shifts with morning peaks occurring after they wake (Crown and 
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Lightman, 2005, Scott et al., 1978). Further, bolus delivery of glucocorticoid 
replacement therapy produces smooth hormone levels rather than mimicking the 
underlying pulsatile ultradian rhythm. This is thought to result in relatively 
constant glucocorticoid receptor occupancy, and abnormal glucocorticoid-
dependent gene transcription. It has been proposed that this may contribute to 
side effects associated with the use of glucocorticoids, and may even be a causal 
factor for the excessive morbidity and mortality of patients on glucocorticoid 
regimes. Near physiological patterns of both circadian and ultradian rhythms can 
be reproduced in humans using a specialized pump and simple subcutaneous 
infusion technique (Russell et al., 2014).  
Posttranscriptional regulation of mRNA levels of glucocorticoid responsive 
genes such as the ‘period circadian protein homolog’ (Per1) gene, may be 
important for regulating the circadian rhythm of glucocorticoids (Doherty and 
Kay, 2012, Koike et al., 2012, Morf et al., 2012). Per1 is rhythmically expressed 
in the SCN. In a study of adrenalectomised rats treated with corticosterone 
pulses, each glucocorticoid pulse was associated with transient GR activation in 
neurons in the hippocampus, and a ‘pulse’ of Per1 transcription. This suggests 
that glucocorticoids can regulate Per1 in areas of the brain with high expression 
of GR (Conway-Campbell et al., 2010).  
Glucocorticoid pulse characteristics (eg. amplitude, frequency and pattern) can 
be highly variable, both within and between individuals, and changes in the 
pattern of ultradian pulsatility are associated with transitions throughout the 
lifespan, physiological or pathological states. Disruptions in cortisol pulse 
characteristics have been described in pathological conditions such as psychotic 
and depressive states (Young et al., 1994, Young et al., 2004, Deuschle et al., 
1997), where elevated troughs particularly at the nadir result in a flattened 
circadian rhythmicity (Young et al., 1994). In Cushing’s syndrome, the normal 
variation of cortisol is diminished due to elevations in cortisol levels during the 
quiescent period (van Aken et al., 2005, Boyar et al., 1979). In other disorders 
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that are less obviously related to glucocorticoids such as Parkinson’s, 
Huntington’s, obstructive sleep apnoea and panic disorders, the HPA axis shows 
changes in pulse characteristics (Henley et al., 2009b, Hartmann et al., 1997, 
Abelson and Curtis, 1996, Aziz et al., 2009). Disruption in cortisol pulsatile 
secretion has been observed during the post-surgical period following cardiac 
surgery (Gibbison et al., 2015). 
Currently it is not known whether the disorganisation in pulsatile pattern is the 
cause or the consequence of the various diseases. In general, daily variations in 
glucocorticoid hormone concentrations are thought to be fundamental for the 
maintenance of physiology, and overall metabolic, cognitive and behavioural 
well being (Young et al., 2004, Herbert et al., 2006, de Kloet et al., 2005, 
Dallman et al., 2003).  
Dysregulation of ultradian rhythmicity is also apparent in stress-related disease 
(Deuschle et al., 1997, Hartmann et al., 1997), although its precise function still 
remains unknown (Young et al., 2004, de Kloet and Sarabdjitsingh, 2008, 
Lightman et al., 2008). Studies using adrenalectomised animals replaced with 
various regimes of corticosterone have demonstrated that there are interactions 
between the HPA axis response to stress and the circadian rhythm (Akana et al., 
1992, Dallman et al., 2004, Jacobson et al., 1988, Akana et al., 1988). There is 
also now evidence that stress responsiveness is related to ultradian hormone 
profiles. Analysis of hormone profiles of rats exposed to noise stress have 
demonstrated that the animals only responded with an increase in corticosterone 
when the stressor occurred during the ascending phase of an ultradian pulse 
(Windle et al., 1998b). Animal studies also suggest that it is the pulsatile pattern 
as opposed to absolute concentrations of corticosterone that determine 
subsequent responsiveness to stress (Sarabdjitsingh et al., 2010a, Sarabdjitsingh 
et al., 2010b), and that after a disruption to the ultradian rhythm, that return of 
normal behaviour may lag behind the return of normal HPA axis (Sarabdjitsingh 
et al., 2010b). Taken together, these studies suggest that it is the pulsatile pattern 
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rather than the absolute concentrations of corticosterone exposure that 
determines subsequent responsiveness to stress, and this has obvious 
implications for understanding the pathogenesis of stress-related disease.  
Given the relationship between glucocorticoid pulsatility, transcriptional 
regulation and the possible implications for disease processes, a better 
understanding of this ultradian rhythm may assist both diagnosis and treatment of 
conditions associated with altered cortisol levels, whilst also aiding the 
development of novel therapeutic interventions. Current therapies which tend to 
be based on a bolus or slow-release of therapeutic glucocorticoid may lead to a 
non-pulsatile level of circulating cortisol, that may cause dysregulation of 
glucocorticoid responsive genes.  
 
1.2.1.3 Cortisol Sampling Methods and Indices  
Cortisol is a dynamic hormone, and levels fluctuate throughout the day, due to 
the combination of the diurnal rhythm, the ultradian rhythm, and the response to 
physiological and psychological stressors. Light exposure and food consumption 
have also been linked to cortisol secretion (Rosmond et al., 2000, Scheer and 
Buijs, 1999). 
Daily circulating cortisol concentrations can be measured by sampling saliva, 
blood (plasma or serum), or urine. Saliva cortisol indexed ‘free’ or unbound 
cortisol, while blood and urine measurements reflect the total cortisol. A longer-
term measure of cortisol concentrations can be assessed from hair, which stores 
cortisol, and has been shown to correlate with 24-hour glucocorticoid metabolites 
of urinary free cortisol (UFC) (Sauve et al., 2007). These methods of sampling 
can be used to assess different measures of cortisol activity. These include the 
cortisol awakening response (CAR), diurnal slope, total daily output, cortisol 
reactivity, and longer-term output.  
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The CAR (Figure 1-3) is the rise in cortisol levels that occurs early in the 
morning at the time of waking (Pruessner et al., 2003). Abnormalities of this 
index could include a ‘blunted’ or ‘exaggerated’ response, and such irregularities 
have been linked with mental and physical health ailments (Bjorntorp and 
Rosmond, 2000, Fries et al., 2009). 
A greater CAR has also been demonstrated in individuals who are chronically 
stressed (Schulz P, 1998). The CAR is normally followed by a declining diurnal 
slope (Pruessner et al., 2003) (Figure 1-3). The significance of a flatter diurnal 
slope, which may have been preceded by a lesser CAR, or have failed to decline 
sufficiently by the evening, is that such patterns in cortisol change during day-
time have been linked to negative physical and mental health outcomes (Fries et 
al., 2009). To assess the diurnal slope, multiple cortisol measurements obtained 
at various time-points throughout the day are required. As this can be 
burdensome for patients, some studies use either a single time point, or examine 
portions of the slope such as the ‘early decline’ or ‘late decline’.  
Total daily cortisol output is typically a cumulative measure of cortisol 
concentrations throughout a day. This can be measured from serum, plasma, 24-
hour collection of urine, or multiple days of diurnal blood or saliva sampling. 
Multiple sampling for a diurnal measure can be used to generate a profile of 
cortisol concentrations, from which the area under the curve (AUC) can be 
calculated.  
‘Cortisol reactivity’ describes the cortisol concentrations in response to acute 
physical or psychosocial stress.  
Longer-term cortisol output can be assessed through measurements of hair 
cortisol. Hair stores cortisol and grows at approximately one centimetre per 
month, thus can give an indication of cortisol concentrations over a longer period 
of time (Stalder and Kirschbaum, 2012). 
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Figure 1-3. Twenty-four hour cortisol profile demonstrating awakening 
response and diurnal slope.  
 
 
1.2.2 The HPA-axis in Obesity 
Altered levels of HPA axis hormones have been reported in association with 
different weight statuses. Hypocortisolism is associated with weight loss, such as 
in Addison’s disease (Lovas and Husebye, 2007), or after adrenalectomy 
(Bethune, 1989). In animal studies, adrenalectomy prevents genetic and diet-
induced obesity (Okada et al., 1993). Hypercortisolism, such as in Cushing’s 
syndrome, is associated with weight gain (Hankin et al., 1977). In adipose tissue, 
glucocorticoids promote the differentiation of pre-adipocytes into mature 
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adipocytes and also increase lipoprotein lipase activity. Together these promote 
adipose tissue increase and weight gain (Tataranni et al., 1996). 
However, there is conflict in the literature about whether obesity promotes 
dysregulation of the HPA axis or vice versa. Studies examining this have 
measured different parameters of HPA axis activity including general cortisol 
activity using saliva, blood, urine and hair, and have tested adipocyte cortisol 
metabolism by assessing 11β-HSD1 and 11β-HSD2 in adipose tissue biopsies. 
Variation in study outcomes is compounded from the difference in 
anthropometric indices selected, which include generalised obesity indexed by 
BMI, and abdominal adiposity indexed by measures such as the waist to hip ratio 
(WHR), waist circumferences, and sagittal diameter. 
Studies of the relationship between obesity (generalised or abdominal) and the 
cortisol awakening response include reports of a negative relationship and 
blunted CAR (Ljung et al., 1996, Champaneri et al., 2013, Ranjit et al., 2005, 
Ursache et al., 2012, Duclos et al., 2005), reports of a positive relationship and 
exaggerated CAR (Wallerius et al., 2003, Steptoe et al., 2004, Therrien et al., 
2007), and reports of no relationship between obesity and CAR (Filipovsky et al., 
1996, Kumari et al., 2010). A recent systematic review examining these studies 
suggested that when considering the strength of the methodologies, that a blunted 
CAR in obesity is the more reliable perturbation (Incollingo Rodriguez et al., 
2015).  
Obesity has been linked to a flatter decline of the diurnal slope throughout the 
day, using both BMI (Champaneri et al., 2013) and WHR (Steptoe et al., 2004). 
Evening cortisol has also been reported to be higher with increasing BMI in men 
(Abraham et al., 2013), but not in women (Ranjit et al., 2005). Imprecision of 
measuring the diurnal slope between studies, with use of single time proxies may 
contribute to these inconsistencies (Incollingo Rodriguez et al., 2015). One study 
reported a relationship between abdominal obesity, a flatter diurnal slope, and a 
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higher risk of cardiovascular disease, stroke and type 2 diabetes (Rosmond and 
Bjorntorp, 2000).  
An increase in urinary glucocorticoid metabolites has been reported in 
association with increased BMI (Stewart et al., 1999, Rask et al., 2001, Rask et 
al., 2002) and with increased WHR (Marin et al., 1992), suggesting that obesity 
is associated with increased renal clearance of glucocorticoid metabolites. 
Hypocortisolism has also been reported in obesity, with significantly lower levels 
of urinary free cortisol in association with increased WHR (Vicennati and 
Pasquali, 2000). There are also studies describing no relationship between 
urinary free cortisol output when testing with BMI (Champaneri et al., 2013) or 
WHR (Duclos et al., 2005). 
Greater consistency can be seen in literature describing the relationship between 
obesity and cortisol reactivity to stressors. This suggests that abdominally obese 
individuals demonstrate greater cortisol reactivity to stress than those with 
peripheral body fat (Marin et al., 1992, Rosmond et al., 1998, Duclos et al., 2005, 
Vicennati and Pasquali, 2000). One study showed that women with low BMI but 
high WHR had significantly higher levels of cortisol than women with low BMI 
and low WHR (Epel et al., 2000).  
A significant positive relationship has been reported between BMI and hair 
cortisol (Stalder et al., 2012, Wester et al., 2014), but these studies did not 
measure abdominal obesity.  
Studies of adipocyte cortisol metabolism in obese females have described a 
positive relationship between 11β-HSD1 expression with BMI (Rask et al., 2002, 
Desbriere et al., 2006, Westerbacka et al., 2003, Mariniello et al., 2006, Munoz 
et al., 2009), waist circumference (Engeli et al., 2004, Desbriere et al., 2006), and 
sagittal diameter (Desbriere et al., 2006); and that 11β-HSD2 is lower in 
abdominally obese females than non-abdominally obese, measured by waist 
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circumference (Engeli et al., 2004). Taken together, these findings suggest there 
is a greater potential for cortisol regeneration in the adipose tissue of obese.  
Hepatic 11β-HSD1 activity may be impaired in the human liver. In obese men, 
greater glucocorticoid excretion as metabolites of cortisone than cortisol was 
reported (Rask et al., 2001), and in obese women, similar findings were reported 
with a higher cortisone: cortisol ratio (Rask et al., 2002) than non-obese controls. 
Incollingo Rodriguez et al., 2015 suggested that increased intracellular adipocyte 
cortisol regeneration may contribute to lower central cortisol secretion, and a 
lesser hepatic regeneration may contribute to a compensatory activation of the 
HPA axis in obesity, promoting metabolic disease and the obese phenotype 
(Rask et al., 2001, Rask et al., 2002). 
 
1.3 The HPA Axis in Pregnancy 
1.3.1 Gestational Changes to the HPA Axis 
During normal human pregnancy, a number of endocrine changes lead to 
dramatic activation of the maternal HPA axis, which result in an exponential 
increase in maternal cortisol levels (Duthie and Reynolds, 2013, Lindsay and 
Nieman, 2005). The placenta has significant endocrine properties, and secretes 
CRH from the second trimester onwards, which contributes to maternal cortisol 
production and creates a complex feed-forward loop with cortisol also 
stimulating CRH from the placenta (Lindsay and Nieman, 2005, Jung et al., 
2011). Estrogen and progesterone are also secreted by the placenta, and may 
mediate levels of free, bioavailable cortisol (Jung et al., 2011, MacLaughlin et 
al., 1972). Estrogen stimulates hepatic production of CBG during pregnancy 
(Mazer, 2004), which contributes to an increase in both bound and ‘free’ cortisol. 
Progesterone can act to displace cortisol from CBG (MacLaughlin et al., 1972). 
Although the circadian rhythm of cortisol release is maintained during pregnancy 
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(Entringer et al., 2010, Nolten et al., 1980, Nolten and Rueckert, 1981, Cousins 
et al., 1983), the cortisol awakening response and physiological response to 
stress become attenuated as gestation advances (Lindsay and Nieman, 2005). 
One study, using 30-minute serum sampling, demonstrated that cortisol pulses 
are maintained in the third trimester of human pregnancy (Magiakou et al., 
1996), but how and whether the ultradian rhythm of cortisol secretion changes 
across gestation is unknown.  
 
1.3.2 In Utero Cortisol Exposure 
1.3.2.1 Fetal Growth 
Glucocorticoids are vital for normal fetal growth and organ maturation. 
Prophylactic corticosteroids administered antenatally to women at risk of 
delivering preterm are known to accelerate lung maturation and reduce the 
incidence of respiratory distress syndrome (RDS) in both extremely preterm 
(Morgan et al., 2016) and nearer term babies (Saccone and Berghella, 2016).  
In addition to promoting maturation of fetal organs, increased cortisol levels may 
also increase availability of glucose for the developing fetus, via mobilisation of 
substrates for hepatic gluconeogenesis (Reynolds et al., 2003). This would 
suggest that increased fetal glucocorticoid exposure may lead to increased fetal 
growth. However, contrary to this suggestion both human and animal studies 
indicate that fetal overexposure to glucocorticoids is in fact linked with fetal 
growth restriction (Stewart et al., 1995). Timing of fetal glucocorticoid exposure 
may also be critical; amniotic fluid cortisol levels (a surrogate marker for fetal 
glucocorticoid exposure) at 15-18 weeks are negatively correlated with 
birthweight (r=-0.25, p<0.001) and gestational age (r=-0.18, p<0.05) 
(Baibazarova et al., 2013). This suggests that cortisol exposure in the second 
trimester of human pregnancy may influence fetal growth.  
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Maternal cortisol levels have also been shown to predict offspring birthweight. 
High maternal serum cortisol at 20 weeks gestation has been shown to be 
negatively associated with offspring birthweight (Goedhart et al., 2010). Higher 
salivary cortisol waking response at 13-18 weeks gestation is negatively 
correlated with shorter offspring length at birth (Bolten et al., 2011). At 36 weeks 
both higher morning cortisol and a steeper morning decline in cortisol levels are 
associated with lower birthweight (Kivlighan et al., 2008). Taken together, these 
studies suggest that a flattening of the diurnal rhythm of cortisol secretion may 
protect the fetus from overexposure to glucocorticoids during the morning peak.  
 
1.3.2.2 Length of Gestation 
The mechanisms that determine the length of gestation and the onset of 
parturition multifactorial, and are not well understood, but several studies 
suggest that the HPA axis plays a role in these processes.  
Maternal plasma CRH, which predominately originates from the placenta during 
pregnancy, has been linked to the timing of birth (Wolfe et al., 1987, Warren et 
al., 1992, Hobel et al., 1999, Wadhwa et al., 1998). Levels of CRH in the 
maternal circulation increase exponentially with advancing gestation, and peak at 
delivery. At the end of human pregnancy, production the circulating binding 
protein for CRH (CRHBP) declines, thus increasing the bioavailability of CRH 
(Linton et al., 1990, Linton et al., 1993). CRH has been shown to induce 
production of chemokines and cytokines in vitro, in myometrium at term and 
subsequently results in the cascade of inflammation in the uterus. The 
inflammation induced by CRH may lead to the onset of parturition (You et al., 
2014). Preterm labour is associated with a more rapid increase in CRH levels 
(Torricelli et al., 2011, McLean et al., 1995), while women with prolonged or 
post-term pregnancies have a slower rise in CRH (Torricelli et al., 2006). Taken 
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together, these findings suggest that CRH plays a key role in governing the 
length of gestation and triggering the onset of labour. 
An early abnormal rise of endogenous cortisol at 15-19 weeks of gestation was 
shown to be associated with preterm labour (Sandman et al., 2006) whereas the 
gestational increase in fetal cortisol appears to be blunted in the postmature fetus 
(Nwosu et al., 1975). In the 1960s exogenous glucocorticoids were shown to 
induce labour in sheep (Liggins, 1968), and subsequent clinical studies 
investigated whether glucocorticoids also induced labour in humans (Craft et al., 
1976, Katz et al., 1979, Nwosu et al., 1976, Elliott and Radin, 1995). Synthetic 
glucocorticoids administered into amniotic fluid were more effective at initiating 
labour than when systemically administered (Craft et al., 1976). This suggests 
that glucocorticoids may have an effect in the intrauterine tissues to initiate 
labour. Intramuscular administration of glucocorticoids has not been shown to 
result in delivery in humans. 
The synthetic glucocorticoids used in clinical practice to promote fetal lung 
maturation and in clinical trials to induce labour (dexamethasone and 
betamethasone), are, unlike endogenous cortisol, not substrates for placental 
11β-HSD2 (Seckl, 1997), which inactivates cortisol into cortisone (described in 
more detail in section 1.3.3.3). These synthetic glucocorticoids therefore pass 
through the placenta and into the fetal compartment intact, and contribute to a 
negative feedback effect on the fetal HPA axis. The result of this is a decrease in 
fetal cortisol synthesis, and subsequent reduction in placental estrogen synthesis 
(Craft et al., 1976, Ogueh et al., 1999, Ohrlander et al., 1977). This negative 
feedback effect may negate any effect of systemic administration of synthetic 
glucocorticoids on induction of labour. Endogenous circulating cortisol increases 
throughout gestation. Further, fetal membranes and the decidua express 
increasing 11β-HSD1 (which regenerates cortisol from cortisone) with 
advancing gestation (Alfaidy et al., 2003). These tissues are considered to be 
important sources of extra-adrenal cortisol within intrauterine tissues (Murphy, 
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1977), and increasingly regenerate cortisol with advancing gestation (Tanswell et 
al., 1977). 
 
1.3.2.3 Cardio-Metabolic Disease 
Fetal glucocorticoid exposure has been linked to the development of cardio-
metabolic disease later in life. Glucocorticoids increase insulin resistance and 
inhibit glucose-stimulated insulin secretion from pancreatic beta cells (Reynolds 
and Walker, 2003). Glucocorticoids also cause hypertension, vasoconstriction 
and dyslipidaemia, all of which increase the risk of myocardial and cerebral 
infarction. 
Offspring of women who received antenatal corticosteroid therapy for suspected 
preterm labour have been reported to have higher blood pressure at age 14 years 
(Doyle et al., 2000), and higher insulin levels at age 30 years (Dalziel et al., 
2005). Exposure to increased levels of endogenous glucocorticoids during 
pregnancy as a result of reduced placental 11β-HSD2 activity (estimated from 
cord blood cortisol and cortisone concentrations) associates with increased blood 
pressure at aged 3 years (Huh et al., 2008). 
Higher maternal cortisol during pregnancy is associated with higher fat mass 
index in female offspring, and with lower fat mass index in male offspring (Van 
Dijk et al., 2012).  
Studies using cohorts with birthweight records have reported that low 
birthweight associates with increased cortisol levels and adrenal responsiveness 
to ACTH, and an adverse metabolic profile in adulthood (Phillips et al., 1998, 
Reynolds et al., 2001, Phillips et al., 2000, Reynolds et al., 2005). This supports 
the hypothesis that increased exposure to glucocorticoids over the lifespan may 




1.3.3 The Protective Role of the Placenta 
During pregnancy, the placenta, which is the primary barrier between the 
maternal and fetal circulations, acts as the renal, respiratory, gastrointestinal, 
endocrine and immune systems for the developing fetus. In the 1950s and 1960s, 
birth defects cause by thalidomide highlighted that the placenta is not a complete 
barrier for drug transfer. Subsequent research has focused on characterising the 
mechanisms by which drugs and nutrients pass across the placenta.   
 
1.3.3.1 Placental Structure and Development 
Placental development begins with decidualisation of the uterus, which means 
that the uterus is ready for implantation of the embryo. During decidualisation 
uterine stromal cells are converted into large, secretory decidual cells, and 
macrophages and lymphocytes are recruited (Malassine et al., 2003). In humans 
the first signs of decidualisation can occur before conception, and as early as day 
23 of the menstrual cycle. At this time, spiral arteries become prominent in the 
endometrium (Kliman, 2000). After the blastocyst adheres to the decidua, the 
blastocyst differentiates into an embryoblast (which later develops into the 
embryo and fetus), and the outer layer of the blastocyst is the trophoblast, which 
later becomes the placenta.   
The trophoblast further divides into two layers: the underlying ‘cytotrophoblast’, 
and the overlying ‘syncytiotrophoblast’ layers, which is a multinucleated cell 
layer covering the surface of the placenta and therefore has a role in the ‘barrier’ 
role of the placenta. As gestation advances the placenta continues to grow as a 
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discoid-shaped organ. By the end of the first trimester of pregnancy, blood 
supply from the maternal circulation is complete.  
In human pregnancy, the chorionic villus (the basic structural and functional unit 
of the mature placenta) is established as early as day 21 after ovulation 
(Malassine et al., 2003). These are an inner network of vascular projections of 
fetal tissue surrounded by the outer syncytiotrophoblast (directly in contact with 
the intervillous space containing maternal blood), and the inner cytotrophoblast. 
The intervillous space contains maternal blood. With advancing gestation as the 
villi mature, there is a reduction in the cytotrophoblast and by term, there is only 
a single layer of syncytiotrophoblast separating maternal blood from the fetal 
capillaries. Spiral arteries from the uterus penetrate the placenta and supply the 
intervillous space with maternal blood.  
There are two umbilical arteries that arise from the fetal internal iliac arteries that 
carry deoxygenated blood from the fetus via the umbilical cord to the placenta. 
These umbilical arteries divide into chorionic arteries and end as capillaries 
within the chorionic villi. Substances contained within the maternal blood pass in 
the intervillous space pass through the syncytiotrophoblast and fetal capillary 
endothelium into the fetal blood. Fetal capillaries drain into chorionic veins that 
then empty into a single umbilical vein. 
The placenta grows with advancing gestation and at term is about 15-20 cm in 
diameter, 2-3 cm thick and has a surface area of up to 15 m2 (Moore KL, 2008). 
 
1.3.3.2 Placental Function 
The placenta is the primary interface between the maternal and fetal 
bloodstream. The syncytiotrophoblast performs multiple functions; it’s primary 
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role is in absorption, exchange of gases, nutrients and waste, and hormone 
production.   
Infant size at birth is thought to be determined by fetal nutrient supply (Fowden 
et al., 2006), which is influenced by placental size, morphology and capacity for 
nutrient transport (Fowden and Forhead, 2004). Placental weight is positively 
correlated with fetal weight near term in a number of species (Baur, 1977, 
Fowden et al., 2009). Placental production of nutrients and hormones are also 
known to affect fetal growth (Fowden and Forhead, 2004). A growing body of 
evidence suggests that specific alterations in placental transporter function are 
implicated in fetal growth pathologies (Jansson and Powell, 2006, Sibley et al., 
2005). 
Alterations in the HPA axis during pregnancy may have an impact on placental 
nutrient transport. Glucocorticoids have been shown to down regulate placental 
glucose transporters (GLUT1 and GLUT3) (Hahn et al., 1999), to reduce activity 
of human placental lipoprotein lipase, which is involved in lipid transport to the 
fetus (Magnusson-Olsson et al., 2006) and to up regulate System A Amino Acid 
Transporter 2 (SNAT2). CRH has been shown to down regulate system A 
activity (Giovannelli et al., 2011) and down regulate placental GLUT3 (Gao et 
al., 2012). Estradiol, estriol and progesterone have also been shown to inhibit 
placental monosaccharide transport (Johnson and Smith, 1980). Taken together 
these findings suggest that alterations in the HPA axis during pregnancy may 
influence availability of nutrients for the developing fetus and may be an 
underlying mechanism for glucocorticoid associated growth abnormalities.  
As previously mentioned, the placenta has significant endocrine properties and 
produces a number of steroid and peptide hormones including human chorionic 
lactogen, human placental lactogen, human growth hormone variant, estrogen, 
progesterone and CRH.  
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1.3.3.3 Placental 11β-HSD2  
The placenta is equipped with several ‘defence mechanisms’ which are thought 
to help prevent the fetus from the harmful effects of overexposure to 
glucocorticoids, such as fetal growth restriction (Stewart et al., 1995). 
Glucocorticoids are thought to be liphophilic, meaning that they can freely cross 
the placenta between the maternal and fetal compartments. Maternal plasma 
cortisol is significant as an independent predictor of amniotic fluid cortisol, after 
adjusting for maternal age, gestational age and time of collection (Sarkar et al., 
2008), and increases with increasing gestation (Sarkar et al., 2008, Baibazarova 
et al., 2013, Gitau et al., 1998, Glover et al., 2009).  
One relatively well characterised ‘defence mechanism’ is the cortisol inactivating 
enzyme, 11β-HSD2, which converts active cortisol into inactive cortisone, thus 
limiting fetal glucocorticoid exposure. 11β-HSD2 is present at higher 
concentrations in the placenta with advancing gestation, and its activity falls 
dramatically at term, to correspond with fetal lung maturation and parturition 
(McTernan et al., 2001, Murphy and Clifton, 2003, Benediktsson et al., 1993). 
Due to the action of 11β-HSD2, fetal glucocorticoid levels are up to 10-fold 
lower than maternal levels (Edwards et al., 1993), although it is thought that up 
to 20% of maternal glucocorticoids cross to the fetal compartment (Benediktsson 
et al., 1997).  
Both human and animal studies have suggested that the efficiency of placental 
11β-HSD2 may be reduced by specific dietary substances, or the presence of 
inflammation, hypoxia and stress. Reduced enzyme efficiency would allow a 
greater transplacental passage of cortisol to the developing fetus (Seckl, 2004, 
Cottrell and Seckl, 2009). Given that maternal cortisol levels are considerably 
higher than fetal levels, even subtle changes in placental 11β-HSD2 activity 
would have the potential to significantly alter fetal glucocorticoid exposure 
(Gitau et al., 1998, Gitau et al., 2001). 
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In animal studies, both pharmacological and genetic modifications to reduce 
11β-HSD2 activity have been shown to associate with lower birthweight (Seckl, 
2004, Cottrell and Seckl, 2009). Similarly lower levels of 11β-HSD2 in human 
placenta associates with lower birthweight (Stewart et al., 1995, McTernan et al., 
2001), and babies homozygous for deleterious mutations of 11β-HSD2 weigh on 
average 1.2 kg less than heterozygote siblings (Dave-Sharma et al., 1998). 
Women who consume large quantities of liquorice during pregnancy (which 
contains glycyrrhizin, an 11β-HSD inhibitor) have shorter gestation (Strandberg 
et al., 2001, Strandberg et al., 2002). Taken together, these studies suggest that 
placental 11β-HSD2 activity, which regulates fetal glucocorticoid exposure, is 
critical for fetal growth and length of gestation. 
Placental biology may also be altered by exposure to stress in utero. In late 
pregnancy, maternal anxiety associates with up regulation of GR and MR mRNA 
(Reynolds et al., 2015) and down regulation of 11β-HSD2 (O'Donnell et al., 
2012). Together, these may increase placental glucocorticoid sensitivity and 
increase fetal cortisol exposure. 
 
1.4 Aims, Hypothesis and Outline of Thesis 
With recognition that the prevalence of obesity and maternal obesity is 
increasing, and an increasing body of evidence describing both short-term 
pregnancy outcomes, and longer-term offspring health outcomes; studies 
investigating the underlying mechanisms in obese related pregnancy outcomes 
are an important focus for current research.  
Glucocorticoids are implicated in both fetal growth and length of gestation. 
Further, epidemiological, clinical and laboratory studies support the hypothesis 
that fetal exposure to glucocorticoids in utero is a mediator of longer-term 
programming of cardiovascular, metabolic and neuroendocrine disorders in adult 
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life (Seckl, 2004, Reynolds, 2013) (Figure 1-4). Although inconclusive, 
available evidence suggests that non-pregnant obesity is associated with 
dysregulation of the HPA axis, and there is limited evidence from two recent 
studies that reported lower cortisol in obese compared with lean pregnant 
women, suggesting that HPA axis dysregulation may be maintained in obese 
during pregnancy (Putignano et al., 2001, Goedhart et al., 2010, Berglund et al., 
2016). In 2010, Goedhart et al., reported findings from the Amsterdam Born 
Children and their Development cohort (Goedhart et al., 2010). This large 
prospective cohort study (n=2810 pregnant women, of which 105 women had a 
BMI ≥ 30 kg/m2) examined the relationship between maternal cortisol with 
birthweight and risk of offspring being small for gestational age. A single 
measurement of maternal total serum cortisol was obtained at 13 weeks’ 
gestation, demonstrated that maternal cortisol was significantly lower with 
increasing maternal BMI (p<0.001). More recently in 2016, Berglund et al., 
reported findings from an observational cohort study of 331 pregnant women 
(normal weight n=132, overweight n=56 and obese n=64). Maternal serum 
cortisol was significantly lower in obese than normal weight women at 24 
weeks’ (p=0.05) and at delivery (p=0.007).  
Further studies are required to corroborate these findings, to investigate the 
effects of maternal obesity on other indices of cortisol activity, to test 
associations with short- and longer-term clinical outcomes, and to identify 
underlying mechanisms.  
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Figure 1-4. Possible in utero programming effect via influence of maternal 
obesity on maternal HPA axis, thus affecting fetal glucocorticoid exposure. 
 
 
This Thesis aimed to characterise HPA axis activity in obese pregnancy, and to 
identify possible underlying mechanisms in its regulation. The overarching 
hypothesis was that HPA axis activity is dysregulated in maternal obesity, and 
that this may be associated with altered release, clearance and placental 
metabolism of cortisol, and with clinical outcomes related to fetal size and length 
of gestation. This hypothesis was tested in prospective longitudinal pregnancy 
cohorts of women with severe obesity and lean controls (Chapters 3 and 5), and 
using pregnancy blood samples obtained at the time of delivery (Chapters 4 and 
6). This Thesis contains an overall methods chapter (Chapter 2) and four results 
chapters (Chapters 3 – 6): 
	54	
In Chapter 3, the effects of maternal obesity on the maternal HPA axis are 
explored through measurement of circulating cortisol, CBG, CRH, estrogens 
(estradiol (E2) and estriol (E3)), and progesterone (P4) throughout pregnancy in 
a cohort of very severely obese and lean women. Associations with clinical 
outcomes related to birthweight and length of gestation were tested. It was 
hypothesised that HPA axis hormones would be lower in obese throughout 
pregnancy, and would associate with increased fetal size and longer gestation.  
In Chapter 4, the effects of maternal BMI on maternal and fetal glucocorticoids 
at delivery are assessed by measuring cortisol, cortisone, corticosterone and 11-
dehydrocorticosterone from samples of maternal and cord blood obtained at 
delivery. It was hypothesised that maternal and cord glucocorticoids would be 
lower at delivery. 
In Chapter 5, the effects of both maternal BMI and pregnancy gestation on the 
ultradian rhythm of glucocorticoids are investigated through a longitudinal study 
of obese and lean pregnant, and non-pregnant women. It was hypothesised that 
ultradian pulse characteristics would be altered in obese compared with lean 
subjects, and would be altered with advancing gestation of pregnancy.  
In Chapter 6, placental cortisol transport is studied using a dual perfused ex vivo 
placental perfusion model combined with mathematical modeling. A model of 
placental cortisol transfer and metabolism was developed which can be used in 








Materials and Methods 
2.1 Clinical Methods 
2.1.1 Tommy’s Centre for Maternal and Fetal Health Research  
The work in this Thesis is based on clinical research funded by Tommy’s the 
Baby Charity, and has been carried out at the Tommy’s Centre for Maternal and 
Fetal Health Research at the University of Edinburgh. The Edinburgh Tommy’s 
Centre work includes studying the impact of maternal obesity on fetal exposure 
to glucocorticoids in utero.  
 
2.1.2 Recruitment Methods 
Participants were recruited from the NHS Lothian Health board region.  
Obese pregnant women were recruited from the Metabolic Antenatal Clinic 
(MAC, Chapters 3 and 5); this is a pan-Lothian clinic held at the Royal 
Infirmary of Edinburgh, that provides specialized and Consultant-led 
multidisciplinary care for severely obese pregnant women with a BMI > 40 
kg/m2 at booking. The MAC was launched at the Simpson’s Centre for 
Reproductive Health in 2008, initially funded by Tommy’s, and now funded by 
NHS Lothian. Normal weight (booking BMI 18.5 – 25 kg/m2) pregnant 
‘controls’ were recruited from community Antenatal Clinics in Edinburgh 
(Chapters 3 and 5).  
Non-pregnant obese (BMI > 30 kg/m2) participants were recruited from Bariatric 
Surgery Clinics in NHS Lothian (Chapter 3) and community weight 
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management clinics (Chapter 5). Non-pregnant, normal weight (BMI 18.5 – 25 
kg/m2) volunteers were recruited as volunteers responding to advertisements 
(Chapters 3 and 5).    
 
2.1.3 Edinburgh Clinical Research Facility 
The Edinburgh Clinical Research Facility is a purpose-built unit for clinical 
research at the Royal Infirmary of Edinburgh. It is a joint venture between the 
University of Edinburgh and NHS Lothian, staffed by experienced research and 
nursing staff. This facility was used for participant study visits in Chapters 3 
and 5.  
 
2.1.4 Edinburgh Reproductive Tissue BioBank 
Biological samples from pregnant women (Chapters 4 and 6) were obtained via 
the Edinburgh Reproductive Tissue BioBank (ERTBB; ethical approval 
REC09/S0704/3). The ERTBB stores anonymised tissue specifically collected 
for pregnancy research from women who give written consent, by trained 
research midwives and research technicians. The majority of samples collected at 
the time of elective Caesarean section. Tissue samples are linked to a database 
containing clinical records.  
 
2.2 Clinical Studies 
The work presented in this Thesis relates to the following studies and approvals: 
1. Hormones in Pregnancy (HIP; ethical approval 08/S1101/39). 
Chief Investigator, Professor Rebecca Reynolds. 
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2. Altered Metabolic Processes in Obese Pregnant Women 
(AMPOP; ethical approval 09/S1103/6). Chief Investigator 
Professor Jane Norman; Principle Investigator, Dr Sarah Barr. 
3. The Effect of Maternal Weight and Gestation on Cortisol 
Pulsatility in Pregnancy (PIPa; ethical approval 13/SS/0176). 
Chief Investigator Professor Rebecca Reynolds; Principle 
Investigator Dr Laura Stirrat.  
 
2.2.1 Hormones in Pregnancy HIP  
Obese pregnant women (BMI ≥ 40 kg/m2) were recruited from the metabolic 
antenatal clinic, and normal weight (BMI 18.5 – 25 kg/m2) from the Lauriston 
community antenatal clinic, to participate in a longitudinal study of obesity in 
pregnancy from 2008 – 2013. Figure 2-1 illustrates the protocol of this 
prospective longitudinal study. Trained research nurses and midwives carried out 
recruitment and conducted anthropometric measurements. Participants completed 
a demographic information questionnaire that covered demographics, social 
history and medical history prior to pregnancy. Fasting venous blood samples 
were obtained at 16, 28 and 36 weeks of gestation, and at 3-6 months postnatal. 
Three saliva samples were obtained at 16 weeks gestation in a subset of women 
at bedtime, at waking and at 30 minutes after waking, to assess the cortisol 
awakening response.  Eligible women were aged 18-45 years and were 
Caucasian. Exclusion criteria were diabetes, active endocrine disorders, use of 
glucocorticoid medication and multiple pregnancy. Clinical outcomes were 




Figure 2-1. Flow Chart of Hormones in Pregnancy (HIP) Study 
This longitudinal study of obesity in pregnancy forms the basis of Chapter 3 in 
this Thesis.  
Key: wk (weeks gestation) 
 
 
2.2.2 Altered Metabolic Processes in Obese Pregnant Women AMPOP  
Obese pregnant women (BMI ≥ 40 kg/m2) were recruited from the MAC, and 
normal weight (BMI 18.5 – 25 kg/m2) from the Lauriston community antenatal 
clinic, from 2009 – 2012. Non-pregnant volunteers were recruited following 
response to advertisement, were women who had previously attended the MAC 
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and had given their permission to be contacted about future studies, and from the 
Bariatric Surgery clinic in NHS Lothian. Recruitment was carried out by Dr 
Sarah Barr (Clinical Research Fellow).  
Study participants provided 24-hour urine collections for analysis of urinary 
glucocorticoid metabolites. Samples were collected at 19 weeks and 36 weeks of 
gestation, and non-pregnant participants provided one collection. Eligible women 
were Caucasian. Exclusion criteria were diabetes, active endocrine disorders, use 
of glucocorticoid medication and multiple pregnancy. 
 
2.2.3 The Effect of Maternal Weight and Gestation on Cortisol Pulsatility in 
Pregnancy PIPa  
Obese pregnant women (BMI ≥ 40 kg/m2) were recruited from the MAC, and 
normal weight (BMI 18.5 – 25 kg/m2) from the Lauriston community antenatal 
clinic, from 2014 – 2016. Figure 2-2 illustrates the protocol of this prospective 
case-control study. Non-pregnant volunteers were recruited following response 
to advertisement, or from NHS Lothian community weight management clinics. 
Inclusion criteria were singleton pregnancy, normal booking ultrasound scan and 
Caucasian ethnicity. Exclusion criteria were smoking, diabetes at recruitment, 
regular glucocorticoid medication, severe mental health disorder or anaemia. 
Pregnant women attended for two study visits (visit 1 at 16 – 24 weeks gestation; 
visit 2 at 30 – 36 weeks gestation) and non-pregnant volunteers attended for one 
study visit in the luteal phase of the menstrual cycle. Study visits took place at 
the Edinburgh Clinical Research Facility. 
Participants attended study visits following an overnight fast. Fasting blood 
samples were obtained at 10-minute intervals between 08.00h – 11.00h and 
between 16.00h – 19.00h via a peripheral cannula. Interstitial fluid from the 
subcutaneous area of the abdomen was obtained at 20-minute intervals starting 
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between 0830h and 0900h for 24-hours, via a portable microdialysis and 
automated collection device (described in greater detail: Section 2.3.4). 
Participants continued to wear this at home overnight, and it was collected from 
them the following morning.  
 
Figure 2-2. The Effect of Maternal Weight and Gestation on Cortisol 
Pulsatility in Pregnancy (PIPa) Study 
This case-control study forms the basis of Chapter 4 in this Thesis. Details of 





2.2.4 Studies of Blood and Tissue at Delivery 
Samples of paired maternal and cord blood (Chapter 4), and whole placentas 
(Chapter 6) were obtained from pregnant women who had consented for storage 
and use of tissue in the Edinburgh Reproductive Tissue BioBank for pregnancy 
research. Specific inclusion and exclusion criteria are details in Chapters 4 and 
6. Collection procedures and experimental protocols are described in sections 
2.3.1 (blood) and 2.4.5 (placenta).  
 
2.3 Tissue Collection  
2.3.1 Blood  
Peripheral venous blood was collected into the appropriate container (Sarstedt 
Monovette ®, UK), for plasma (anti-coagulated with sodium EDTA), or serum 
(container with separation polyacrylic ester gel). Cord blood (arterial or venous) 
was collected immediately after delivery and cord clamping. Samples were 
transported on ice, and plasma or serum were separated within 30 minutes after 
collection by centrifugation at 1200 rpm for 10 minutes at 4 oC. Blood fractions 
were stored at -80 oC until analysis. Both serum and plasma are widely used for 
measurement of circulating cortisol levels in humans. Consistent use of either 
serum or plasma within a given study will reduce the potential for assay 
variation. The studies in Chapters 3 and 5 collected serum samples for cortisol 
analysis. In Chapter 4 plasma samples were used, as there was greater 
availability of plasma than serum samples, thus a larger sample size could be 




2.3.2 Saliva  
Saliva samples were collected using a Salivette® collector (Sarstedt, Numbrecht, 
Germany); at bedtime, at waking, and 30 minutes after waking, to assess the 
cortisol awakening response. Samples were centrifuged and stored at -20 oC until 
later analysis. 
 
2.3.3 Twenty-Four Hour Urine Collection  
Urine samples were collected by Dr Sarah M Barr as part of the AMPOP study. 
Participants provided urine samples in a Twenty-Four Hour Urine Container 2.5 
L (Medline, Oxon, UK). Total urine volume was recorded and stored in 20 mL 
aliquots at -80 oC until analysis.  
 
2.3.4 Interstitial Fluid  
Interstitial fluid cortisol concentrations (which are mostly free cortisol) (Sandeep 
et al., 2005) can be measured using microdialysis techniques. Microdialysis is an 
in vivo sampling technique for measuring endogenous and exogenous solutes in 
the extracellular space of tissue. A small probe equipped with a semi-permeable 
hollow fibre can be inserted superficially into the dermis, and perfused with a 
solution that forms an equilibrium, with diffusible molecules in the immediate 
surroundings (Schnetz and Fartasch, 2001) (Figure 2-3). A novel miniaturized 
sampling system that combines the technique of microdialysis with the ability to 
collect multiple samples automatically over 24 hours was developed by Professor 
Stafford Lightman’s group (Bristol) (Bhake et al., 2013). Samples are obtained at 
20-minute intervals for 24 hours, then decanted manually into marked tubes and 
stored at -80 oC for later laboratory analysis.  
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Figure 2-3. Schematic Representation of Microdialysis Membrane 
 
 
2.3.5 Term Placentas  
Whole placentas were obtained at delivery for placental perfusion studies, from 
term pregnancies (Chapter 6) from women undergoing elective Caesarean 
section at the Royal Infirmary of Edinburgh. Placentas were transported to the 
laboratory on ice for immediate assessment of suitability for experimental use.  
 
2.4 Laboratory Studies 
Laboratory studies and analytical techniques were performed at the Tommy’s 
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Centre for Maternal and Fetal Health Research, or the Mass Spectrometry Core 
of the Edinburgh Clinical Research Facility, unless stated otherwise.  
 
2.4.1 Ex Vivo Placental Perfusion  
Functional studies of the human placenta are challenging, due to the potential 
risk of harm to a pregnant women or the developing fetus. Ethical constraints 
mean that in vivo studies of human pregnancy are restricted, so for this reason ex 
vivo experiments have a key role in human placental research. The ex vivo dual 
perfused human placental cotyledon is the only experimental model that 
facilitates study of placental transfer in organized human placental tissue. 
Briefly, this technique involves establishing a maternal and fetal circulation, and 
creating an environment to maintain tissue viability by supplying it with 
nutrients, gasses and maintaining temperature, all of which are intended to mimic 
physiological conditions. Perfusion of a single human placental cotyledon where 
the maternal and fetal circulations are separate was originally described in 1962 
(Panigel, 1962), was developed further by the groups of Schneider (Schneider et 
al., 1972) and Miller  (Miller et al., 1989), and is widely used today. The success 
rate of perfusion experiments in placentas that are suitable for being connected to 
a perfusion circuit, is only about 50% (Myllynen and Vahakangas, 2013). The 
perfusion method for the work presented in this Thesis was based on previous 
studies (Brownbill et al., 2000, Cleal et al., 2007). 
Whole placentas were obtained with informed consent following elective 
Caesarean section of uncomplicated term pregnancies, via the Edinburgh 
Reproductive Tissue BioBank. Immediately following delivery of the placenta 
with gentle controlled cord traction, the umbilical cord was clamped and placed 
into a plastic bag before being transported to the laboratory on ice.  
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In the laboratory, placentas were examined for evidence of tissue damage during 
delivery. Vein and artery pairs with minimal branching that supplied a well-
defined and macroscopically intact cotyledon were identified. A non-
recirculating circulation was established. Fetal vessels were cannulated (fetal 
artery 19 G blunt needle with internal diameter 0.7 mm, and fetal vein 14 G blunt 
needle with internal diameter 1.6 mm; OctoInkJet, UK), sutured in place (4-0 
Polysorb, Coviden, UK), and fetal circulation started with perfusion of perfusion 
buffer at 6 mL/min. If required, collateral vessels adjacent to the cotyledon were 
tied off. The perfused cotyledon was then placed with the ‘fetal side’ facing 
downwards in the perfusion chamber (custom made for a previous study and 
gifted for this work by Dr Fiona Denison, Reader and Honorary Consultant in 
Maternal Fetal Medicine, University of Edinburgh). The fetal side was covered 
with Parafilm® (Bemis NA, Neenah, WI, USA), to prevent any sagging or undue 
stretch on the vessel and placental tissue. Placental edges were trimmed, 
allowing a generous margin to minimize fluid leaks.  
The perfused cotyledon was identified on the ‘maternal side’ by slight blanching. 
Maternal perfusion was established by introducing three blunt cannula (Cole-
Parmer Instrument Company, London, UK) into the intervillous space, by 
penetrating the basal plate to a depth of approximately 1-2 cm. The maternal 
infusion was started at 14 mL/min. Maternal perfusate that returned from the 
intervillous space continuously drained by a venous catheter placed at the lowest 
level of the maternal surface, to avoid significant pooling of perfusate. 
A waterbath was utilized to maintain the perfusate reservoirs at 37 oC and the 
tubing passed through a second water bath (also at 37 oC) before entering the 
perfusion chamber itself was placed inside an incubator (Hybaid, UK), also at 37 
oC.  
The maternal and fetal circulations were driven by a peristaltic pump (Watson-
Marlow, Cornwall, UK). The different flow rates (maternal 14 mL/minute, fetal 
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6 mL/minute) were achieved by using different bore tubing segments for the 
pump (maternal bore 3 mm and fetal bore 2 mm, Elkway Precision Laboratory 
Consumables, Hampshire, UK). Tubing for the rest of the circuit was 2.0 mm 
bore (Portex®, Smiths Medical, Kent, UK). In vitro flow rates on the maternal 
and fetal sides have been estimated as being around 20 mL/min per 30 g of 
lobule (Kirkinen et al., 1983). However, this has been shown to result in villous 
oedema in ex vivo dual perfused models (Kaufmann, 1985).  
The initial perfusate was Earle’s bicarbonate buffer (EBB) with additional BSA 2 
g/L added. The perfusion system was gassed using gas exchange devices (HiQ, 
BOC, UK). The maternal circulation was equilibrated with 95% air and 5% CO2 
(BOC, UK), and the fetal perfusate was equilibrated with 95% N2 and 5% CO2 
(BOC, UK).  
Although this model has been used experimentally for decades, there are no 
standardized criteria for monitoring and validation.  The parameters selected to 
monitor the system and estimate viability in the perfusions presented in this 
Thesis are as follows: 
Volume conservation: Fetal output was measured be collecting the fetal effluent 
over 5 minute intervals, knowing that the input was 6 mL/minute. Venous return 
flow of > 95% of the input flow was enforced throughout each perfusion (Cleal 
et al., 2007).  
Pressure: Fetal perfusion pressure of > 70 mmHg has been shown to lead to 
damage of the fetal villi during an ex vivo perfusion (Jauniaux et al., 1991). A 
pressure transducer (Memscap®, Skoppum, Norway) was inserted into the fetal 
artery section of the circuit and continuously detected pressure that was reported 
by a computer program (Labchart v7.0, ADInstruments, Oxford, UK). Fetal 
artery pressures up to 70 mmHg were considered successful, and the perfusion 
was considered unsuccessful if pressure in the fetal circuit exceeded 70 mmHg. 
	67	
Inability to achieve adequate circuit perfusion rates within fetal inflow pressure 
ranging 40 – 70 mmHg perfusion was stopped. 
As the placenta suffers an ischaemic ‘insult’ injury at delivery, experiments tend 
to allow a 30-60 minute recovery period after the perfusion experiment has 
commenced to allow metabolic functions to recover. For the experiments in this 
Thesis, 30 minutes was considered appropriate to wash out the endogenous 
glucocorticoids that remained in the placenta (Benediktsson et al., 1997). Most 
published studies have reported perfusing placentas for 2-6 hours, but perfusions 
up to 48 hours have been reported (Miller et al., 1989, Heikkila et al., 2002, Woo 
et al., 2012). The infusion protocol for the experiments presented in this Thesis is 
outlined in Figure 2-4. On completion of the perfusion experiment, the wet 
weight of the perfused cotyledon was obtained and samples of perfused tissue 




Figure 2-4. Placental Perfusion Protocol 
Maternal circulation was established fifteen minutes after fetal circulation was 
established and ensured > 95% venous return. Perfusion into the maternal 
circulation was 0-30 minutes EBB alone, 30-60 minutes EBB + 20 nM D4-
Cortisol, 60-90 minutes EBB + 200 nM D4-Cortisol, 90-120 minutes EBB + 800 
nM D4-Cortisol, 120-150 minutes EBB + 800 nM D4-Cortisol, 150-170 minutes 
EBB alone. Fetal and maternal venous outputs were sampled at 5-minute 
intervals.  




2.5 Laboratory Methods and Materials  
2.5.1 ELISA   
Commercially available ELISA kits were used according to manufacturers’ 
instructions. Details of the kits and validation parameters are specified in results 
chapters.  
Enzyme-linked immunoassay (ELISA) is a plate-based immunoassay technique 
used for detecting and quantifying hormones, proteins, peptides and antibodies. 
The ELISA kits used in this Thesis were based on the principle of competitive 
binding. An unknown amount of antigen (hormone of interest) present in the 
sample and a fixed amount of enzyme (horseradish peroxidase) labeled antigen 
compete for the binding sites of the antibodies coated onto the wells of a 96-well 
plate. After incubation the wells are washed to stop the competition reaction, and 
any unbound conjugate is washed off (typically, phosphate buffered saline with 
Tween detergent (PBS-T); wash buffer supplied with each kit was used). A 
detection substrate solution is then applied. The detection solution contains a 
molecule such as 3,3’5,5’-tetramethylbenzidine (TMB), which releases a 
coloured dye as a response to peroxidase enzyme activity. This forms 3,3’5,5’-
tetramethylbenzidine diimine which has a blue colour. This reaction is stopped 
by adding ‘stop solution’ (sulphuric acid) which causes the blue colour to change 
to yellow. Following this substrate reaction, the colour intensity is inversely 
proportional to the amount of antigen in the sample. Spectrophotometry is used 
to measure light absorption at 450 nm.  Results of samples can be determined 
directly using the standard curve.  
In Chapter 3 the following ELISA assays were used: 
• Plasma Total Estradiol (Demeditec DE2693; inter-assay CV 6.72 – 
9.39%) 
• Plasma Total Estriol (Demeditec DE2996; inter-assay CV ≤ 10%) 
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• Plasma Total Progesterone (Demeditec DE 1561; inter-assay CV 5.4 – 
6.99%) 
• Plasma Sex-Hormone-Binding-Globulin (Demeditec DE 2996; inter-
assay CV 3.1 – 8.0%) 
• Saliva Cortisol (Salimetrics, 1-3002; inter-assay CV 3 – 11%) 
The ELISA for measurements of CBG were performed by John Lewis at the 
Canterbury Health Laboratories in New Zealand, using a previously reported 
method (Lewis and Elder, 2013, Kassebaum et al.). Measurements included 
‘total’ CBG and ‘intact’ CBG (which has binding affinity for cortisol). ‘Cleaved’ 
CBG (which lacks binding affinity for cortisol) was then calculated as a ratio of 
total:intact CBG. 
In Chapter 5 the following ELISA assays were used: 
• Plasma Adenocorticotropic Hormone (Demeditec DE3647; inter-assay 
CV 6.9 – 7.1%) 
• Saliva cortisol (IBL, RE52611; inter-assay CV 4.2 – 17.0%)*  
Interstitial fluid cortisol levels were determined using saliva cortisol ELISA 
(IBL, RE52611)* using the method reported by (Bhake et al., 2013). Free 
cortisol values were expected to be above the highest standard, therefore were 
diluted to 1:10 in the assay zero standard and results were corrected for dilution.  
 
2.5.3 Radioimmunoasay  
Radioimmunoasay (RIA) is another technique used to measure concentrations of 
‘antigens’ (such as hormones) by use of antibodies. To perform an RIA, a known 
quantity of the antigen (hormone of interest) is labeled with a radioactive isotope 
of iodine (such as I125). The biological sample (eg. serum), containing an 
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unknown quantity of the same antigen is then added to the plate well. 
Radiolabeled and unlabeled antigens then compete for antibody binding sites on 
the plate. At increasing concentrations of unlabeled antigen, more of it binds to 
the antibody, thus preventing the radiolabeled antigen from binding and reducing 
the ratio of antibody-bound radiolabeled antigen to free radiolabeled antigen. The 
unbound and bound antigens are separated, and radioactivity of the bound 
antigen is measured using a gamma counter. Results of samples can be 
determined by reading from a standard ‘binding curve’.  
In Chapter 3 total serum cortisol was measured by RIA by Graham Harold 
(Senior Technician) using ImmunChem Cortisol I125;ICN Biomedicals 07221102. 
Corticotrophin releasing hormone was measured in plasma by extracted 
radioimmunoassay by Maria Bowman and Roger Smith at the University of 
Newcastle, Australia, using a previously reported method (Smith R, 2009).  
 
2.5.4 Liquid- and Gas-Chromatography Tandem Mass Spectrometry 
Mass spectrometry is regarded as the ‘gold standard’ for quantifying steroid 
concentrations (Stanczyk and Clarke, 2010). The advantage of this technique 
over immunoassays is that it can precisely measure multiple analytes at low 
concentration concomitantly, from a small sample volume. Chromatography is 
employed prior to mass spectrometry to separate analytes with different 
molecular masses in a mixture on the basis of their elution times as they pass 
along a column (Figure 2-5).  
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a technique 
where a sample mixture is separated by liquid chromatography prior to being 
ionized and characterized by mass to charge ratio and relative abundance using 
two mass spectrometers in series. This method can analyse biochemical, organic 
and inorganic compounds. The sample is forced by a liquid at high pressure 
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(mobile phase) through a column packed with irregular or spherical particles 
(stationary phase) that accomplish separation of the sample. Interactions between 
the different analytes and the stationary phase influence movements of the 
compounds in the mixture through the column, so that they are eluted at different 
times depending on their molecular mass.  
Gas chromatography tandem mass spectrometry (GC-MS/MS) follows similar 
principles but uses an inert gas for the mobile phase (such as helium), and a thin 
layer of liquid for the stationary phase.  
Tandem mass spectrometry (MS/MS) consists of several steps of mass 
spectrometry selection between which some form of fragmentation occurs. In the 
first stage of mass spectrometry, ions are formed and then separated by mass to 
charge ratio. Ions of a particular mass to charge ratio (known as precursor ions) 
are selected and fragment ions (known as product ions) are created by a 
collision-induced dissociation. The ions that result are separated and detected in 




Figure 2-5 Chromatography and Mass Spectrometry   
Key: t (retention time), m/z (mass to charge ratio). 
 
 
In Chapter 3 urine glucocorticoid metabolites from 24-hour urine collections 
were extracted by solid phase extraction and hydrolysis of conjugates and 
formation of their methoxime-trimethylsilyl derivatives, as previously described 
(Stimson et al., 2014). Analytes were quantified by GC-MS/MS spectrometry, as 
previously described (Andrew et al., 1998). Extraction and mass spectral analysis 
was performed by Alison Rutter (Research Technician). 
In Chapters 4-6, glucocorticoids were quantified by LC-MS/MS. In Chapter 4 
maternal and cord glucocorticoids (cortisol, cortisone, corticosterone and 11-
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dehydrocorticosteone) were extracted from plasma by liquid-liquid extraction, by 
George Just (Mass Spectrometry Core Lab Manager). In Chapter 5, maternal 
glucocorticoids (cortisol, cortisone, corticosterone and 11-dehydrocorticosterone) 
were extracted from serum via supported liquid extraction (SLE). In Chapter 6, 
endogenous glucocorticoids (cortisol, cortisone, corticosterone and 11-
dehydrocorticosterone) and exogenous tracer glucocorticoids (D4-Cortisol, D3-
Cortisone and D3-Cortisol) were extracted from placental tissue and perfusate 
via solid-phase extraction. Details of the extraction procedures and mass spectral 
conditions are included in the relevant chapters. 
 
2.5.5 Coolens’ Equation 
In Chapter 3, estimated free cortisol was calculated using Coolens’ equation 
(Coolens et al., 1987), which uses total cortisol and CBG levels. Unbound 
cortisol is represented by U (μM), molar concentration of total cortisol in by C 
(μM), proportion of albumin-bound cortisol by N, and the affinity of CBG for 
cortisol at 37 oC by K. As precise albumin levels were unavailable, a value for K 
can be assumed as 3x10-7 M-1, and a value for N to be 1.74. The following 
equation can be used: 
! =  !! + 0.0122! − ! 
Where Z = 0.0167 + 0.182 (T-C) μM.  
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2.6 Materials  
2.6.1 General Chemicals  






Sex hormone binding globulin ELISA 
Demeditec 
Saliva cortisol ELISA (saliva) Salimetrics 
Saliva cortisol ELISA (Interstitial fluid) IBL 
Cortisol RIA DIASource 





VWR Chemicals, Boh Prolabo 








D4-cortisol QMX Laboratories 
D3-cortisol Cambridge Isotope Laboratories 
Calcium chloride + 2H2O 
Sodium phosphate dibasic dehydrate 
BDH Analytical Chemicals 







2.4.2 Equipment  
Equipment Manufacturer 
MTS 4 Microtitre Shaker IKA®  
Stuart ® Roller Mixer SRt6 Cole Palmer 
LabSystems Multiskan EX Original 
Plate Reader 
ThermoFisher Scientific 
Heraeus™ Megafuge™ 16 Centrifuge 
Series 
ThermoFisher Scientific 
LKB Wallax 1261 Multigamma 
Gamma Counter 
Pharmacia 
SPE Dry 96 Dual, Argonaut Biotage 
Dri-Block DB 3A Techne 
IST VacMaster 96 Biotage 
Collection device tubing Cole Parmer 
3M Tegaderm Dressing Bunzl Healthcare 
MD 66 Linear Catheter 
T1 Perfusion Fluid 
Pump Syringe 
Pump Battery 
MD 107 Pump 
Linton 
Red Tubing Adapeters 
FEP Tubing 
MAB 8 Connector 
Royem Scientific 
IP300 Printer Brady® 
Blunt needles (14G, 19G) OctoInkjet 
Polysorb 4-0 Suture Coviden 
Surgical instruments Sigma 
Parafilm ® Bemis Na 
Waterbath Grant 
Peristaltic pump Watson Marlow 
Peristaltic pump tubing Elkway 
2mm tubing Portex ® 
Gas 
95% air + 5% CO2 
95% N2 + 5% CO2 
BOC 







MasterPlex® Readerfit MairiBio Hitachie Solutions America, 
Ltd 




SPSS v21 IBM 
Prism v7.0 GraphPad 





2.4.4 Buffer Solution  
The following solution was prepared with Milli-Q water in Chapter 6.  
Earle’s Bicarbonate Buffer (EBB): 5 mmol l-1 glucose, 1.8 mmol l-1 CaCl2, 0.4 
mmol l-1 MgSO4, 116.4 mmol l-1 NaCl, 5.4 mmol l-1 KCl, 26.2 mmol l-1, 
NaHCO3, 0.9 mmol l-1 NaH2PO4 
 
2.6 Statistical Analysis  
Normal distribution of data was assessed visually using histograms. Data that 
were not normally distributed were normalized with the natural log 
transformation. Correlations of normally distributed variables were analysed 
using the Pearson correlation.   
Adjustments for confounding factors (specified in text when describing relevant 
analysis) were performed using linear regression. Details of statistical methods 
used for each experimental paradigm are detailed in the results chapters 
(Chapters 3-6). 
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Data in text are presented as mean (± SD), and data on figures are presented as 
mean (± SEM). Statistical significant was considered at p<0.05. Analysis was 
performed using SPSS v21 (IBM, New York, USA) and figures were prepared 





Adrenal Axis Activity in Very Severely Obese 
Pregnancy: associations with birthweight and 
gestation at delivery 
The following materials have been published in Psychoneuroendocrinology in 
2016 (Stirrat et al., 2016) under the same title by Laura I Stirrat (LS), Dr James R 
O’Reilly (JR), Dr Sarah M Barr (SB), Professor Ruth Andrew (RA), Dr Simon C 
Riley (SR), Dr Alexander F Howie (AF), Maria Bowman (MB), Professor Roger 
Smith (RS), Dr John G Lewis (JL), Dr Fiona C Denison (FD), Dr Shareen Forbes 
(SF), Professor Jonathan R Seckl (JS), Professor Brian R Walker (BW), 
Professor Jane E Norman (JN) and Professor Rebecca M Reynolds (RR). All 
participants were cared for by RR, FD, SF and JN. LS conducted laboratory 
analyses of cortisol estradiol, estriol, progesterone, sex hormone binding globulin 
(SHBG), collated and analysed all data. JR conducted cortisol laboratory 
analyses. MB and RS conducted CRH assays. JL conducted CBG assays. SB 
conducted the study from which urine samples were obtained. LS prepared the 
first draft of the manuscript under the guidance of RR. All authors provided 
critical insight for the manuscript.  
In summary, this work demonstrated that severely obese pregnant women had 
significantly lower levels of circulating cortisol, CRH, CBG, estradiol, 
progesterone and SHBG compared with lean pregnant women. Total urinary 
glucocorticoid metabolites increased significantly in lean pregnancy, but not in 
obese. Lower maternal cortisol in obese tended to be associated with increased 
birthweight, and lower CRH was a significant predictor of longer gestational 
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length. This work concluded that lower maternal cortisol without an increase in 
urinary glucocorticoid clearance may indicate a lesser activation of the HPA axis 
than in lean pregnancy and that this may offer a novel mechanism underlying 







Background: The maternal HPA axis undergoes dramatic activation during 
pregnancy. Increased cortisol and CRH associate with low birthweight and 
preterm labour. In non-pregnant obesity, the HPA axis is activated but circulating 
cortisol levels are normal or lower than in lean women. We hypothesized that 
maternal cortisol levels would be lower in obese pregnancy, and would associate 
with increased fetal size and gestation at delivery.  
Method: Fasting serum cortisol was measured at 16, 28 and 36 weeks gestation 
and at 3-6 months postpartum in 276 severely obese and 135 lean women. In a 
subset of obese (n=20) and lean (n=20) we measured CRH, hormones that 
regulate bioavailable cortisol (corticosteroid-binding-globulin, estradiol, estriol, 
progesterone). Urinary glucocorticoid metabolites were measured in pregnant 
(obese n=6, lean n=5) and non-pregnant (obese n=7, lean n=7) subjects. 
Results: Maternal cortisol and HPA axis hormones were lower in obese 
pregnancy. Total urinary glucocorticoid metabolites increased significantly in 
lean pregnancy, but not in obese. Lower maternal cortisol in obese tended to be 
associated with increased birthweight (r=-0.13, p=0.066). In obese, CRH at 28 
weeks correlated inversely with gestational length (r=-0.49, p=0.04), and 
independently predicted gestational length after adjustment for confounding 
factors (mean decrease in CRH of -0.25 pmol/L (95% CI -0.45 to -0.043 pmol/L) 
per day increase in gestation).  
Conclusion: In obese pregnancy, lower maternal cortisol without an increase in 
urinary glucocorticoid clearance may indicate a lesser activation of the HPA axis 
than in lean pregnancy. This may offer a novel mechanism underlying increased 
birthweight and longer gestation in obese pregnancy.   
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3.2 Introduction 
There has been a global rise in obesity in the last three decades (Ng et al., 2014). 
Around 64% of women of reproductive age in the United States are overweight 
and 35% are obese (Flegal et al., 2012) with a similar pattern in Europe 
(Heslehurst et al., 2010, Fitzsimons et al., 2010). There is a strong temporal 
gradient of increasing risk of adverse outcomes with increasing maternal body 
mass index (BMI; kg/m2) (Denison et al., 2008, Denison et al., 2014) including 
increased birthweight (Ehrenberg et al., 2004) with associated cardiovascular 
disease in adulthood (Ornoy, 2011), prolonged pregnancy (Caughey et al., 2009) 
and stillbirth (Chu et al., 2007). Mechanisms underlying the links between 
maternal obesity and adverse pregnancy outcomes are unknown.  
Glucocorticoids are vital for fetal growth and organ maturation, but fetal over-
exposure to cortisol is associated with intrauterine growth restriction (Stewart et 
al., 1995), and increased cardiovascular risk in later life (Reynolds, 2013). 
During pregnancy, the maternal HPA axis is activated, resulting in an 
exponential increase in the maternal circulating levels of cortisol and CRH 
(Duthie and Reynolds, 2013). A number of endocrine changes contribute to the 
increase in total cortisol levels. The placenta releases CRH from the second 
trimester (~16 weeks gestation) onwards leading to a complex feed-forward loop, 
with placental CRH activating the maternal HPA axis, which generates cortisol, 
and maternal cortisol simultaneously stimulates placental CRH synthesis, thus 
further increasing cortisol levels (Jung et al., 2011). Increased hepatic synthesis 
of CBG (the predominant binding protein of cortisol) during pregnancy, driven 
by estrogen stimulation (Mazer, 2004), is considered to contribute to the rise in 
maternal total cortisol (Jung et al., 2011). Rising levels of progesterone, which 
displaces cortisol from CBG, may also contribute to excess of free, bioavailable 
cortisol (MacLaughlin et al., 1972). Pregnancy is associated with increased 
cortisol clearance (via hepatic metabolism and urinary excretion), suggesting that 
in addition to elevated CRH and CBG, an overall increase in maternal HPA axis 
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activity contributes to the increase in total maternal cortisol with advancing 
gestation (Jung et al., 2011). The HPA axis is thought to play a key role in 
governing the length of gestation and triggering the onset of parturition. High 
maternal circulating CRH at 31-33 weeks gestation is associated with preterm 
labour (< 37 weeks), and low levels with post-term pregnancy (> 41 weeks) 
(Sandman et al., 2006, Wadhwa et al., 2004). It is not known whether maternal 
CRH is altered in obese pregnancy, or whether these alterations influence the 
duration of pregnancy.  
Non-pregnant obesity is also associated with activation of the HPA axis, and also 
with increased clearance of cortisol (Marin et al., 1992) leading to normal or 
lower levels of total circulating cortisol (Praveen et al., 2011). Further, increased 
BMI has been negatively correlated with awakening cortisol levels (Champaneri 
et al., 2013). Preliminary evidence from two recent studies of obese pregnant 
women suggests that the HPA axis changes in non-pregnant obesity may be 
maintained during obese pregnancy. Obese women (BMI ≥ 30 kg/m2) in early 
pregnancy were found to have lower morning salivary cortisol (Aubuchon-
Endsley et al., 2014), and lower total cortisol (Luiza et al., 2015) than pregnant 
women with a normal BMI.  
To our knowledge, there are no reports of HPA axis hormones and their 
association with clinical outcomes in very severely obese (BMI ≥ 40 kg/m2) 
pregnant women. We therefore aimed to measure total morning cortisol levels in 
very severely obese (grade 3 obesity, BMI ≥ 40 kg/m2) pregnant women and a 
lean control group (BMI < 25 kg/m2). In sub-studies we further characterized the 
HPA axis in obese pregnancy to identify potential underlying mechanisms for the 
predicted lower maternal cortisol in obese pregnancy. We hypothesized that 
maternal CRH and factors that may reduce (CBG, estradiol) or increase 
(progesterone) free cortisol levels would be altered in obese pregnancy, in favour 
of lowering maternal cortisol, and that urinary glucocorticoid metabolites would 
be increased in obese pregnant women, in-keeping with increased HPA axis 
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activity, similar to non-pregnant obesity. Finally to test the hypothesis that 
reduced fetal glucocorticoid exposure in obese pregnancy would contribute to 
higher birthweight and longer gestation we explored associations with clinical 




We recruited 286 severely obese and 137 lean pregnant women with singleton 
pregnancies to a longitudinal study of obesity in pregnancy (Hormones in 
Pregnancy; HIP). Eligible women had a singleton pregnancy and a normal 
booking ultrasound scan. Women who used regular glucocorticoid medication 
during pregnancy (obese n=7, lean n=1) or received antenatal steroids for 
suspected preterm delivery were excluded (obese n=3, lean n=1), resulting in a 
final dataset of 276 obese and 135 lean women. Ethical approval and written 
informed consent were obtained. Participants reported demographic information 
on questionnaires and attended for study visits at 16 weeks, 28 weeks, and 36 
weeks gestation and between 3 and 6 months postpartum. At each study visit, 
fasting morning blood samples were obtained between 08.30h and 09.30h. At the 
first study visit, a subset of women (obese n=14, lean n=38) collected three 
saliva samples for analysis of cortisol, to assess the cortisol awakening response, 
using a Salivette® collector (Sarstedt, Numbrecht, Germany); samples were 
collected at bedtime, at waking, and 30-minutes after waking, and were stored at 
-80 oC until analysis.  
A separate cohort of women provided 24-hour urine collections for analysis of 
glucocorticoid metabolites. Obese and lean pregnant women provided collections 
at 19 weeks and 36 weeks gestation, and non-pregnant obese and lean controls 
provided one collection (obese pregnant n=6, obese non-pregnant n=7, lean 
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pregnant n=5, lean non-pregnant n=7). Groups are referred to as LNP (lean non-
pregnant), ONP (obese non-pregnant), LP1 (lean pregnant visit 1, approximately 
19 weeks gestation), LP2 (lean pregnant visit 2, approximately 36 weeks 
gestation), OP1 (obese pregnant visit 1, approximately 19 weeks gestation) and 
OP2 (obese pregnant visit 2, approximately 36 weeks gestation). Total urine 
volume was recorded and stored in 20 mL aliquots at -80 oC until analysis. 
Eligible women were aged between 18-45 years and were Caucasian. Exclusion 
criteria were diabetes, active endocrine disorders, use of glucocorticoid 
medications or multiple pregnancy.  
Clinical outcomes were extracted from medical records. Macrosomia was 
defined as a birthweight ≥ 4000 g at term (≥ 37 weeks). Low birthweight was 
defined as ≤ 2500 g.  
 
3.3.2 Laboratory Methods 
Commercially available radioimmunoassay kits were used for the analysis of 
total serum cortisol (ImmuChem Cortisol
125
I; ICN Biomedicals, CA, USA; inter-
assay CV 7.6%). We measured CBG, CRH, estradiol, estriol, progesterone and 
SHBG in plasma samples from a subset of the HIP study cohort (obese n=20, 
lean n=20). CBG was measured by ELISA as described by Lewis et al., (Lewis 
and Elder, 2013); this included ‘total’ CBG and ‘intact’ CBG (which has binding 
affinity for cortisol). ‘Cleaved’ CBG (which lacks binding affinity for cortisol) 
was then calculated as a ratio of total:intact CBG. Free cortisol was calculated 
when both cortisol and CBG measurements were available using Coolens’ 
equation (Coolens et al., 1987), which uses total cortisol and CBG levels. CRH 
was measured by extracted radioimmunoassay as described by Smith et al., 
(Smith R, 2009). ELISA kits were used to measure total estradiol (Demeditec 
DE2693; inter-assay CV 6.72-9.39%), total estriol (Demeditec DE3717; inter-
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assay CV ≤10%) total progesterone (Demeditec DE1561; inter-assay CV 5.4-
6.99%), and SHBG (Demeditec DE2996; inter-assay CV 3.1-8.0%).  
Urine glucocorticoid metabolites were quantified in 24-hour urine collections by 
gas chromatography electron impact tandem mass spectrometry following solid 
phase extraction hydrolysis of conjugates and formation of their methoxime-
trimethylsilyl derivatives, as previously described (Stimson et al., 2014). 
Metabolites included urinary free cortisol and its metabolites (5β-
tetrahydrocortisol (THF), 5α-tetrahydrocortisol (α-THF), α-cortol, and β-cortol); 
and urinary cortisone and its metabolites (tetrahydrocortisone (THE), α-
cortolone, β-cortolone). We measured the sum of total glucocorticoid metabolites 
(THF, α-THF, THE, α-cortol, β-cortol, α-cortolone, β-cortolone), as a measure 
of total cortisol production. The ratio of cortisol:cortisone were examined as a 
marker of 11beta-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) enzyme 
activity, which converts active cortisol into inactive cortisone; the ratio of α-
THF:cortisol as a measure of 5α-reductase activity, which metabolises cortisol to 
α-THF; and the ratio of (THF+α-THF):THE as an indicator of the balance of 
whole-body 11beta-hydroxysteroid dehydrogenase enzyme activities (11β-HSD1 
and 11β-HSD2 activity (Andrew et al., 1998). 
 
3.3.3 Statistical Analysis 
Data distribution was assessed for normality by visually assessing histograms. 
Data that were not normally distributed were normalized using the natural-log 
transformation. The independent t-test was used to test for differences between 
continuous variables and the chi-squared test for categorical variables. Repeated 
measures analysis of variance (ANOVA) was used to compare the pattern of 
change in hormones with advancing gestation between obese and lean. 
Correlations between HPA axis hormones with birthweight and gestation at 
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delivery were tested and regression analysis used to adjust for confounding 
factors, including smoking status, baby gender, and gestational age at delivery. 
Analysis was performed using SPSS v20 (IBM). Data in text are mean ± (sd), 
and data in figures are mean ± SEM. Statistical significance was considered at 
p<0.05. 
Power calculations:  A formal sample size calculation was not performed for 
either cohort. We aimed to generate data for over 200 very severely obese and 
100 lean control women for the HIP study. Post-hoc power calculations using 
G*Power3.1 software (Faul et al., 2009) showed that a sample size of n=462 was 
required for 80% power to demonstrate an inverse correlation between cortisol 
and birthweight at the 5% significance level. 
 
 
3.4 Results  
3.4.1 Demographics 
Table 3-1 shows characteristics of the 276 obese and 135 lean women and their 
babies. Obese women were younger than lean, had greater social deprivation (P, 
2004), were of higher parity and were more likely to smoke. Appendix Table 3-
1 shows characteristics of women included in the subset of obese (n=20) and lean 
(n=20) for analysis of CBG and sex steroids; and Appendix Table 3-2 shows 







Obese (n=276) Lean (n=135) p-Value  
Age (years) 31.2 (5.3) 33.0 (4.6) <0.001 
BMI (kg/m2) 44.0 (4.0) 22.7 (1.7) < 0.001 
Parity n (%) 
- Prim 
- Para 1 


































Smoking Status n (%) 
- Never Smoked 
- Ex-smoker 












Labour onset Mode n (%) 
- Spontaneous 
- Induced 











Mode of Delivery n (%) 
- Spontaneous vertex delivery 
- Assisted vaginal delivery 
- Emergency Caesarean section 














Medical Complications n (%) 
- Gestational diabetes 
- Pre-eclampsia 













 TERM BABIES (≥ 37 weeks) Obese (n=262) Lean (n=132) p-value 
Baby Sex 
- Male n (%) 









Gestational age at delivery (days) 280.4 (8.6) 282.5 (8.3) 0.02 
Birthweight (g) 3629.1 (531.8) 3571.6 (498.4) 0.30 
Macrosomia (>4000g) 
- Yes n (%) 










Low birth weight (<2500g) 







Weight at 3months of age (kg) 3583.0 (580.6) 3554.0 (507.6) 0.62 
PRETERM BABIES  
(< 37 weeks) 
Obese (n=14) Lean (n=3) p-value 
Birthweight (g) 2721.1 (780.6) 2776.7 (257.9) 0.91 











Gestational age at delivery (days) 250.4 (14.5) 256.3 (1.5) 0.91 
Table 3-1. Maternal and Neonatal Characteristics 
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Table 3-1. (cont.) 
Parity was defined as ‘prim’ (no previous pregnancies delivered after 24 weeks), 
‘para 1’ (one previous delivery after 24 weeks gestation) and ‘para ≥ 2’ (two or 
more previous deliveries after 24 weeks gestation). Socioeconomic status was 
measured using deprivation category (DepCat) scores based on postcode (P, 
2004). DepCat score 1-3 represents the least deprived; score 4+ represents the 
most deprived. DepCat information was unavailable for 1 obese woman. 
‘Smokers’ were defined as those who considered themselves as current smokers. 
Term babies characteristics excludes those who were exposed to antenatal 
glucocorticoids. Missing data: smoking status (obese n=2), labour onset mode 
(obese n=4), mode of delivery (obese n=3). Data are mean (sd) or N (%). 
 
3.4.2 Gestational Changes in HPA Axis Hormones 
3.4.2.1 Cortisol and CBG Levels are Lower in Obese Pregnancy 
Total serum cortisol concentrations were higher in pregnancy than in non-
pregnancy in obese and lean women but were significantly lower in obese than in 
lean at each time-point during pregnancy and postpartum (Figure 3-1a). The 
diurnal pattern of cortisol measured from saliva cortisol (peak cortisol levels on 
waking) was maintained in both obese and lean women (Figure 3-1b). Obese 
women had apparent ‘blunting’ of the cortisol awakening response with 
significantly lower cortisol levels in samples collected at 30-minutes after 
waking than in lean women. Bedtime and waking saliva cortisol did not differ 
between obese and lean. Mean total cortisol at 16 weeks gestation did not differ 
according to maternal age, social class, parity or smoking status during 
pregnancy (data not shown). There were no differences in cortisol levels at any 
time according to gestational diabetes or pre-eclampsia status (data not shown). 
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Total and intact CBG rose similarly throughout pregnancy in both lean and obese 
women (Figure 3-2). Total CBG levels were significantly lower in obese 
compared with lean women at 28 weeks and postpartum. Intact CBG did not 
differ between obese and lean at any time-point, and cleaved CBG was 
significantly lower in obese postpartum. Free cortisol levels calculated using 
intact CBG values were significantly lower in obese than in lean at 28 and 36 
weeks, while free cortisol calculated using total CBG was lower in obese 
compared with lean at 36 weeks (Table 3-2). Although absolute levels of free 
cortisol calculated with intact CBG levels appeared higher than levels calculated 
using total CBG values, this was not statistically significant.  
 
Figure 3-1. Total Serum Cortisol (3-1a) and Saliva Cortisol (3-1b) 
Total serum cortisol was significantly lower in obese than lean at 16 weeks 
(p=0.02), 28 weeks (p=0.003), 36 weeks (p=0.001) and postnatally (p=0.01). 
Pattern of cortisol change in pregnancy was similar in obese and lean (p=0.79) 
Diurnal rhythm was maintained in saliva cortisol profiles similarly in obese and 






































(p=0.02). Data are mean (sem); *p<0.05, **p≤0.01, ***p≤0.0001. Sample size 
obese (n=276), lean (n=135). 
 
Figure 3-2a-c. Total corticosteroid binding globulin (CBG) (3-2a), Intact 
CBG (3-2b) and Cleaved CBG (3-2c) 
The patterns of change throughout pregnancy were similar in obese and lean for 
total CBG (p=0.66), intact CBG (p=0.35) and cleaved CBG (p=0.64). Total CBG 
was significantly lower in obese at 28 weeks (p=0.005) and postnatal (p=0.003). 
Cleaved CBG was significantly lower postpartum (p=0.003). Intact CBG did not 












































differ significantly between obese and lean. Data are mean (sem); *p<0.05, 
**p≤0.01. Samples size obese (n=20), lean (n=20).  
 
 
Free Cortisol (nmol/L) Obese (n=20) Lean (n=20) p-Value 
Calculated with Total CBG 
16 weeks 
28 weeks 






































Table 3-2 Free Cortisol calculated using total and intact CBG levels. 
Data are mean (sd).  
 
 
3.4.2.2 In Obese Pregnancy, Hormones Regulating Cortisol Levels are 
Lower 
CRH concentrations rose throughout pregnancy. The greatest increase was 
between 28 and 36 weeks, but the rise was less marked in obese women (Figure 
3-3a). CRH levels were significantly lower in obese women at 28 weeks (obese 
42.2 ± 26.7 pmol/L, lean 25.2 ± 17.1 pmol/L; p=0.02) with a similar trend at 36 
weeks (obese 316.1 ± 244.4 pmol/L, lean 193.7 ± 141.1 pmol/L; p=0.06). 
Estradiol, estriol and progesterone concentrations all rose throughout pregnancy, 
but the rise was less marked in obese women (Figure 3-3b). Estradiol (Figure 3-
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3b) and estriol (Figure 3-3c) were significantly lower in obese compared with 
lean at 28 and 36 weeks while progesterone (Figure 3-3d) was significantly 
lower in obese throughout pregnancy. SHBG concentrations rose throughout 
pregnancy, and were not different in lean and obese pregnant women during 








Figure 3-3a-d. Corticotrophin releasing hormone (CRH) (3a), estradiol (3b), 




























































Figure 3-3a-d. (cont.) 
The pattern of rise was significantly different between lean and obese in CRH 
(p=0.025), estradiol (p<0.0001), estriol (p=0.001) and progesterone (p<0.0001). 
CRH was significantly lower in obese at 28 weeks (p=0.02) with a trend at 36 
weeks (p=0.06). Total estradiol was significantly lower in obese at 28 weeks 
(p<0.0001) and 36 weeks (p=0.025). Total estriol was significantly lower in 
obese at 28 weeks (p=0.002) and 36 weeks (p=0.01). Total progesterone was 
significantly lower in obese women at 16 weeks (p=0.001), 28 weeks 
(p<0.0001), 36 weeks (p=0.001) but not post-partum. (p=0.67). SHBG was 
significantly lower in obese post-partum (p=0.019). Data are mean (sem); 
*p<0.05, **p≤0.01, ***p≤0.0001. Sample size obese (n=20), lean (n=20). 
 
 
3.4.2.3 Urine Glucocorticoid Metabolites are not Increased in Obese 
Pregnancy Compared with Non-Pregnancy 
Total urinary glucocorticoid metabolites were significantly higher in obese non-
pregnant than in lean non-pregnant women (consistent with increased HPA axis 
activity and cortisol production; Figure 3-4a). In lean, total glucocorticoid 
metabolites were significantly higher at LP1 and LP2 compared to LNP. In 
contrast in obese, total glucocorticoid metabolites were similar during pregnancy 
and in non-pregnancy. There was a similar pattern of findings with urinary free 
cortisol (Figure 3-4b) free cortisone (Figure 3-4c), total cortisol metabolites 
(Figure 3-4d) and total cortisone metabolites (Figure 3-4e), with higher levels in 
lean pregnant compared with LNP and no significant change in obese pregnant 
compared to ONP.  
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The ratios of cortisol:cortisone (Figure 3-4f) and THFs:THE (Figure 3-4g) 
decreased with advancing gestation in lean pregnant compared to LNP consistent 
with increasing conversion of cortisol to cortisone (by whole-body 11β-HSD2), 
and/or decreasing regeneration of cortisol from cortisone (by 11β-HSD1). 
Neither ratio changed significantly during pregnancy in obese women.   
The ratio of α-THF:cortisol was higher in ONP compared to LNP women 
(Figure 3-4h). In keeping with this, levels of αTHF were significantly higher in 
ONP compared with LNP, and were higher at LP1 and LP2 compared to LNP 
women (data not shown). Taken together, these data suggest that metabolism of 
cortisol to α-THF (by 5α-reductase) is higher in LNP compared to ONP women, 
and that such metabolism increases in lean women with advancing gestation. The 
opposite pattern was observed in obese; with a lower ratio of α-THF:cortisol and 
lower levels of α-THF in obese pregnant compared to ONP, suggesting that 
metabolism of cortisol to α-THF (by 5α-reductase) is blunted in obese 
pregnancy.  
The ratio of THE:cortisone was lower in LNP compared to ONP women, and 
was lower at LP1 and LP2 compared to LNP women (Figure 3-4i). There were 
no significant changes in the obese with advancing gestation. This suggests 
metabolism of cortisone to THE (by 5β-reductase) increases with advancing 
gestation in lean women, but may be blunted in obese women during pregnancy.  
The ratios of cortisol:cortisone (3-4f), THFs:THE (3-4g), αTHF:cortisol (3-4h) 
and THF:cortisone (3-4i) decreased in lean with advancing gestation, but not in 
obese, suggesting that activities of 11β-HSD2, 11β-HSD1, 5α-reductase and 5β-



















































































































































Figure 3-4a-n Urine Glucocorticoid Metabolites  
 (3-4a-e) Total glucocorticoid metabolites, urinary free cortisol, urinary free 
cortisone, total cortisol metabolites and total cortisone metabolites increased 
during pregnancy in lean (*), but not in obese. The ratios of cortisol:cortisone (3-
4f), THFs:THE (3-4g), αTHF:cortisol (3-4h) and THF:cortisone (3-4i) decreased 
in lean with advancing gestation, but not in obese. Data are mean (sem); 
*p<0.05, **p≤0.01, ***p≤0.0001. Sample size LNP (n=7), ONP (n=7), LP (n=5) 
and OP (n-7).  
Key: LNP (lean non-pregnant), ONP (obese non-pregnant), LP1 (lean pregnant 
visit 1, approximately 19 weeks gestation), LP2 (lean pregnant visit 2, 
approximately 36 weeks gestation), OP1 (obese pregnant visit 1, approximately 
19 weeks gestation), OP2 (obese pregnant visit 2, approximately 36 weeks 
gestation), THF (5β-tetrahydrocortisol), α-THF (5α-tetrahydrocortisol), THE 
(tetrahydrocortisone), 11β-HSD1 (11beta-hydroxysteroid-dehydrogenase-type 1) 
and 11β-HSD2 (11beta-hydroxysteroid-dehydrogenase-type 2). 
 
 
3.4.3 Associations of HPA Axis Hormones with Birthweight and Gestation at 
Delivery 
Birthweight did not differ between lean and obese in the unadjusted analysis 
(Table 3-1), but was significantly higher in obese after adjustment for gestation 
at delivery, sex of baby, maternal age and smoking status (β=0.102, p=0.03). In 
lean women, increased cortisol at 16 weeks was positively associated with 
birthweight in unadjusted analysis though this was not significant after adjusting 
for smoking status, DepCat score, gestational age at delivery and baby gender 
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(r=0.19, p=0.032, pa=0.10). In contrast, in the obese there was a weak negative 
correlation between lower cortisol at 16 weeks and higher birthweight, though 
this was not significant in adjusted analyses (r=-0.13, p=0.066, pa=0.33). Cortisol 
at 28 weeks was lower in lean women with macrosomic babies compared to 
appropriate for gestational age babies (1760 ± 729 nmol/L vs 2551 ± 4228 
nmol/L; p=0.048), but did not differ in obese women with macrosomic babies, or 
in women with low birthweight babies. CRH did not correlate with birthweight 
in lean or obese. 
Obese women delivered at an earlier gestation than lean women (Table 3-1) due 
to a higher proportion of elective Caesarean deliveries (obese 17.8% vs. lean 
5.9%; p<0.0001), as there were more previous Caesarean sections (obese 49.4% 
vs lean 28.6%; p=0.01). A higher rate of medical complications in obese women 
meant that there was a higher rate of induction of labour before 40 weeks (obese 
30.2% vs. lean 17.6%; p<0.0001). In women who did not undergo early 
iatrogenic delivery before 40 weeks the mean gestation was not significantly 
different between lean and obese (lean 283 ± 8 days, obese 282 ± 11 days; 
p=0.53). In obese, there was an inverse correlation between CRH at 28 weeks 
and gestational length (r=-0.49, p=0.04). After adjusting for maternal smoking 
and mode of delivery, this remained significant as an independent predictor of 
gestation at delivery (mean decrease in CRH of -0.25 pmol/L (95% CI -0.45 to -
0.043 pmol/L) per day increase in gestation). Cortisol did not associate with 
gestational age at delivery in lean or obese.  
 
3.5 Discussion 
Our findings demonstrated lower fasting morning cortisol levels in very severely 
obese women throughout pregnancy compared with a lean control group; a 
pattern similar to non-pregnant severe obesity (Champaneri et al., 2013). The 
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lack of an increase in urinary clearance of glucocorticoids during pregnancy in 
obese women suggests that in contrast to non-pregnant obesity (Marin et al., 
1992, Strain et al., 1980), the activation of the HPA axis, which normally occurs 
during pregnancy (Duthie and Reynolds, 2013, Lindsay and Nieman, 2005) was 
blunted in these very severely obese pregnant women. Further, the apparent 
‘blunting’ of the cortisol awakening response we observed in obese pregnant 
women would also support the notion that obese pregnant women have lower 
production of cortisol. Our exploratory analysis suggests this HPA axis 
dysregulation may contribute to complications of obese pregnancy including 
higher birthweight and prolonged gestation.  
Our observation that hormones regulating circulating cortisol levels including 
CBG, CRH and estrogens were also lower in obese pregnancy suggests these 
may contribute to the lower maternal cortisol in obese pregnant compared to lean 
pregnant women. CRH was lower in obese pregnant compared to lean pregnant 
women. The positive feedback loop between glucocorticoids and placental CRH 
(King et al., 2001) raises the question of whether lower cortisol in obese was a 
cause or consequence of lower CRH. Elevated maternal total cortisol at 15 weeks 
is predictive of a subsequent surge in placental CRH at 31 weeks in women who 
deliver preterm (Sandman et al., 2006). This would support lower cortisol levels 
in very severely obese pregnancy at an earlier gestation as the driving factor for 
the lower CRH we observed later in pregnancy in obese. Alternatively, if lower 
cortisol in obese pregnancy is a consequence of lower placental CRH; a 
relatively reduced drive on the maternal HPA axis (as a result of lower placental 
CRH) may result in lower production of ACTH from the pituitary gland, and 
thus lower cortisol production.  
Our observations of lower progesterone and estrogen levels in very severe obese 
pregnancy may not be due to altered SHBG levels, which did not differ between 
lean and obese during pregnancy. Further, our data are consistent with recent 
observations in less severely obese pregnant women (Lassance et al., 2015), 
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where it was proposed that impaired mitochondrial function in the placentas of 
obese pregnant women limits placental sex steroid biosynthesis. Cortisol is not 
considered to be synthesised in the placenta, so it is unlikely that this contributes 
to the lower cortisol we found in very severely obese pregnancy. In contrast to 
our findings of lower cortisol and lower estrogen in very severely obese pregnant 
women, a small study in postmenopausal women suggested that higher estrogen 
levels may magnify the negative feedback of cortisol on the HPA axis in 
postmenopausal women, leading to lower cortisol levels (Sharma et al., 2014). 
To the best of our knowledge, there are no other data describing the effects of 
estrogen on cortisol in severely obese pregnant women. Evidence from in vitro 
studies would suggest that lower progesterone and estrogen may limit CRH 
production (Ni et al., 2002, Ni et al., 2004), which in turn could reduce total 
cortisol levels.  
The measurements of total and intact CBG allowed us to calculate free, 
bioavailable cortisol levels, which were also lower in obese pregnant women. 
The reason for the lesser rise in total CBG in obese women is unknown, but 
likely reflects the lower estrogen levels we observed (Jung et al., 2011). Other 
factors that may alter CBG levels include altered metabolic, inflammatory or 
genetic factors. The very severely obese women in our cohort had higher levels 
of insulin, inflammatory markers and liver enzymes than the lean women (Forbes 
et al., 2015); all factors which would be anticipated to increase CBG levels. 
However, as we have previously demonstrated that very severely obese women 
failed to accumulate hepatic fat during pregnancy, we can speculate that the 
associated improvement in hepatic insulin sensitivity may also drive a reduction 
in CBG synthesis in very severely obese pregnancy. Although it has been 
suggested that the placenta synthesises CBG (Misao et al., 1999), whether this 
differs in obese and lean placental tissue is not known. Our recent observation 
that morning cortisol levels are genetically determined through cortisol binding 
to CBG (Bolton et al., 2014) implies a further mechanism for regulation of 
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maternal and fetal glucocorticoid exposure, which requires further exploration. 
Alternatively, if CRH is the primary driving force mediating cortisol levels, the 
lower CBG may be a mechanism by which the maternal liver balances regulation 
of fetal cortisol exposure and the normal physiological roles of cortisol in the 
mother. 
The lack of rise in urinary total glucocorticoid metabolites, free cortisol, free 
cortisone, total cortisol metabolites and total cortisone metabolites in obese 
pregnant compared to lean pregnant women is consistent with decreased activity 
of the HPA axis in obese pregnancy, resulting in lower production of cortisol. 
This contrasts to the findings in the lean where total urinary glucocorticoid 
metabolite excretion increased with advancing gestation, paralleling the rising 
circulating cortisol levels, and also contrasts to non-pregnant obesity where 
urinary glucocorticoid clearance is increased compared to lean controls. Further, 
our data suggests that the changes in activity of whole-body 11β-HSD2, 11β-
HSD1, 5α-reductase and 5β-reductase enzymes may be blunted in obese 
pregnant compared to lean pregnant women. These preliminary data would 
suggest that the lower circulating levels of cortisol in obese cannot be explained 
by increased metabolism or clearance of cortisol. Further studies are needed to 
explore this, and to investigate possible alternative explanations for the apparent 
lack of increased clearance of cortisol which has been reported in non-pregnant 
obesity (Marin et al., 1992).  
Our data add to the emerging literature in humans that exposure to endogenous 
cortisol is a critical factor regulating growth and length of gestation (Duthie and 
Reynolds, 2013). In exploratory analyses we observed a weak inverse trend 
between lower cortisol at 16 weeks and higher birthweight in obese, as well as 
lower cortisol levels in lean women with macrosomic babies. Further, lower 
CRH at 28 weeks gestation in obese was also significant as an independent 
predictor of longer gestation. Although our study was under-powered to look at 
birth outcomes this is the first study to show that dysregulation of the HPA axis 
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may contribute to the complications of obese pregnancy including increased fetal 
size and prolonged gestation.  
Strengths of this study include the large sample size, which allowed for repeated 
measures of cortisol from blood in the same individual including in pregnancy 
and postpartum, the careful timing of morning samples and the detailed 
assessment of hormones controlling cortisol release. Further, the marked 
differences in BMI levels between the severely obese pregnant and lean pregnant 
groups meant our two groups were very different for comparison. A limitation is 
that total cortisol was measured by immunoassay, which has been reported to 
detect lower levels of cortisol during pregnancy, compared with liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) (Jung et al., 2011), 
however, we were still able to detect significant differences between the lean and 
obese study groups. Further limitations of the study are that we used Coolens’ 
equation (Coolens et al., 1987) to estimate free cortisol levels; this has been used 
in other studies of cortisol in pregnancy (LeWinn et al., 2009) but not validated. 
The single time-point sampling would not account for variation in cortisol levels 
caused by hormone oscillations. Studies investigating the ultradian rhythm 
generated by cortisol pulsatility are on-going.  Finally placental cortisol 
metabolism and transfer in obese pregnancy remain unknown and further studies 
are needed to understand more about the contribution of the placenta to maternal 
and fetal glucocorticoid exposure.  
In conclusion, our study suggests that there is dysregulation of the HPA axis in 
obese pregnancy resulting in lower circulating levels of cortisol and its 
regulatory hormones consistent with decreased HPA axis activity. Our 
preliminary data suggests this may contribute to some of the adverse 
complications of obese pregnancy, increased fetal size and prolonged pregnancy. 
A better understanding of the role of HPA axis dysregulation in adverse 
pregnancy outcomes may inform us which high-risk pregnancies should be 
targeted to improve the health of the pregnant woman and the developing baby.  
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3.6 Appendices 
Maternal Characteristics Obese (n=20) Lean 
(n=20) 
p-Value 
Age (years) 32.6 (5.2) 33.5 (3.0) 0.53 
BMI (kg/m2) 43.3 (4.1) 22.4 (1.8) <0.0001 
Parity n (%) 
- Primiparous 
- Para 1 























Appendix Table 3-1. Maternal Characteristics 
Parity was defined as ‘nulliparous’ (no previous pregnancies), ‘primiparous’ (no 
previous pregnancies delivered after 24 weeks), ‘para 1’ (one previous delivery 
after 24 weeks gestation) and ‘para ≥ 2’ (two or more previous deliveries after 24 
weeks gestation). ‘Smokers’ were defined as those who considered themselves as 











Maternal Characteristics ONP (n=7) LNP (n=7) OP (n=6) LP 
(n=5) 
P-value 
Age (years) 35.2 (5.3) 25.9 (2.0) 27.1 (4.1) 35.2 (1.9) <0.0001 
BMI (kg/m2) 40.8 (4.2) 22.6 (1.8) 42.1 (5.8) 27.1 (4.1) <0.0001 
Parity n (%) 
- Nulliparous 
- Primiparous 
- Para 1 










































Appendix Table 3-2. Maternal characteristics 
Parity was defined as ‘nulliparous’ (no previous pregnancies), ‘primiparous’ (no 
previous pregnancies delivered after 24 weeks), ‘para 1’ (one previous delivery 
after 24 weeks gestation) and ‘para ≥ 2’ (two or more previous deliveries after 24 
weeks gestation). ‘Smokers’ were defined as those who considered themselves as 
current smokers. Data are mean (sd) or N(%).  
Key: LNP (lean non-pregnant), ONP (obese non-pregnant), LP1 (lean pregnant 
visit 1, approximately 19 weeks gestation), LP2 (lean pregnant visit 2, 
approximately 36 weeks gestation), OP1 (obese pregnant visit 1, approximately 







3.7 Chapter Conclusion 
In support of the overarching hypothesis of this Thesis, the work presented in 
Chapter 3 suggests that the HPA axis is dysregulated and in fact decreased in 
maternal obesity. The findings of lower maternal cortisol in obese pregnancy, 
without an increase in total urinary glucocorticoids suggest that the lower 
circulating cortisol was not due increased urinary clearance. To further support 
the overarching hypothesis, in obese pregnancy lower maternal cortisol tended to 
associate with increased birthweight and lower maternal CRH associated with 
longer length of gestation. Decreased HPA axis activity in maternal obesity may 
be a novel mechanism underlying increased birthweight and longer gestation in 
this high-risk population.   
Chapter 3 laid the foundation for the subsequent chapters in this Thesis, which 
aimed to further characterise the HPA axis in obese pregnancy, and to identify 
potential underlying mechanisms for this dysregulation. Chapter 3 did not 
examine the time of delivery. In Chapter 4 this was investigated by studying 





Glucocorticoids are lower at delivery in 
maternal, but not in cord blood of obese 
pregnancies 
The following materials have been published in Scientific Research and Reports 
under the same title by Laura I Stirrat (LS), George Just (GJ), Natalie ZM Homer 
(NH), Ruth Andrew (RA), Jane E Norman (JN) and Rebecca M Reynolds (RR). 
LS designed the study, selected the samples, collated and analysed all data. GJ 
conducted the laboratory analysis with guidance from NH. LS prepared the first 
draft of the manuscript under the guidance of RR. All authors provided critical 
insight for the manuscript.  
In summary, this work demonstrated that at the time of delivery, active 
glucocorticoids cortisol and corticosterone were significantly higher in maternal 
than cord blood. Inactive versions were significantly higher in cord than maternal 
blood. Increased maternal BMI associated with lower maternal cortisol, 
corticosterone and 11-dehydrocorticosterone. Despite significant positive 
correlations between maternal and cord blood glucocorticoid levels, increased 
maternal BMI was not associated with lower cord blood glucocorticoid levels.  
This work concluded that conditions at delivery may overcome any potential 
negative effects of low maternal glucocorticoids on the fetus in the short-term. 
This may not preclude the longer-term effects of fetal exposure to lower 





Glucocorticoids are vital for lung maturation. We previously showed that cortisol 
is lower in obese pregnancy. Whether this is maintained at delivery is unknown 
but is clinically relevant as maternal and cord blood cortisol levels are correlated 
and offspring of obese are more likely to need neonatal respiratory support. We 
hypothesized that glucocorticoids are lower in maternal and cord blood at 
delivery in obese pregnancies.  
Glucocorticoids (cortisol and corticosterone) and their inactive versions 
(cortisone and 11-dehydrocorticosterone) were measured by LC-MS/MS in 
maternal and cord plasma from 259 Caucasian women at delivery (BMI 18-55 
kg/m2). Analyses adjusted for labour status, delivery mode, offspring gender, 
birthweight and gestational age.  
Cortisol and corticosterone were significantly higher in maternal than cord blood. 
Inactive versions were significantly higher in cord than maternal blood. 
Increased maternal BMI associated with lower maternal cortisol, corticosterone 
and 11-dehydrocorticosterone. Despite significant positive correlations between 
maternal and cord blood glucocorticoid levels, increased maternal BMI was not 
associated with lower cord blood glucocorticoid levels. 
Conditions at delivery may overcome any potential negative effects of low 
maternal glucocorticoids on the fetus in the short-term. This may not preclude 







Glucocorticoids are vital for fetal growth and lung maturation. This has been 
demonstrated therapeutically when glucocorticoids are administered antenatally 
to women at threat of preterm labour with consequent reduced respiratory 
morbidity in both extremely preterm (Morgan et al., 2016), and nearer term 
babies (Saccone and Berghella, 2016). We and others have shown that 
circulating maternal cortisol levels are lower in obese compared with lean 
women during pregnancy (Stirrat et al., 2016, Berglund et al., 2016, Goedhart et 
al., 2010) and postpartum (Stirrat et al., 2016). Whether or not lower maternal 
cortisol levels in obese are maintained at delivery is clinically relevant as 
maternal and cord blood cortisol levels are correlated (Sarkar et al., 2008, 
Baibazarova et al., 2013, Gitau et al., 1998). As offspring born to obese women 
are more likely to need respiratory support at delivery (Blomberg, 2013), it is 
plausible that exposure to comparatively lower levels of glucocorticoids in utero 
could limit fetal lung maturation in this group. One previous study reported 
lower maternal cortisol, but not cord cortisol at delivery in obese compared to 
normal weight women (Berglund et al., 2016), but did not adjust for mode of 
delivery or labour; both factors are known to influence cord cortisol levels (Gitau 
et al., 2001, Smith et al., 2011, Vogl SE, 2006, Mears et al., 2004, Wynne-
Edwards et al., 2013).  
While cortisol is the major circulating glucocorticoid hormone in humans, there 
is increasing interest in the potential physiological roles of corticosterone, which 
comprises 5-10% of total plasma glucocorticoids (Nixon et al., 2016). The 
observation of proportionally greater increases in cord blood corticosterone than 
cortisol according to ‘stressful’ labour and mode of delivery has led to the 
suggestion that the full-term human fetus preferentially secretes corticosterone in 
response to fetal stress (Wynne-Edwards et al., 2013).  
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To our knowledge there are no studies measuring maternal corticosterone levels 
at time of delivery and it is not known whether corticosterone levels differ in 
obese and lean pregnancy. Both cortisol and corticosterone can freely cross the 
placenta from mother to fetus, and are metabolised to their inactive forms 
(cortisone and 11-dehydrocorticosterone, respectively) by the placental enzyme 
11beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2).  
We hypothesized that cortisol and corticosterone levels measured at the time of 
delivery would be lower in the maternal and cord blood of obese pregnancies 
than lean, even after adjusting for potentially confounding factors such as labour 
and mode of delivery. We tested this hypothesis by testing associations of 
maternal BMI with cortisol, corticosterone and their metabolites, measured in 
maternal and cord blood samples obtained at delivery from women across a 
range of obesity levels. 
 
4.3 Method 
4.3.1 Clinical Methods / Participants 
We selected matched maternal and cord blood samples of 259 pregnancies from 
the Edinburgh Reproductive Tissue BioBank (ERTBB; ethical approval 
REC09/S0704/3), collected between January 2010 – December 2014. The 
ERTBB stores anonymised tissue specifically collected for pregnancy research 
with the majority of samples collected prior to the start of elective Caesarean 
section. Tissue samples are linked to a database containing clinical records. Our 
sample set comprised 102 lean (BMI 18.5 – 24.9 kg/m2), 79 overweight (BMI 
25.1 – 29.9 kg/m2), 45 obese (BMI 30 – 39.0 kg/m2) and 33 severely obese (BMI 
≥ 40 kg/m2) women. Eligible women were Caucasian, had a singleton pregnancy, 
a normal booking ultrasound scan, and had not received any glucocorticoid 
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therapy during their pregnancy. Clinical outcomes were extracted from clinical 
records. Macrosomia was defined as birthweight ≥ 4000 g at term (≥ 37 weeks).  
 
4.3.2 Biological Samples 
Trained research midwives and research technicians collected maternal and 
umbilical cord plasma at the time of delivery. Maternal samples were obtained 
during the first stage of labour from women who laboured, or when intravenous 
access was sited prior to elective Caesarean section.  Samples were collected in 
chilled EDTA vials and centrifuged within one hour of collection. Plasma was 
separated and stored at -80 oC until analysis.  
 
4.3.3 Laboratory Methods  
Plasma steroid extraction and LC-MS/MS quantification: A method was 
developed to measure cortisol, cortisone, corticosterone and 11-
dehydrocorticosterone simultaneously by liquid chromatography tandem mass 
spectrometry (LC-MS/MS), using an ABSciex QTRAP® 5500 (Warrington, UK) 
operated in positive ion electrospray ionisation, with a Waters Acquity™ UPLC 
system (Manchester, UK). Analytes were extracted from plasma (200 µL) via 
liquid-liquid extraction (chloroform 10:1 (v/v)) with epi-cortisol (25 ng; 
Steraloids, USA), epi-corticosterone (25 ng; Steraloids, USA) and 9,11,12,12 
[2H4] cortisol (d4-cortisol; 25 ng: QMX Laboratories, UK) included as internal 
standards. Analytes were separated at 40 oC on a Waters SunfireTM C18 (2.1 x 
150 mm; 3.5 mm) column (Manchester, UK) using an isocratic solvent system 
(70:30 of water with 0.1% formic acid and acetonitrile with 0.1% formic acid) 
with a gradient run of 7.1 minutes. Mass spectral conditions are demonstrated in 
Appendix Tables 4-1 and 4-2. Inter-assay precision and accuracy were within 
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acceptable limits (Appendix Table 4-3). The ratio of cortisol: cortisone was 
examined as a marker of 11β-HSD2 enzyme activity. 
 
4.3.4 Statistical Analysis 
Data distribution was assessed for normality by visually assessing histograms. 
Data that were not normally distributed were normalized using the natural-log 
transformation. The independent t-test was used to test for differences between 
continuous variables and chi-squared test for categorical variables. The one-way 
ANOVA was used to compare change in hormone levels between different 
groups. Simple linear regression was used to test for associations between 
maternal and cord blood glucocorticoid levels, and maternal BMI as a continuous 
variable (unadjusted beta; β). Using multiple linear regression analysis we 
adjusted (βa) for covariates and confounding factors known to influence 
glucocorticoid levels including mode of delivery or labour (McTernan et al., 
2001, Murphy and Clifton, 2003), and gestational age (Sandman et al., 2006, 
Nwosu et al., 1975), or that differed between groups in our sample such as 
offspring birthweight. Model 1 adjusted for gestational age at delivery, offspring 
birthweight and mode of delivery. Model 2 adjusted for gestational age at 
delivery, offspring birthweight and labour status (labour or non-labour). Analysis 
was performed using SPSS v21 (IBM). Data in text are mean ± sd, and data in 








Maternal and neonatal characteristics are demonstrated in Table 4-1. Obese and 
severely obese women were younger than lean women. Severely obese women 
had the highest numbers of current smokers. Women were well matched for 
parity, mode of delivery, gestational age at delivery and offspring gender. The 
most common mode of delivery in all BMI groups was elective Caesarean 
section, representative of samples in the ERTBB. Induction of labour was highest 
in the severely obese group. Offspring birthweight was highest in the obese and 
severely obese groups. Lean women had significantly lower birthweight than 
both obese and severely obese women offspring. Rates of macrosomia were 






















Maternal age (years) 34.2 (5.0) 34.6 (6.2) 32.0 (5.2) 31.7 (5.0) 0.017 
Maternal BMI (kg/m2) 22.6 (1.6) 27.3 (1.4) 34.2 (2.8) 44.3 (3.6) <0.0001 
























































































































































































Table 4-1. Maternal and Neonatal Characteristics  
Parity was defined as ‘prim’ (no previous pregnancies delivered after 24 weeks), 
‘para 1’ (one previous delivery after 24 weeks gestation) and ‘para ≥ 2’ (two or 
more previous deliveries after 24 weeks gestation). ‘Smokers’ were defined as 
those who considered themselves as current smokers. Macrosomia was defined 
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as ≥ 4000 g. Data are mean (sd) or N (%). P-value is from one-way ANOVA for 
continuous variables, and chi-squared test for categorical variables.  
Missing data: n=1 baby gender missing from offspring of severely obese  
Key: BMI (body mass index), CS (Caesarean section), ElCS (elective Caesarean 




4.4.2 Relationship Between Maternal and Cord Hormone Levels 
Levels of cortisol and corticosterone were significantly higher in maternal blood 
than cord blood, whereas cortisone and 11-dehydrocorticosterone were 




Figure 4-1 (a-d). Maternal and cord plasma levels of glucocorticoids  
Cortisol (1a), cortisone (1b), corticosterone (1c) and 11-dehydrocorticosterone 
(1d). Data are mean (sem); ***p<0.0001.  
 
 
Maternal and cord blood levels of all the monitored steroid hormones were 
significantly positively correlated (Figure 4-2). Maternal cortisol and 
corticosterone were also positively correlated with cord blood cortisone and 11-

























































Figure 4-2 (a-d). Correlations of maternal and cord blood levels of 
glucocorticoids  
Cortisol (r=0.392, p<0.0001; 1a), cortisone (r=0.432, p<0.0001; 1b), 
corticosterone (r=0.437, p<0.0001; 1c), 11-dehydrocorticosterone (r=0.481, 
p<0.0001; 1d). 
 
4.4.3 Predictors of Glucocorticoid Levels at Delivery 
None of the hormones differed according to parity, maternal smoking or 
maternal age. Maternal corticosterone was significantly higher in labouring than 
non-labouring deliveries and was associated with greater ‘stress’ (vaginal 
delivery higher than emergency and elective Caesarean sections) (Table 4-2). 
Cord corticosterone was significantly higher in labouring than non-labouring 
deliveries but did not differ with mode of delivery. Cord cortisone was 





































































significantly higher in labouring than non-labouring, and was significantly higher 
in deliveries associated with greater ‘stress’ (vaginal delivery higher than 
elective Caesarean section). 
The association of maternal BMI with glucocorticoid hormone levels is 
demonstrated in Table 4-3. In the unadjusted analysis, increased maternal BMI 
was associated with lower maternal cortisol, corticosterone and 11-
dehydrocorticosterone. Maternal BMI remained significant as an independent 
predictor of these hormones in the adjusted analyses (Table 4-3). In cord blood, 
there were no associations between maternal BMI and glucocorticoid levels in 
the unadjusted or adjusted analyses. Table 4-4 demonstrates maternal and cord 
blood glucocorticoids levels in women who were delivered by elective Caesarean 
section, in different BMI groups. Maternal glucocorticoid levels tended to 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Our findings demonstrate that increased maternal BMI was associated with lower 
maternal cortisol, corticosterone and 11-dehydrocorticosterone measured at time of 
delivery. Despite significant positive correlations between maternal and cord blood 
hormone levels, maternal BMI was not associated with cord blood glucocorticoid 
levels. 
Our observation that cortisol and corticosterone were higher in maternal than cord 
blood, and that cortisone and 11-dehydrocorticosterone were higher in cord than 
maternal blood supports the hypothesis that the placenta acts as a barrier to protect the 
fetus from overexposure to active glucocorticoids (Benediktsson et al., 1997). Indeed, 
maternal cortisol and corticosterone were positively correlated with cortisone and 11-
dehydrocorticosterone respectively. We also found a significant positive correlation 
between maternal and cord hormone levels (for all hormones), consistent with studies 
showing that maternal plasma and amniotic fluid cortisol levels are correlated during 
pregnancy (Sarkar et al., 2008, Baibazarova et al., 2013, Gitau et al., 1998, Glover et 
al., 2009).  
Our findings are consistent with literature showing that labour and mode of delivery 
are associated with both a maternal and fetal endocrine (glucocorticoid hormone) 
stress response. For example, both higher maternal and cord blood cortisol levels have 
been reported where delivery was by vaginal or emergency Caesarean section (i.e. 
where labour had occurred), compared with delivery by elective Caesarean section 
(i.e. pre-labour) (Vogl SE, 2006, Wynne-Edwards et al., 2013, Gitau et al., 2001). 
While it is generally considered that higher glucocorticoid levels are a consequence of 
‘stressful’ conditions at delivery such as labour, an alternative hypothesis could be 
that higher glucocorticoid levels could be linked to the ‘cause’ of labour. 
Glucocorticoids are thought to play a role in human parturition (Li et al., 2014), 
although the mechanisms are not known.   
Our finding of higher corticosterone (but not cortisol) in labouring cord samples was 
in-keeping with a previous study (Wynne-Edwards et al., 2013) who found highest 
corticosterone levels in vaginal deliveries, followed by emergency Caesarean 
deliveries (who would have laboured), and lowest levels in elective Caesarean 
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deliveries (no labour). It has been suggested that this may be due to developmental 
changes in fetal glucocorticoid synthesis with preferential secretion of corticosterone 
in utero, and a shift towards the adult pattern of preferential cortisol synthesis after 
delivery (Wynne-Edwards et al., 2013). These observations suggest that fetal adrenal 
corticosterone may be a better marker of fetal stress (Wynne-Edwards et al., 2013). In 
addition, we showed for the first time that maternal corticosterone levels were higher 
in labouring than non-labouring women, which may suggest this hormone is released 
into the maternal circulation in response to the ‘stress’ associated with labour.  
However, we did not replicate previous findings of higher cord cortisol in cases where 
labour has occurred (Gitau et al., 2001, Smith et al., 2011, Vogl SE, 2006); a large 
proportion of our subjects were delivered by elective Caesarean section, and more 
labouring samples may be required to replicate this finding.  
Smith et al., (Smith et al., 2011) found no effect of maternal mood or anxiety 
disorders on cord blood cortisol at delivery, and suggested that conditions at delivery 
per se overwhelm the possible smaller diagnosis of treatment-related differences in 
hypothalamic-pituitary-adrenal axis responses during pregnancy. However, they did 
not adjust for mode of delivery or labour.  Our data suggest that even in the 
‘controlled’ conditions of elective Caesarean section, in accord with these findings 
(Smith et al., 2011) the conditions at delivery per se may overwhelm the effects of 
BMI on cord cortisol. While detailed studies conducted at elective Caesarean section 
have informed our knowledge of maternal, placental and fetal glucose transfer 
(Holme et al., 2015) such studies are less likely to be informative about glucocorticoid 
transfer between the maternal, placental and fetal unit.  
In rodents, corticosterone is the major circulating glucocorticoid hormone and a 
handful of studies have measured maternal and fetal glucocorticoid levels in animal 
models of obesity in pregnancy. Two studies in mice and rats fed a high-fat diet 
reported increased levels of maternal corticosterone (Bellisario et al., 2015, Desai et 
al., 2014) suggesting that a high-fat diet acts as a stressful challenge during rodent 
pregnancy. However, in contrast to both of these studies, another study in rats 
measured rhythmic 21-hour profiles of maternal and fetal corticosterone and 11-
dehydrocorticosterone, and found that these were unaffected by obesity (Crew et al., 
2016). Whilst rodent studies can more easily control for complications of labour and 
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delivery than human studies and so are important comparisons for the effect of 
obesity on glucocorticoid levels, the species in maternal glucocorticoid responses to 
obesity/high fat diet need to be considered in interpreting the observations.  
Strengths of our study are the large sample size, with a high proportion of elective 
Caesarean deliveries, and a wide range of maternal BMI. Our finding of higher 
birthweight in offspring of obese women is representative of what is expected in this 
sub-population of pregnant women (Ehrenberg et al., 2004). Our samples were 
analysed by liquid chromatography tandem mass spectrometry, which is the gold 
standard for measuring glucocorticoid hormones, and facilitated the simultaneous 
analysis of multiple hormones from a small sample volume (200 μL). We are also the 
first to describe the relationship of all these glucocorticoid hormones between 
maternal and cord blood.  
A limitation of this study is that, like others (Vogl SE, 2006, Smith et al., 2011) our 
cord blood samples were mixed cord artery and vein meaning we were unable to 
conduct a detailed assessment of the placental and fetal contribution to corticosterone 
metabolism. This was due to limited availability of cord blood in our setting, where 
delayed cord clamping is practiced and clinical bloods are required for blood gas 
testing; thus, the volume of blood available for research purposes was limited. Some 
studies have demonstrated differences in levels of cortisol and corticosterone between 
cord artery and vein (Gitau et al., 2001, Wynne-Edwards et al., 2013). For example, in 
a study of 256 matched arterial and venous cord blood samples, Wynne-Edwards et 
al., reported an increase in both cortisol and corticosterone from the venous to the 
arterial circulation, suggesting that the fetal adrenal contributed corticosteroids to the 
arterial circulation while placental 11β-HSD2 was clearing both corticosteroids 
(Wynne-Edwards et al., 2013). Ex vivo studies using the placental perfusion model 
(Benediktsson et al., 1997) combined with deuterated cortisol tracers (Andrew et al., 
2002) would allow more details assessment of the fetal and placental contribution to 
corticosteroid levels.  
In conclusion, our study suggests that maternal glucocorticoids are lower at delivery 
in obese pregnancy, and that conditions at delivery may overwhelm any effect of BMI 
on cord glucocorticoid levels. This should be considered in studies investigating 
glucocorticoids at delivery. Though conditions at delivery may overcome any 
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potential negative effects of low glucocorticoids on the fetus in the short-term, this 
may not preclude the longer-term effects of lower glucocorticoid exposure during 



























































































































































































































































































































































































































Appendix Table 4-2. Lower limits of quantitation 



















Cortisol 1.4 - 2762 3.5 
Cortisone 1.4 - 2906 6.9 
Corticosterone 1.5 - 2777 3.6 
11-Dehydrocorticosterone 1.4 - 2890 3.6 
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Cortisol Low (3.5) 3.7 (0.6) 14.7 108 
Mid (691) 742 (35) 2.5 107 
High (2762) 2463 (177) 7.2 89 
Cortisone Low (3.5) 7.2 (1.4) 18.7 105 
Mid (694) 718 (43) 6.0 103 
High (2778) 2467 (171) 6.9 89 
Corticosterone  Low (3.6) 4.3 (0.7) 15.5 99 
Mid (723) 725 (46.2) 6.3 100 
High (2980) 2754 (98.3) 3.6 95 
11-dehydrocorticosterone  Low (3.6) 3.8 (0.4) 13.0 105 
Mid (727) 794 (76) 3.4 104 
High (2906) 2602 (291) 11.2 89 
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4.7 Chapter Conclusion 
The work in Chapter 4 suggests that the finding of lower maternal glucocorticoids 
during the antenatal period of obese pregnancy in Chapter 3, is maintained in 
maternal blood at the time of delivery. Increased maternal BMI associated with lower 
maternal cortisol, corticosterone and 11-dehydrocorticosterone. However, despite 
significant positive correlations between glucocorticoids levels in maternal and cord 
blood, increased maternal BMI did not associate with lower cord blood glucocorticoid 
levels. It was suggested that in the short-term, conditions at delivery may overcome 
potential negative effects of lower maternal glucocorticoids on the fetus.   
Potential underlying mechanisms for the pattern of lower maternal glucocorticoids 
and decreased HPA axis activity described in Chapters 3 and 4, were investigated 
and described in Chapters 5 and 6. Chapter 5 relates to a clinical study that 





Pulsatility of Glucocorticoids Hormones in 
Pregnancy: Changes with Gestation and Obesity 
The following materials are in revision in Clinical Endocrinology under a similar title 
by Laura I Stirrat (LS), Jamie J Walker (JW), Ksenia Stryjakowska (KS), Natalie 
Jones (NJ), Natalie ZM Homer (NH), Ruth Andrew (RA), Jane E Norman (JN), 
Stafford L Lightman (SL) and Rebecca M Reynolds (RR). LS designed the study, 
applied for ethical approval, recruited participants, conducted study visits, laboratory 
analysis, collated and analysed data; with guidance from RR and JN. JW conducted 
the analysis of pulsatility using the Cluster algorithm. KS assisted with recruitment 
and study visits for six months. NJ optimised the liquid chromatography tandem mass 
spectrometry assay with guidance of NH and RA. LS prepared the first draft of the 
manuscript under the guidance of RR. All authors provided critical insight for the 
manuscript. 
In summary, this work demonstrated that serum cortisol AUC (measured during six 
day-time hours) increased significantly with gestation in lean and obese pregnant 
compared with non-pregnant subjects. Peripheral tissue interstitial fluid cortisol was 
found to be pulsatile in human pregnancy. Pulse frequency was decreased with 
increasing gestation in obese pregnant women. These findings may be potential 









Background: Hypothalamic-pituitary-adrenal-axis (HPA) activity is decreased in 
obese pregnancy and associates with increased fetal size. Pulsatile release of 
glucocorticoid hormones regulates their action in target tissues. Glucocorticoids are 
essential for normal fetal growth but little is known about glucocorticoid pulsatility in 
pregnancy. We aimed to investigate the ultradian rhythm of glucocorticoid secretion 
during obese and lean pregnancy and non-pregnancy.  
Method: Serum cortisol, cortisone, corticosterone and 11-dehydrocorticosterone were 
measured by LC-MS/MS from samples obtained at 10-minute intervals between 
08.00-11.00h and 16.00h-19.00h, from eight lean (BMI < 25 kg/m2) and seven obese 
(BMI > 35 kg/m2) pregnant women between 16-24 weeks gestation and again at 30-
36 weeks), and non-pregnant controls (lean n=3, obese n=4) during the luteal phase of 
their menstrual cycle. Interstitial fluid cortisol was measured by ELISA, from samples 
obtained using a portable microdialysis and automated collection device at 20-minute 
intervals over 24-hours. 
Results: Serum cortisol AUC, highest peak, and lowest trough increased significantly 
with gestation in lean and obese pregnant compared with non-pregnant subjects. 
Pulsatility of cortisol was detected in interstitial fluid. In pregnant subjects, interstitial 
fluid pulse frequency was significantly lower with advancing gestation in obese, but 
not in lean.  
Conclusions: We demonstrate cortisol pulsatility in interstitial fluid. Pulse frequency 
is altered with increased gestation and BMI. This may be a novel mechanism to 
explain decreased HPA activity in obese pregnancy.  
 






Glucocorticoids are vital for normal fetal growth and organ development, but fetal 
over-exposure to the major circulating glucocorticoid, cortisol, is associated with 
intrauterine growth restriction (Stewart et al., 1995), and an increased risk of 
cardiovascular disease in later life (Reynolds, 2013). During pregnancy a number of 
endocrine changes cause the maternal hypothalamic-pituitary-adrenal (HPA) axis to 
undergo dramatic activation resulting in cortisol levels that are around three-fold 
higher than in non-pregnancy (Duthie and Reynolds, 2013, Jung et al., 2011, Lindsay 
and Nieman, 2005). Dysregulation of the maternal HPA axis has been implicated in 
pregnancy complications including preterm birth (Smith, 2007) and pre-eclampsia 
(Aufdenblatten et al., 2009, Vianna et al., 2011). The glucocorticoid corticosterone, 
which is known to circulate at significantly lower levels than cortisol in non-
pregnancy (Raubenheimer et al., 2006) is increasingly being recognised as a key 
player in HPA axis regulation (Nixon et al., 2016). It has been suggested that the fetus 
preferentially secretes corticosterone over cortisol in response to stress, and therefore 
has been proposed to be an important biomarker of fetal stress at the time of delivery 
(Wynne-Edwards et al., 2013, Stirrat et al., 2017), but little is known about how it 
changes during pregnancy.  
The circadian rhythm of the HPA axis, which in humans is characterised by peak 
levels of cortisol early in the morning, is maintained in pregnancy (de Weerth and 
Buitelaar, 2005). More detailed studies of circadian rhythmicity in animals (Droste et 
al., 2008) and in non-pregnant humans (Bhake et al., 2013) have identified an 
underlying ‘ultradian rhythm’ (Veldhuis et al., 1989) of cortisol pulses within blood 
and target tissues (Spiga et al., 2014), occurring approximately once per hour 
(Veldhuis et al., 1989, Follenius et al., 1987, Jasper and Engeland, 1991). Pulse 
amplitude and frequency increase during the circadian peak of secretion when 
circulating cortisol levels are at their highest (Veldhuis et al., 1989), and in response 
to food (Fall et al., 2002). These pulses are important for optimal gene transcription 
and metabolic functions (Lightman and Conway-Campbell, 2010). Altered ultradian 
rhythm patterns have been linked to pathological consequences and manifestations of 
disease (Lightman and Conway-Campbell, 2010) such as psychotic and depressive 
states (Young et al., 1994, Young et al., 2004), where elevated troughs at the nadir 
	 133	
result in a flattened circadian rhythmicity. In pregnancy, excess glucocorticoid 
exposure is thought to induce a long lasting effect on peripheral tissue expression of 
glucocorticoid sensitive genes (Cottrell and Seckl, 2009). However, the underlying 
mechanisms for such changes are unknown. One study of cortisol pulsatility in 
pregnancy used 30-minute serum sampling and detected 2-3 pulses of cortisol in 12 
hours in the third trimester of human pregnancy (Magiakou et al., 1996), but the 
authors acknowledged that 30-minute sampling was suboptimal for accurate detection 
of pulse rates of hormones with rapid clearance rates. Whether or not and how the 
ultradian rhythm of cortisol secretion changes across gestation is unknown. This 
information will improve understanding of pathways to fetal growth as well as the 
aetiology of pregnancy complications. 
We aimed to determine whether there are changes in cortisol pulsatility in two 
physiological contexts of altered HPA axis activity; firstly the increase in circulating 
cortisol levels that occur with advancing gestation, and secondly in maternal obesity, 
where we and others have reported lower maternal circulating cortisol levels in obese 
than in lean pregnant women (Stirrat et al., 2016, Berglund et al., 2016). We 
hypothesised that pulse amplitude and frequency would increase with advancing 
gestation, and that these characteristics would be lower in obese compared with lean 
pregnant women. To test this hypothesis we studied day-time serum profiles of both 
cortisol and corticosterone as well as their inactive metabolites (cortisone and 11-
dehydrocorticosterone, respectively), and 24-hour interstitial fluid cortisol levels in 
obese and lean pregnant, and non-pregnant women. We conducted more frequent 
sampling than has previously been performed (Magiakou et al., 1996) to maximise the 




5.3.1 Participants and Clinical Protocol 
We recruited lean (BMI 18.5-24.9 kg/m2) pregnant (LP; n=8), obese (BMI ≥ 30 
kg/m2) pregnant (OP; n=7), lean non-pregnant (LNP; n=3) and obese non-pregnant 
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(ONP; n=4) women. One obese participant was studied in non-pregnancy and again 
during pregnancy. Pregnant women were recruited from antenatal clinics in NHS 
Lothian. Non-pregnant volunteers were recruited from the University of Edinburgh, 
and community weight loss clinics in NHS Lothian. Eligible pregnant women were 
Caucasian, had a normal booking ultrasound scan and a singleton pregnancy. Non-
pregnant women had a regular menstrual cycle, and did not use hormonal 
contraception. Exclusion criteria were smoking, pre-existing diabetes, regular 
glucocorticoid medication, severe mental health disorder, and anaemia. Ethical 
approval and written informed consent were obtained.  
Participants attended study visits at the Edinburgh Clinical Research Facility, Royal 
Infirmary of Edinburgh. Pregnant women attended for study visits at 16-24 weeks’ 
and between 30-36 weeks’ gestation, and non-pregnant volunteers attended for one 
study visit in the luteal phase of the menstrual cycle.  
At each study visit, fasting blood samples were obtained at 10-minute intervals 
between 08.00h-11.00h and between 16.00h-19.00h via a peripheral venous cannula. 
Participants were fasted from bed-time the night before each study visit, then were fed 
a standardized breakfast meal after completion of sampling at 11.00h (toast, cup of tea 
or coffee, and carton of fruit juice), and lunch at 13.00h (sandwich, yoghurt, piece of 
fruit, cup or tea or coffee and biscuit). Fasting was re-commenced by 15.00h until 
after completion of the second sampling session at 19.00h. Participants could drink 
water freely throughout study visits.   
Subcutaneous interstitial fluid samples for measurement of free cortisol (Sandeep et 
al., 2005) were obtained at 20-minute intervals over 24 hours by microdialysis. A 
linear microdialysis catheter (Linton, Norfolk, UK) was inserted subcutaneously into 
the interstitial compartment of the anterior abdominal wall, and collected via a novel, 
miniaturised, portable collection device as described by Bhake et al., 2013 (Bhake et 
al., 2013).  
Serum was separated immediately and stored at -80 oC for later laboratory analysis. 
Clinical outcomes including maternal booking BMI, gestation at delivery, birthweight 
and offspring gender were extracted from medical records.  
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5.3.2 Laboratory Methods 
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS): We measured 
cortisol, cortisone, corticosterone and 11-dehydrocorticosterone simultaneously by 
liquid chromatography tandem mass spectrometry, using a Waters Acquity™ UPLC 
(Manchester, UK), liquid chromatography system followed by mass spectral analysis 
on an ABSciex QTRAP® 5500 (Warrington, UK) mass spectrometer. Mass spectral 
conditions are described in Appendix Table 5-1 in conjunction with ion spray 
voltage (5500 V) and source temperature (700 oC). Following enrichment of serum 
(200 mL) with internal standards epi-cortisol (25 ng; Steraloids, USA), epi-
corticosterone (25 ng; Steraloids, USA), and 9,12,12,12 [2H4]-cortisol (D4-cortisol 25 
ng; QMX Laboratories, England, UK), and dilution with water (200 mL) analytes 
were extracted via supported liquid extraction (ISOLUTE® SLE+ 400 μl 96-well 
plate, Biotage, Sweden) and eluted with 98:2 dichloromethane:2-propanol. Analytes 
were separated on an ACE Excel 2 C18-AR (150 x 2.1 mm, 2 µm) column (Advanced 
Chromatography Technologies Ltd, UK) at 40oC. The elution process started with 
70:30 water with 0.1% formic acid (FA) (solution A) and acetonitrile with 0.1% FA 
(solution B), was maintained for 4 minutes followed by a 1-minute linear rise to 60% 
solution B, a subsequent rise to 90% solution B, before returning to 30% solution B 
by 6.1 minutes at a constant flow rate of 0.5 mL/min. 
Validation parameters (intra- and inter-assay precision, accuracy; Appendix Table 5-
2) were within acceptable limits (the lowest levels being acceptable < 20% RSD with 
all following < 15%). Levels of corticosterone and 11-dehydrocorticosterone in some 
samples were close to or below the limit of quantification in all subjects, and at all 
gestations of pregnancy. The ratios of cortisol: cortisone and corticosterone: 11-
dehydrocorticosterone were used as a marker of 11beta-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2) enzyme activity.  
Commercially available ELISA kits were used for the analysis of plasma ACTH 
(Demeditec DE3467; inter-assay CV 6.9-7.1%), and interstitial fluid cortisol (IBL 
International RE52611; inter-assay CV 4.2-17.0%), as previously used by Bhake et al. 
(Bhake et al., 2013)  Free cortisol values were expected to be above the top standard, 
therefore were diluted to 1:10 in the assay zero standard and results were corrected for 
dilution. 
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5.3.3 Statistical Analysis 
Data distribution was assessed for normality by visually assessing histograms. Data 
that were not normally distributed were normalised using the natural-log 
transformation. The independent t-test was used to test for differences in subject 
characteristics between continuous variables and chi-squared test for categorical 
variables. For cortisol measurements the ‘highest peak’ was the highest value in any 
given profile, and the ‘lowest trough’ was the lowest value. The area under the curve 
(AUC) for hormone profiles was used as a marker for total glucocorticoid levels over 
the study period. Pulse analysis was performed using Cluster analysis (Veldhuis and 
Johnson, 1986), a statistically-rigorous peak detection algorithm that has been widely 
used to quantify the pulsatile dynamics of various hormones, including cortisol (van 
Aken et al., 2005). Cluster analysis defines a pulse as a statistically significant 
increase in a ‘cluster’ of hormone values followed by a statistically significant 
decrease in a second cluster of values. The increase and decrease are judged in 
relation to the actual experimental error expressed by replicates in the presumptive 
nadir and peak results. The algorithm detected statistically-significant interstitial fluid 
cortisol pulses, pulse frequency (pulses/hr), pulse height (ug/dL) and mean 
concentration (ug/dL) in a given cortisol time series. Cluster parameters used in the 
analysis were as follows: minimum detectable concentration of the assay (MDC, 
0.015 ug/dL); intra-assay coefficient of variation (CV, 12.08%); test cluster size for 
sliding nadir (2.0); test cluster size for sliding peak (1); t-statistic for significant 
increase in the data (2.0); t-statistic for significant decrease in the data (2.0); 
minimum peak size (0.0 ug/dL). One-way ANOVA was used to compare changes in 
pulse characteristics between different groups. The paired t-test was used to assess 
differences in pulse characteristics between pregnant women who attended for two 
study visits. Analysis was performed using SPSS v21 (IBM). Data in text are mean ± 








Maternal and neonatal characteristics are demonstrated in Table 5-1. In pregnant 
participants, OP were younger and had higher systolic and diastolic blood pressure 
than LP. The timing of study visit 1 tended to be earlier in LP, and gestation at 
delivery was earlier in OP. There were no differences in parity, birthweight percentile 
or standard deviation birthweight score. In non-pregnant participants, obese subjects 




















































































































































































































































































































































































































































































































































































































































































































 5 3 






























































































































































5.4.2 Serum Hormone Profiles (08.00h-11.00h and 16.00h-19.00h) 
Figure 5-1 shows an example of serum glucocorticoid hormone profiles in non-
pregnancy and during the two pregnancy visits, as illustrated by the data collected 
from the obese subject who was studied in non-pregnancy (two months pre-
pregnancy), and during pregnancy at visit 1 (17+2 weeks’ gestation), and visit 2 
(30+6 weeks’ gestation). Levels of cortisol (Figure 5-1a), cortisone (Figure 5-1b), 
corticosterone (Figure 5-1c) and 11-dehydrocorticosterone (Figure 5-1d) were higher 
in pregnancy than in non-pregnancy and all hormone levels increased with advancing 
gestation. Profiles of serum cortisol, cortisone, corticosterone and 11-
dehydrocorticosterone for all other study participants are shown in Appendix Figures 
1-4. There were no samples from some subjects for the following reasons: did not 
attend visit 2 (LP2 n=1, OP2 n=2), delivered before visit 2 (OP2 n=1). With visual 
assessment of hormone profiles, we observed inter-individual variation in pattern of 
profiles, but there were no obvious differences in characteristics between women that 
had particularly quiescent or dynamic profiles. Only one cortisol pulse was detected 
in the sampling from one subject so serum pulse characteristics are not reported. 
Interstitial fluid pulses were detected in the profiles of all subjects. Pulse 






Figure 5-1 a-f. Serum and Interstitial Fluid. Profiles of serum cortisol (1a), 
cortisone (1b), corticosterone (1c), and 11-dehydrocorticosterone (1d)  
Each figure demonstrates the individual hormone profiles of one representative 
subject who was studied two months pre-pregnancy, at visit 1  (17+2 weeks’ 
gestation) and visit 2 (third trimester (30+6 weeks’ gestation). Interstitial fluid cortisol 
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profiles from two representative lean subjects obtained at 17+2 and 31 weeks (1e) and 
18+3 and 32+3 weeks (1f).  
Key: LOQ (limit of quantification) 
 
5.4.3 Serum Cortisol and Cortisone 
Fasting serum cortisol and cortisol AUC were significantly higher in pregnancy than 
non-pregnancy in lean and obese (Figure 5-2 a-b). During pregnancy, cortisol AUC 
increased significantly with advancing gestation in lean, but not in obese (Figure 5-2 
a-b). Plasma ACTH rose with advancing gestation in both lean and obese groups 
(Figure 5-2c).  The mean ‘highest peak’ and ‘lowest trough’ increased significantly 
with gestation in both lean and obese (Appendix Table 5-3).  
Serum cortisone AUC was higher in pregnancy than non-pregnancy in both lean and 
obese. During pregnancy overall cortisone levels rose (Figure 5-1b). Cortisone 
‘lowest trough’ increased significantly during pregnancy in obese, but not in lean 
(Appendix Table 5-3).  
The mean cortisol:cortisone ratio of serum profiles was highest at pregnancy visit 1 
(Table 5-2). The ratio of the baseline (08.00h) sample was significantly higher in 






Figure 5-2 (a-c) Fasting serum cortisol (2a) increased with advancing gestation in 
lean and obese (one-way ANOVA: lean p=0.017, obese p=0.027), and was 
significantly higher at OP2 than OP1 (paired t-test p=0.012), and at OP2 than ONP 
(post-hoc Tukey, p=0.046). Cortisol AUC of serum profile (2b) increased with 
advancing gestation in lean and obese (one-way ANOVA: lean p<0.0001, obese 
p<0.0001). AUC increased significantly between visit 1 and visit 2 in lean pregnant 
women (LP1 17937  ± 7141 nM vs LP2 2345 ± 7328 nM, p=0.001), but not in obese 
(OP1 14498 ± 5794 vs OP2 24660 ± 8937nM, p=0.06). Plasma ACTH levels (2c) 
increased during pregnancy and were significantly higher at pregnancy visit 2 than 
non-pregnancy in lean (p=0.017) and obese (p=0.045).  
Key: Lean non-pregnant (LNP), lean pregnant visit 1 (LP1), lean pregnant visit 2 
(LP2), Obese non-pregnant (ONP), obese pregnant visit 1 (OP1), obese pregnant visit 
2 (OP2). Data on graphs are mean (sem). *p<0.05, **p<0.01, ***p<0.0001. 



































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.4 Serum Corticosterone and 11-Dehydrocorticosterone 
Serum corticosterone levels were highest during pregnancy visit 2 (Figure 5-1c) and 
‘highest peak’ increased significantly in obese during pregnancy (Appendix Table 5-
3). Serum 11-dehydrocorticosterone levels were not significantly different with 
changing gestation (Figure 5-1d) and did not differ between obese and lean. The ratio 
of corticosterone:11-dehydrocorticosterone of the baseline fasting sample was 
significantly higher at LP1 than LP2, but was not different in obese (Table 5-2). 
 
5.4.5 Interstitial Fluid Cortisol 
Interstitial fluid data was available from LNP (n=3), LP1 (n=7), LP2 (n=6), ONP 
(n=4), OP1 (n=7), OP2 (n=3). There were no samples available from some subjects 
for the following reasons: technical issues (LP1 n=1, OP2 n=1), participant declined 
(LP2 n=1), did not attend for visit 2 (LP2 n=1, OP2 n=2), delivered before visit 2 
(OP2 n=1). Representative profiles from two subjects are shown in Figure 5-1 e-f. 
Both pulsatility and the morning rise in cortisol were detected in the interstitial fluid 
sampling (Figure 5-1 e-f). Pulses were detected in interstitial fluid samples  
(Appendix Table 5-3). In lean women pulse frequency was consistently around 0.2 
pulse/hr (approximately one pulse every 5 hours) and did not differ between lean non-
pregnant and pregnant women at visit 1 and visit 2 (LNP: 0.23 ± 0.09 pulses, LP1: 
0.20 ± 0.14 pulses, LP2:  0.23 ± 0.13 pulses; p=0.591). In obese women, pulse 
frequency was similar to lean in non-pregnancy (0.22 ± 0.12 pulse/hr).  Pulse 
frequency was significantly lower with advancing gestation in obese women (visit 1: 
0.18 ± 0.12 pulse/hr, visit 2: 0.04 ± 0.003 pulse/hr; t-test p=0.025). There were no 
differences in pulse amplitude or mean concentration of the whole profiles with 
increasing gestation, or between lean and obese.  
 
5.5 Discussion 
Using two paradigms of altered HPA axis activity in pregnancy to investigate 
ultradian rhythms of glucocorticoid hormone secretion, we have demonstrated 
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changes in serum glucocorticoid levels that occur across gestation and in pregnancies 
complicated by obesity. Total circulating serum cortisol levels were higher in 
pregnancy than non-pregnancy in lean and obese, and increased significantly with 
advancing gestation in lean but not in obese. In addition, through measurement of 
interstitial fluid cortisol levels we show evidence, for the first time, of tissue cortisol 
pulsatility in human pregnancy. In obese pregnancy, interstitial fluid pulse frequency 
was lower with advancing gestation. 
The observation that serum cortisol AUC significantly increased during pregnancy in 
lean women, but not in obese women adds to the previous observations of lower 
morning fasting cortisol in obese (Stirrat et al., 2016, Berglund et al., 2016), and 
supports the hypothesis that HPA axis activity is reduced throughout the day in obese 
pregnancy (Stirrat et al., 2016). These data, together with our finding that interstitial 
fluid pulse frequency was lower with advancing gestation in obese pregnant women, 
suggest that an altered ultradian rhythm (characterised by reduced interstitial fluid 
pulse frequency) may underlie decreased HPA axis in obese pregnancy. In the 
absence of repeated ACTH sampling, it is not possible to determine the influence of 
adrenal delay in cortisol release or altered central negative feedback on pulse 
frequency.   
To the best of our knowledge, we are the first to describe circulating corticosterone 
levels across the day in human pregnancy and in non-pregnant women. Our finding of 
higher levels of corticosterone in pregnancy than non-pregnancy suggests that like 
cortisol, the synthesis and release of this hormone is influenced by increased 
activation of the maternal HPA axis (Duthie and Reynolds, 2013). Unlike cortisone, 
levels of 11-dehydrocorticosterone did not change significantly with advancing 
gestation, suggesting that there may be a lesser breakdown of corticosterone than 
cortisol by 11β-HSD2 or alternative pathways of corticosterone clearance. For 
example the ABC-transporters ‘p-glycoprotein’ (P-gp, encoded by ABCB1) and 
‘multidrug resistant protein-1’ (MRP1, encoded by ABCC1) which preferentially 
export cortisol or corticosterone, respectively are present in the placenta (St-Pierre et 
al., 2000), and ABCB1 mRNA expression is reported to be lower in placentas of 
pregnancies complicated by severe obesity (Mina et al., 2015). Further studies are 
needed to understand the metabolism of corticosterone in pregnancy. 
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Our study is the first to measure interstitial fluid cortisol in women, and in human 
pregnancy. We analysed the pulsatile characteristics of this data using the well-
established Cluster algorithm (Veldhuis and Johnson, 1986). This is a statistically-
rigorous method that takes into account assay prevision and is not adversely 
influenced by drifting baseline hormone secretion. Moreover, its model-independent 
nature means that it is not reliant on a priori assumptions about the system (eg. 
parameters defined dynamics of hormone secretion or clearance) that we have little 
information about in lean or obese pregnancy conditions. Using this algorithm, we 
demonstrated tissue cortisol pulsatility in women, and in human pregnancy. In all 
women, interstitial fluid cortisol pulse frequency was similar to the findings of a 
previous study of circulating serum cortisol in pregnancy. Magiakou et al., (Magiakou 
et al., 1996) used the Detect pulse analysis method (Oerter et al., 1986) to identify 
cortisol pulses in samples obtained at 30 minute intervals, and observed 2-3 pulses in 
a 12-hour period in pregnant women between 34-36 weeks gestation. Though the 
authors acknowledged that the 30 minute sampling may have limited their detection 
of cortisol pulses, our observations of no serum cortisol pulses over the 6 hour 
sampling frame in all but one subject, and the similar interstitial fluid cortisol 
pulsatility to Magiakou et al., 1996 suggests that circulating cortisol pulsatility in 
pregnancy is decreased compared with the findings of previous studies of circulating 
cortisol in men (Follenius et al., 1987, Veldhuis et al., 1989) and in rats (Jasper and 
Engeland, 1991) reporting that pulses occur approximately hourly (Veldhuis et al., 
1989, Follenius et al., 1987, Jasper and Engeland, 1991). We sampled serum more 
frequently (10-minute sampling interval) to increase the likelihood of identifying 
serum glucocorticoid pulses and conducted our studies with woman in the fasting 
state to exclude the pulsatile response that has been reported to occur in response to 
food (Fall et al., 2002). For these reasons the sampling duration was shortened (six 
hours at each visit) to limit the total blood volume sampled from pregnant women. 
We can only speculate that this shorter sampling time was not long enough to detect 
pulses using Cluster.   
Studies of the dynamic nature of glucocorticoids in humans are challenging, due to 
the need to obtain frequent samples. This is particularly pertinent in pregnant women 
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where there may be ethical restrictions on the volume of blood sampled over the day.  
However, as our understanding of the role of the ultradian rhythm of cortisol in 
transcriptional regulation increases, and associations between an altered ultradian 
rhythm and disease processes are described (Lightman and Conway-Campbell, 2010), 
there is a need for dynamic studies. This is particularly so in the context of pregnancy, 
where the links between glucocorticoid exposure in utero and adverse fetal outcomes 
are well described but mechanisms are not well understood. Dynamic studies are 
needed to investigate the impact of the ultradian rhythm of cortisol on potential 
targets such as fetal or placental gene expression or function, as a potential underlying 
mechanism for the abnormal fetal growth (Stewart et al., 1995) and increased risk of 
cardiovascular disease later in life (Reynolds, 2013) that have been linked to 
abnormal glucocorticoid exposure.  
Strengths of our study include frequent sampling, matched serum and interstitial fluid 
sampling, sampling at two different points in gestation and use of a robust statistical 
method for pulse detection and analysis. Obtaining serum samples via a peripheral 
cannula, and interstitial fluid samples via a microdialysis catheter, meant that frequent 
sampling could take place without repeated insertion of needles, which would mount 
a stress response. Another strength is that serum samples were analysed with gold-
standard analytical technique of liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), (Jung et al., 2011) which also allowed the simultaneous detection of 
multiple analytes from a small volume of sample.  
A limitation of our study is that the serum sampling periods were relatively short (two 
3-hour study periods), during which only one cortisol pulse was detected in one 
subject’s sampling profile. These durations were selected so that sampling could be 
performed with subjects fasting, to avoid the known pulsatile response to food (Fall et 
al., 2002, Stimson et al., 2014), and so that a comparison could be made between 
morning and evening cortisol levels, whilst considering blood withdrawal restrictions 
of pregnant women. We acknowledge that mathematical algorithms for hormone 
pulse analysis have not been previously tested in a pregnant population, where there is 
an unknown contribution of the placenta to cortisol metabolism and clearance. We 
could not directly examine placental cortisol metabolism and transfer in this study. 
We used the ratio of cortisol:cortisone to infer total body 11β-HSD2 activity, which 
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we assume in pregnancy is largely reflective of the placenta. The relative reduction in 
the ratio between visit 1 and visit 2 of pregnancy, suggests that the activity of 11β-
HSD2 increases at the later gestations, thus serving to protect the fetus from exposure 
to excessively high maternal cortisol levels during the third trimester (Duthie and 
Reynolds, 2013). Further studies are needed to understand more about the 
contribution of the placenta to maternal and fetal glucocorticoid exposure.  
In conclusion, our study has demonstrated that total day-time circulating maternal 
cortisol increases with advancing gestation in lean, but not obese women. Further, we 
have demonstrated the novel finding that tissue cortisol levels are pulsatile during 
human pregnancy, and that interstitial fluid pulse frequency is significantly lower 
with advancing gestation in obese pregnancy. This may be an underlying mechanism 
for the reduced HPA axis activity we previously reported in obese pregnancy (Stirrat 
et al., 2016). Further studies extending the serum sampling time in order to detect 
serum pulses would confirm whether or not this finding is consistent in circulating 
cortisol level. A better understanding of the role of HPA axis dysregulation in adverse 
pregnancy outcomes may inform us which high-risk pregnancies should be targeted to 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix Figure 5-1 Serum cortisol profiles from visit 1 (black line) and visit 
2 (blue line) in lean pregnant (a) and obese pregnant (b); and from single study 
visit in lean non-pregnant (c) and obese non-pregnant (d).  














































































































































































































































































































































































































































































c) Lean Non-Pregnant Cortisol 
 
 
















































































































































































































Appendix Figure 5-2. Serum cortisone profiles from visit 1 and visit 2 in lean 
pregnant (a), obese pregnant (b), lean non-pregnant (c) and obese non-pregnant 
(d).  













































































































































































































































































































































































































































































c) Lean Non-Pregnant Cortisone 
 
 















































































































































































































Appendix Figure 5-3. Serum corticosterone profiles from visit 1 and visit 2 in 
lean pregnant (a), obese pregnant (b), lean non-pregnant (c) and obese non-
pregnant (d).  
Key: LOQ (limit of quantification; 0.29 nmol/L)  

































































































































































































































































































































































































































































































































































































c) Lean Non-Pregnant Corticosterone 
 
 








































































































































































































































































Appendix Figure 5-4. Serum 11-dehydrocorticosterone profiles from visit 1 
and visit 2 in lean pregnant (a), obese pregnant (b), lean non-pregnant (c) and 
obese non-pregnant (d). Key: LOQ (limit of quantification; 0.29 nmol/L)  














































































































































































































































































































































































































































































































































































































































c) Lean Non-Pregnant 11-dehydrocorticosterone 
 




























































































































































































































































































Appendix Figure 5-5. Interstitial fluid cortisol profiles from visit 1 and visit 2 
in lean pregnant (a), obese pregnant (b), lean non-pregnant (c) and obese non-
pregnant (d). Key: LOQ (limit of quantification; 0.41 nmol/L)  








































































































































































































































































































































































































b) Obese pregnant (cont.) 
 
 























































































































































































































































































5.7 Chapter Conclusion 
The work in Chapter 5 examined the effect of increased maternal BMI on 
glucocorticoid hormones. The findings of this study show for the first time that 
cortisol is pulsatile in interstitial fluid. Further, the frequency of cortisol pulses 
in interstitial fluid decreased with advancing gestation in obese pregnancy. An 
altered ultradian rhythm of cortisol in obese pregnancy may influence overall 
glucocorticoid exposure, and may be a mechanism underlying the decreased 
HPA axis activity described in Chapters 3 and 4.  
It was acknowledged in Chapters 3-5 that the contribution of the placenta to 
cortisol transfer and metabolism is not well understood, and may have a 
significant influence on maternal and fetal cortisol levels during pregnancy. 





Transfer and Metabolism of Cortisol by the 
Isolated Perfused Human Placenta 
The following materials have been accepted for publication in the Journal of 
Clinical Endocrinology and Metabolism under a similar title by Laura I Stirrat 
(LS), Bram G Sengers (BS), Jane E Norman (JN), Natalie  ZM Homer (NH), 
Ruth Andrew (RA), Rohan M Lewis (RL) and Rebecca M Reynolds (RR).  
LS designed the study, conducted the placental perfusion experiments and 
laboratory analysis, interpreted data and wrote the first draft of the manuscript. 
BG designed the study, conducted the computational modeling, interpreted data 
and wrote the manuscript. JN interpreted data. NH and RA advised with 
laboratory assay development and data interpretation. RL designed the study, 
conducted computational modeling, interpreted data and wrote the manuscript. 
RR designed the study, interpreted data and wrote the manuscript. All authors 
provided critical insight for the manuscript.  
In summary, this work demonstrated that the placenta presented both metabolic 
and physical barriers to cortisol transfer. This challenges the concept that 
maternal cortisol diffuses freely across the placenta and confirm that 11β-









Context: Fetal overexposure to glucocorticoids in utero is associated with fetal 
growth restriction and is postulated to be a key mechanism linking suboptimal 
fetal growth with cardiovascular disease in later life.  
Objective: To develop a model to predict maternal-fetal glucocorticoid 
transfer. We hypothesised placental 11β-HSD2 would be the major rate-
limiting step in maternal cortisol transfer to the fetus.  
Design: We used a deuterated cortisol tracer in the ex vivo placental perfusion 
model, in combination with computational modeling, to investigate the role of 
interconversion of cortisol and its inactive metabolite cortisone on transfer of 
cortisol from mother to fetus. 
Participants: Term placentas were collected from five women with 
uncomplicated pregnancies, at elective Caesarean delivery.  
Intervention: Maternal artery of the isolated perfused placenta was perfused 
with D4-cortisol. 
Main Outcome Measures: D4-cortisol, D3-cortisone and D3-cortisol were 
measured in maternal and fetal venous outflows. 
Results: D4-cortisol, D3-cortisone and D3-cortisol were detected and increased 
in maternal and fetal veins as the concentration of D4-cortisol perfusion 
increased. D3-cortisone synthesis was inhibited when 11β-HSD activity was 
inhibited. At the highest inlet concentration only 3.0% of the maternal cortisol 
was transferred to the fetal circulation, while 26.5% was metabolised and 
70.5% exited via the maternal vein. Inhibiting 11β-HSD activity increased the 
transfer to the fetus to 7.3% of the maternal input, while 92.7% exited via the 
maternal vein.  
Conclusions: Our findings challenge the concept that maternal cortisol diffuses 
freely across the placenta and confirm that 11β-HSD2 acts as a major ‘barrier’ 
to cortisol transfer to the fetus.   
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6.2 Introduction 
Cortisol, the principal circulating glucocorticoid hormone in humans, is 
essential for normal fetal development and tissue maturation. Fetal 
overexposure to glucocorticoids in utero is associated with intrauterine growth 
restriction (Stewart et al., 1995), and is postulated to be a key mechanism 
linking suboptimal fetal growth with increased risk of cardiovascular disease in 
later life (Reynolds, 2013). Better knowledge of the factors regulating cortisol 
transfer to the fetus is essential to understand the pathophysiology of fetal 
growth restriction and is also relevant for prescribing of antenatal steroids 
which are widely used in clinical management of women at threat of pre-term 
birth.  
Maternal circulating cortisol levels rise dramatically during pregnancy (Jung et 
al., 2011). Although glucocorticoids are lipophilic and thus are believed to 
freely cross the placenta, fetal cortisol levels are 5 to 10-fold lower than 
maternal levels (Beitins et al., 1973) due to the activity of the placental enzyme 
11-beta-hydroxysteroid dehydrogenase-type 2 (11β-HSD2) (Brown et al., 1993, 
Brown et al., 1996b, Krozowski et al., 1995) which catalyses the conversion of 
active cortisol into inactive cortisone. In human placenta 11β-HSD2 is 
localized to the syncytiotrophoblast (Krozowski et al., 1995), which is the 
primary barrier between the mother and the fetus and thus prevents 
glucocorticoids accessing placental cells and the fetal compartment (Chapman 
et al., 2013). Indeed placental 11β-HSD2 has been suggested to inactivate the 
majority of maternal glucocorticoids passing to the fetus in rodents (Cottrell et 
al., 2012) and in humans (Benediktsson et al., 1997). 11-beta-hydroxysteroid 
dehydrogenase-type 1 (11β-HSD1), which regenerates cortisol from inactive 
cortisone, is undetectable in the syncytiotrophoblast, but is localized in the 
extravillous trophoblasts (situated near maternal circulation) and endothelial 
cells lining fetal capillaries in terminal villi (Sun et al., 1997). Whether or not 
the activity of placental 11β-HSD1 regenerates a substantial amount of cortisol 
or contributes significantly to maternal or fetal circulations is not well 
understood. With a number of studies demonstrating links between placental 
glucocorticoid transfer, sensitivity and metabolism and adverse outcomes in 
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infancy, childhood and adolescence (Reynolds et al., 2015, Raikkonen et al., 
2015), understanding of the regulatory mechanisms and rate-limiting steps of 
maternal-fetal cortisol transfer is essential in order to identify whether there are 
any options for targeted intervention to improve pregnancy outcomes.  
Studies using the ex vivo dual perfused placental perfusion model together with 
computational modeling have generated new mechanistic insights into placental 
amino acid and lipid transfer from mother to fetus (Sengers et al., 2010, 
Panitchob et al., 2015, Perazzolo et al., 2017). In the current study we used this 
combined experimental and computational modeling approach to develop a 
model to explore placental cortisol metabolism and transfer and its regulation. 
We hypothesised that activity of placental 11β-HSD2 would be the major rate 




Term placentas from women with uncomplicated pregnancies were collected on 
ice immediately after delivery by elective Caesarean section at the Royal 
Infirmary of Edinburgh, with ethical approval (REC09/S0704/3) and written 
informed consent. Elective Caesarean sections were performed between 39-40 
weeks of gestation. Eight placentas were collected, and experimental data was 
obtained from five of these. Three of these did not meet the required ‘volume 
conservation’ parameter (fetal outflow >95% of fetal inflow) during the first 30 
minutes; this parameter was required for monitoring the system and estimating 
viability  (described in section 2.4.1). These experiments were discontinued.  
 
6.3.1 Placental Perfusions 
Placentas were perfused using the methodology of Schneider (Schneider et al., 
1972) as adapted in a previous study. (Cleal et al., 2007) Non-recirculating 
maternal and fetal circulations were established in an isolated cotyledon within 
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30 minutes of delivery. The fetal circulation and maternal intervillous space 
were perfused with a modified Earle’s bicarbonate buffer (EBB: 5 mmol L-1 
glucose, 1.8 mmol L-1 CaCl2, 0.4 mmol L-1 MgSO4, 116.4 mmol L-1 NaCl, 5.4 
mmol L-1 KCl, 26.2 mmol L-1, NaHCO3, 0.9 mmol L-1 NaH2PO4), with Heparin 
(25,000 units/L; Fannin, Northamptonshire, UK) and bovine serum albumin 
(BSA [Fraction V; 98 %], 2 g/L, Sigma, UK) added. Maternal perfusate was 
equilibrated with 95% air and 5% CO2, and fetal perfusate with 95% N2 and 5% 
CO2 (BOC, UK). Maternal circulation was at 14 mL/min and fetal circulation at 
6 mL/min using a peristaltic pump (Watson-Marlow, UK).  
Approximately 2 mL of venous perfusate was collected from the maternal and 
fetal venous outflows, at 5-minute intervals. Fetal artery pressure was 
maintained between 40 – 70 mmHg and fetal venous return was > 95%. At the 
end of the experiments, the perfused mass was identified on the ‘maternal side’ 
by slight blanching. The perfused placental cotyledon was weighed. Cotyledon 
volume was calculated on the basis of 1 mL per g tissue. Samples of maternal 
and fetal perfusate fluid, un-perfused tissue and perfused tissue were stored at -
80 oC until analysis.  
 
6.3.2 Use of Deuterated Tracers to Investigate Cortisol Metabolism 
Cortisol metabolism by 11β-HSD enzymes and transport between the maternal 
and fetal circulations was investigated using the stable isotope deuterium (D)-
labelled tracer,  [9,11,12,12 2H4]-cortisol “D4-cortisol” (Andrew et al., 2002) 
which is converted to [9,12,12 2H3]-cortisone “D3-cortisone” by 11β-HSD2. 
Measurement of [9,12,12 2H3]-cortisol “D3-cortisol”, which is regenerated from 
D3-cortisone can be used to assess activity of 11β-HSD1 (Figure 6-1). After an 
initial ‘washout’ period of 30 minutes, D4-cortisol (Steraloids, USA) was 
perfused into the maternal circulation with stepped increases in concentrations 
of 20 nM, 200 nM and 800 nM every 30 minutes. The 800 nM D4-cortisol 
concentration was considered to be representative of circulating maternal 
cortisol levels in the third trimester (Stirrat et al., 2016). The HSD inhibitor 
carbenoxolone (Sigma, UK) was added to the perfusion solution in addition to 
	 177	
800 nM D4-cortisol in the final 30 minutes at a concentration of 1000 nM, as 
informed by a previous study (Benediktsson et al., 1997). 
 




Figure 6-1 a-b. Model Schematic and Metabolism of deuterium-labelled 
glucocorticoids 
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Model schematic showing the three compartments (maternal, 
syncytiotrophoblast and fetal; 6-1a) distinguished in the model. It is assumed 
that transfer between compartments is by simple diffusion, while metabolic 
conversion between cortisol and cortisone takes place in the 
syncytiotrophoblast (Equations. 1-6, see methods section). The input 
concentration of D4-cortisol in the maternal compartment varies over time 
according to the experimental protocol, while the input concentration in the 
fetal compartment is zero at all times. The output concentrations of the 
maternal and fetal compartments from the model can be compared to the 
experimental data. 
D4-Cortisol is inactivated by 11β-HSD2 to D3-cortisone, with the loss of the 
deuterium on C11. 11β-HSD1 regenerates D3-cortisol from D3-cortisone, with 
the addition of an unlabeled hydrogen (6-1b).  
 
 
6.3.3 Steroid Extraction and LC-MS/MS Quantification 
Endogenous (cortisol, cortisone) and deuterated (D4-cortisol, D3-cortisone and 
D3-cortisol) glucocorticoids were measured simultaneously by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) using a Waters 
Acquity™ UPLC (Manchester, UK) liquid chromatography system followed by 
mass spectral detection on an ABSciex QTRAP® 5500 (Warrington, UK) 
operated in positive electrospray ionization mode. Mass spectral conditions are 
described in Appendix Table 6-1 in conjunction with ion spray voltage (5500 
V) and source temperature (700 oC). 
 
6.3.4 Perfusate Fluid Extraction 
Following enrichment of perfusate (500 µL) with the internal standard epi-
cortisol (10 ng; Steraloids, USA) and dilution with water (500 µL) analytes 
were extracted using a Sep-Pak C18 40 mg 96-well plate (Waters, Manchester, 
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UK). Plates were primed with methanol (1 mL), then EBB (1 mL) then samples 
(500 µL) were loaded and plates washed with water (1 mL). Analytes were 
eluted from the plate using acetonitrile (1 mL) directly into a 2 mL deep well 
collection plate (Waters, UK). Eluants were dried under oxygen-free nitrogen 
(60 oC) using a 96-well Dry down apparatus, and reconstituted in mobile phase 
(30:70 methanol: water; 100 µL).  
 
6.3.5 Tissue Extraction 
Placental tissue (200 mg) was homogenized in 3 mL 7:2 methanol: water and 
enriched with internal standard epi-cortisol (10 ng, as above) before being 
centrifuged at 3200 g for 45 minutes at 4 oC. Supernatant was transferred to a 
clean glass vial and dried under oxygen-free nitrogen (60 oC) and reconstituted 
in water (5 mL). Analytes were extracted using Sep-Pak C18 360 mg Classic 
Cartridges (Waters). Cartridges were primed with 100% methanol (5 mL) 
followed by water (5 mL). Samples were added to cartridges and allowed to 
flow through with gravity. Cartridges were washed with water (5 mL), and 
analytes were eluted with 100% methanol (2 mL) into a 3.5 mL glass vial. 
Eluants were dried down under oxygen-free nitrogen (60 oC) and reconstituted 
in 100 µL mobile phase.  
 
6.3.6 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 
Samples in the auto-sampler were maintained at 10 oC. Analytes were separated 
at 40 oC on an ACE Excel C18-AR column (100 x 2.1 mm, 1.7 um; Hichrom 
Limited®, Berkshire, UK) at a flow rate of 0.5 mL/min. Samples in the auto-
sampler and sample manager were maintained at 10 oC. Starting with 70% 
water with 0.1% formic acid (FA) (solution A) and 30% acetonitrile with 0.1% 
FA (solution B), maintained for 4 minutes followed by a 1-minute linear rise to 
60% solution B, a subsequent rise to 90% solution B, before restoring to 30% 
solution B at 6.1 minutes. This condition was sustained for 1-minute to re-
equilibrate. Inter- and intra-assay precision and accuracy are displayed in 
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Appendix Table 6-2.  
The peak areas of deuterated steroids were corrected for the abundances of 
naturally occurring isotopomers at baseline. In addition, the peak area of D4-
cortisol was corrected for interference from the M+4 isotopologue of cortisol 
and the M+1 isotopologue of D3-cortisol. The peak area of D3-cortisol was 
corrected for interference from the M+3 isotopologue of cortisol.  
 
6.3.7 Data Analysis 
Deuterated hormone levels were adjusted for flow rate and were normalised to 
tissue weight of the perfused cotyledon. D4-cortisol and D3-cortisol were 
reported in ng, and in the absence of a standard for accurate quantification, D3-
cortisone was measured in arbitrary units. 
 
6.3.8 Computational Model for Placental Transfer 
A compartmental modeling framework was adopted to model the placental 
transfer of cortisol and cortisone in the ex-vivo perfusion experiments, based on 
our previous work. (Sengers et al., 2010, Panitchob et al., 2015, Panitchob et 
al., 2016) The model distinguishes three separate physiological compartments 
associated with the maternal, syncytiotrophoblast and fetal capillary volumes 
(Figure 6-1a). Each compartment is described as well mixed. Transfer between 
compartments is determined by the fluxes across the apical and basal 
membranes and assumed to occur by simple diffusion for both cortisol and 
cortisone. Metabolic conversion from cortisol to cortisone within the 
syncytiotrophoblast is described as unidirectional using Michaelis-Menten 
kinetics. Model equations were implemented in Matlab (R2016a) as outlined 
previously (Panitchob et al., 2015, Panitchob et al., 2016, Sengers et al., 2010) 




















!!" !!! − !!! − !!!!!       [3]  
 
where !!!, !!! and !!! are the concentrations (mol/L) of solute ! which can be 
either D4-cortisol (D4F), D3-cortisone (D3E) or D3-cortisol (D3F) in the 
maternal “m”, syncytiotrophoblast “s” and fetal “f” compartment respectively. 
Similarly, the volumes ! (L) of the different compartments are indicated with 
subscripts using the same notation. !! and !! (L/min) are the fluid flow rates 
in the maternal and fetal circulation. !!!",! is the maternal inlet concentration, 
which is zero for all solute species except D4-cortisol. Note that the fetal inlet 
concentration is zero for all species and therefore has not been included. !!"! 
and !!" denote the effective overall permeability constants (L/min) for the 
microvillous membrane (MVM) and basal membrane (BM) including surface 
area. These diffusive permeability constants were assumed to be the same for 
all solute species. The metabolic conversion rate !!!"#$% (mol/min) depends on 
the solute species as follows: 
 
!!!!!"#$% = − !!!→!!
!"#  !!!!!
!!!!!!!!
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where !!"# (mol/min) is the maximum overall metabolic conversion rate and 
!! (mol/L) is the Michaelis-Menten constant, i.e. the concentration at which 
half the maximum rate occurs. 
 
6.3.8.1 Model Parameters 
The total cotyledon volume was based on the average cotyledon weight from 
the experiments (30.8 × 10-3 kg, n = 5), which was directly equated to the 
volume in L. The volume fractions of the maternal, syncytiotrophoblast and 
fetal compartments distinguished in the model were set to 34%, 15% and 7.4% 
respectively, as in our previous work. (Sengers et al., 2010, Mayhew, 2009) 
The flow rates in the maternal and fetal circulations !!= 14 × 10-3 L/min and 
!!= 6 × 10-3 L/min were directly based on the experimental settings. To 
account for any discrepancies between nominal and actual values, the D4-
cortisol input concentrations !!!" used in the model were calculated based on 
the combined maternal and fetal steady state output during the blocking phase. 
The Michaelis-Menten constant !! was set to 44 × 10-9 mol/L, based on the 
value for the enzyme 11β-HSD2 for cortisol (Brown et al., 1996a). In first 
instance the same value was adopted for both metabolic conversion steps in 
Equations 4-6. 
 
6.3.8.2 Parameter Estimation 
The remaining parameters in the model were determined by fitting the 
experimental data. The following error criterion was defined for a certain 






 !"#,! ! !!,!
! − !!,!!"#,!
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!∈!       [7] 
 
where !!,!!  and !!,!!"#,! are the computed and experimental concentrations at time 
point !, respectively, while !! !"#,! is the mean of the experimental time points 
considered. The model was fitted to the steady state values after each change in 
maternal input concentration, including the blocking phase, therefore the set of 
time points ! consisted of the last 4 time points for each different input phase 
(16 time points in total). 
The D3-Cortisol concentrations measured experimentally were 300 times 
smaller compared to D4-Cortisol and did not contribute significantly to the 
overall mass balance. Therefore the conversion to D3-Cortisol was neglected in 
the parameter estimation by setting !!!→!!!"#  to zero. In addition, the measured 
D3-Cortisone values could not be directly related to concentration. Therefore 
D3-Cortisone was not fitted, but instead the experimental values for D3-
Cortisone were scaled to allow comparison of the relative changes predicted by 
the model. Thus, only the D4-Cortisol values in the maternal and fetal 
compartments (averaged over 5 placentas) were fitted according to the 
following overall error criterion: 
 
!!"! = !!!!! + !!!!!         [8] 
 
In total 3 parameters were fitted, the membrane permeability constants !!"! 
and !!"  and the maximum rate of conversion from cortisol to cortisone 
!!!→!!!"# . Time integration of Equations 1-3 was performed in Matlab (R2016a) 
using the ode45 function (Runge-Kutta (4, 5) method). Parameter estimation by 
minimising Eq. 8 was implemented using the fminsearch function (Nelder-
Mead method). Initial parameter estimates were varied to verify that the 
algorithm converged to a unique solution. 
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A sensitivity analysis was carried out in which the model parameters were 
varied with respect to the values for the reference fit. The reported changes in 
placental transfer predicted by the model were based on the steady state results 
at the highest maternal input concentration. 
 
6.4 Results 
6.4.1 Subject Characteristics 
The mean (sd) maternal age was 36.4 ± 6.3 years, mean gestational length was 
277 ± 2 days (39+4 weeks ± 2 days), and mean birthweight was 3721 ± 223 g. 
 
6.4.2 D4-cortisol, D3-cortisone and D3-cortisol levels 
Figure 6-2 shows the levels of D4-cortisol, D3-cortisone and D3-cortisol 
(plotted data with error bars) in maternal and fetal veins increased as the 
concentration of D4-cortisol in the maternal artery perfusion increased. D4-
cortisol (Figure 6-2 a-b) and D3-cortisone (Figure 6-2 c-d) were detected in 
maternal and fetal vein 5-minutes after commencement of D4-cortisol perfusion 
(20 nM) in the maternal artery. D3-cortisol (Figure 6-2 e-f) at 95-minutes into 
the experiment in the maternal vein (perfusion phase: 800 nM D4-cortisol), and 
at 75-minutes in the fetal vein (perfusion phase: 200 nM D4-cortisol). The 
biggest increase in D4-cortisol and D3-cortisone levels occurred when maternal 
artery D4-cortisol perfusion increased from 200 nM to 800 nM. Levels of D3-
cortisone in the maternal circulation were approximately 5-fold higher than in 
the fetal circulation. When carbenoxolone was added to the maternal artery 
perfusion, D4-cortisol levels further increased in maternal and fetal veins, and 
D3-cortisone synthesis was completely inhibited. D3-cortisol levels were 
around 300-fold lower than D4-cortisol in both maternal and fetal circulations, 
and were close to the assay limit of detection. Levels of D3-cortisol in the 
maternal circulation were approximately 2-3-fold higher than levels in the fetal 
circulation. Proportionately more of the produced D3-cortisol was released into 
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the fetal circulation than maternal circulation, when compared with the 
proportion of D3-cortisol released into maternal and fetal circulations. Samples 
of buffer obtained on completion of the ‘washout’ phase of the experiment 
confirmed that there were no remaining endogenous or labelled glucocorticoids 
within the tubing used for the circuit. 
 
6.4.3 Placental Model Results  
The results of the model fit of the average maternal and fetal D4-cortisol 
measurements demonstrated an excellent overall ability of the computational 
model to represent the experimental data (Figure 6-2, Appendix Table 6-3). 
From the model the estimated effective membrane permeability constant !!"! 
= 0.011 L/min for the maternal facing MVM and !!" = 0.0015 L/min for the 
fetal facing BM. Thus the permeability of the MVM was estimated to be 7.4 
times higher than that of the BM. The estimated maximum rate capacity for the 
conversion of cortisol into cortisone !!!→!!!"#  = 5.0 nmol/min per cotyledon. At 
the highest inlet concentration only 3.0% of the maternal cortisol input was 
transferred to the fetal circulation, while 26.5% was metabolised and the 
remaining 70.5% exited via the maternal vein. Inhibiting 11β-HSD activity 
increased the transfer to the fetus to 7.3% of the maternal input, while 92.7% 
exited via the maternal vein. Based on these results it can also be seen that 
enzyme metabolism reduced transfer to the fetus by 59%. Note that if there 
were no placental barrier and no metabolism then the maternal and fetal vein 
would have an output of respectively 70% and 30% of the maternal inlet, based 
on the difference in flow rates alone (i.e. if concentrations within the placenta 
were perfectly mixed). The comparison between the predicted D3-cortisone and 
the scaled experimental data is shown in Figure 6-2. It can be observed that the 
relative steady state levels correspond well for the fetal D3-cortisone, while the 
maternal D3-cortisone shows some larger discrepancies. In addition, the model 
responds much more rapidly to changes in input conditions. In this respect, the 
sharp peak at t = 150 min predicted by the model is due to the absence of 





Figure 6-2 a-f. Model fit of experimental data 
In maternal circulation was 0-30 minutes EBB alone, 30-60 minutes EBB + 
20nM D4-Cortisol, 60-90 minutes EBB + 200nM D4-Cortisol, 90-120 minutes 
EBB + 800nM D4-Cortisol, 120-150 minutes EBB + 800nM D4-Cortisol + 
0.001M Carbenoxolone, 150-170 minutes EBB alone. The appearance of D4-
cortisol in the fetal circulation is consistent with free transplacental passage of 
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D4-cortisol. Inactivation of D4-cortisol by 11β-HSD2 is indicated by the 
appearance of D3-cortisone in the maternal or fetal circulations, and cortisol 
regeneration from D3-cortisone is indicated by the appearance of D3-cortisol.  
Model fit of the experimental data for D4-cortisol in the maternal (Figure 6-2a) 
and fetal (Figure 6-2b) compartments, with a single set of parameters. Results 
show an excellent correspondence between model (straight line) and 
experiments (plotted data and error bars) (R2 = 0.99). Model prediction of D3-
cortisone in comparison with the scaled experimental data (Figure 6-2 c-d). 
Note the experimental units for D3-cortisone could not be directly related to 
concentration and have been scaled here to allow comparison of the relative 
changes predicted by the model. The scale factor was derived by scaling the 
experimental values to the model predictions for the highest input 
concentration. A single scale factor was determined by averaging the ratio of 
the model predictions and the steady state values of the maternal and fetal 
concentrations. The same conversion factor was applied to both maternal and 
fetal D3-cortisone based on the average ratio between experimental units and 
computed concentrations at the highest input level (time points t = 110, 115 and 
120 min). Experimental data for D3-cortisol (Figure 6-2 e-f). Values were 
comparatively low and were not modeled as they do not contribute significantly 
to the overall mass balance. All experimental results are the average of 5 
placentas, expressed as mean and SEM (n = 5). 





The results of the sensitivity analysis in Figure 6-3 show that when varying 
single parameters the placental transfer of cortisol was affected most by 
changes in !!", the membrane permeability of the BM, and the metabolic 
conversion rate of cortisol into cortisone !!!→!!!"# . In addition, placental transfer 
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was predicted to be moderately sensitive to !!"! , the permeability of the 
MVM, and the maternal flow rate used in the experiment !!. Variations in !! 
only had a small impact as the metabolism continued to operate in the saturated 
regime, while increasing the fetal flow rate !! used in the experiment was 
predicted to only have a minor effect on transfer. Steady state transfer was not 
sensitive to any of the compartment volumes, as expected. To evaluate the 
impact of the overall membrane permeability, an additional study was done in 
which !!"  and !!"!  were both varied simultaneously, demonstrating a 
considerably larger effect than for the permeability of each membrane 
separately (Figure 6-3).  
 
 
Figure 6-3. Sensitivity analysis for D4-Cortisol transfer to the fetus as a 
function of variations in the model parameters 
The model parameters were varied with respect to the values for the reference 
fit. The reported changes in placental transfer predicted by the model were 
based on the steady state results at the highest maternal input concentration. 
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Key: kMVM (MVM permeability constant), kBM (BM permeability constant), Vmax 
(maximum rate of reaction), Km (Michaelis-Menton constant), Vm (maternal 
compartment volume), Vs (syncytiotrophoblast compartment volume), Vf (fetal 





The experiments performed in this study using a deuterated cortisol tracer in 
the ex vivo placental perfusion model allowed investigation of the role of 
interconversion of cortisol and its inactive metabolite cortisone on transfer of 
cortisol from mother to fetus. The application of computational modeling 
enabled interpretation of the transfer mechanisms that underlie these processes. 
Our findings challenge the concept that maternal cortisol diffuses freely across 
the placenta, confirm that 11β-HSD2 acts as a major ‘barrier’ to cortisol 
transfer to the fetus and show preliminary evidence of local cortisol 
regeneration within the placenta.  
Addition of carbenoxolone (a potent HSD inhibitor) to the maternal artery 
perfusion, resulted in no further production of D3-cortisone. This supports the 
role of 11β-HSD2 as a key player in the maternal barrier to fetal glucocorticoid 
exposure. The activity (but not mRNA) of 11β-HSD2 has been shown to 
decrease in the last two weeks before parturition (Murphy and Clifton, 2003). 
The placentas used in the experiments were obtained from elective Caesarean 
sections at between 39-40 weeks gestation, so it is not known when parturition 
would have occurred in these pregnancies. The model allowed an estimation of 
the maximum capacity of 11β-HSD2 for conversion of cortisol to cortisone as 
5.0 nmol/min per cotyledon.  It is not known what the capacity of 11β-HSD2 
would be if exposed to high levels of maternal glucocorticoids for more 
prolonged periods, but studies have demonstrated that 11β-HSD2 mRNA and 
activity is down-regulated by maternal stress (O'Donnell et al., 2012) and 
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inflammatory diseases (Murphy and Clifton, 2003). Further, inhibition of 11β-
HSD2 by maternal liquorice consumption has adverse consequences on child 
development (Raikkonen et al., 2009, Raikkonen et al., 2017). Our study 
supports the premise that the adverse offspring outcomes are due to increased 
fetal glucocorticoid exposure as when 11β-HSD2 was inhibited by 
carbenoxolone, transplacental passage of maternal cortisol to the fetal 
circulation was more than doubled.  
Yet, even when 11β-HSD activity was inhibited using carbenoxolone, less than 
10% of maternal D4-cortisol crossed the placenta in our experiments. This 
observation challenges the concept that cortisol freely diffuses across the 
placenta, and suggests alternate mechanisms to protect the fetus from high 
maternal cortisol levels in addition to the well described inactivation of cortisol 
by 11β-HSD2. Three ABC-transporters; multidrug-resistant protein (MRP1, 
encoded by ABCC1), p-glycoprotein (P-gp, encoded by ABCB1) and breast-
cancer-resistant protein (BCRP, encoded by ABCG2) are localised to placental 
syncytiotrophoblast, and the fetal vessel endothelium (St-Pierre et al., 2000, 
Yeboah et al., 2006) consistent with the potential for active transport of cortisol 
in and out of the placenta. Further studies are needed to investigate the 
contribution of ABC transporters, levels of which are known to alter across 
gestation (Iqbal et al., 2012, Kalabis et al., 2005, Pascolo et al., 2003, Sun et al., 
2006), in regulating maternal cortisol transfer to the fetus and in particular to 
understand the kinetics of efflux transporters, which our preliminary 
observations suggest may also protect the fetus.  
Further we observed approximately a 5-fold higher D3-cortisone release to the 
maternal circulation compared with the fetal circulation. It also needs to be 
considered that the physical process of cortisol diffusion across tissues may be 
more challenging than has been thought previously. In particular, in the 
placenta diffusion across the water filled villous stroma may prove a barrier to 
cortisol diffusion. This is consistent with the observation that cortisone was 
preferentially released into the maternal circulation (2:1 maternal:fetal 
circulation), and the lower placental to fetal permeability calculated within the 
model. 
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A novel finding is the observation of regeneration of cortisol, as evidenced by 
the detection of D3-cortisol in both maternal and fetal circulations. Though the 
absolute levels of D3-cortisol were low, this regeneration of cortisol may have 
local paracrine roles and increased placental 11β-HSD1 mRNA levels have 
been associated with maternal depression and with altered infant regulatory 
behaviours (Raikkonen et al., 2015, Reynolds et al., 2015). Further, 
proportionately more D3-cortisol was transferred to the fetus than D3-
cortisone, which is in line with localisation of 11β-HSD1 to the endothelium 
(Sun et al., 1997). The computational model provided a good overall 
representation of the experimental data under different experimental conditions. 
In general, the compartmental model showed a faster response due to the well-
mixed assumption, but this did not affect the steady state levels. The model 
predicted that changing membrane permeability of the BM would affect 
placental transfer of cortisol. Placental transfer of lipids has been reported to be 
increased in pre-eclampsia (Huang et al., 2013). Further studies are required to 
investigate whether inflammatory conditions such as pre-eclampsia and preterm 
labour alter the permeability of the BM, and thus alter placental cortisol 
transfer.  
Our study has several limitations. Our experiments were conducted using EBB 
buffer and albumin. The findings may be altered in vivo with the presence of 
corticosteroid binding globulin (CBG), the primary binding protein for cortisol 
(Hammond, 2016) and this should be considered in future studies. Including 
such binding effects would not affect the overall modeling results if the 
unbound fraction is constant in the concentration range used, but would become 
important if binding differs between compartments. We were also unable to 
accurately quantify D3-cortisone concentrations, as there are no available 
standards. Nevertheless, we were able to estimate fold-changes in D3-cortisone 
concentrations so this should not limit interpretation of the results. A caveat of 
the model is that it does not account for further interconversion of D3-cortisol 
to D3-cortisone, although the net values of D3-cortisol quantified were very 
low. We did not study other pathways of cortisol metabolism such as the A-ring 
reductase enzymes, although Benediktsson et al., 1997 found that the products 
of 5β-reductase or 20α/β-hydroxysteroid dehydrogenase did not co-elute with 
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cortisol or cortisone in placental perfusion studies, suggesting that these 
pathways may not metabolise cortisol or cortisone in the placenta. The 
contribution of other potential metabolism pathway, such as via carbonyl 
reductase 1 (Phillips et al., 2014) which is located in placenta, is also unknown. 
Direct measurement of arterial input concentrations would also have provided 
additional confidence to this analysis. 
The success rate of placental perfusions is around 50% (Myllynen and 
Vahakangas, 2013) although reasons for this are not well understood. In this 
study five out of eight placentas were successfully perfused (62.5%). 
Unsuccessful perfusions were discontinued due to volume loss (leak) from the 
maternal to fetal side. The ‘failure rate’ of experiments could be considered a 
limitation of this study by eliminating some placentas, reasons for volume loss 
are not well understood, and a recent study showed that volume loss was not 
affected by placental weight, way of delivery or gestation at delivery 
(Karttunen et al., 2015). The success of select placentas could also be 
considered as a strength of this study, with a relatively low variance in the 
successful five placentas. 
Further studies using this model could investigate in more detail the 
contribution of the fetal circulation to maternal cortisol levels. Regeneration of 
cortisol from cortisone could be studied by perfusing the fetal circuit with D2-
cortisone (Hughes et al., 2012), and measuring the regenerated cortisol in the 
maternal or fetal circuits. The potential for free placental passage of cortisol 
from the fetal to maternal circuit could be studied by perfusing the fetal circuit 
with D4-Cortisol and measuring D4-Cortisol, D3-Cortisone and D3-Cortisol in 
the maternal circulation. Future studies utilising inhibitors of ABC transporters 
are also needed to assess their contribution to placental cortisol transport.  
To conclude, we have developed a model to predict maternal-fetal cortisol 
transfer, which can now be used in future experimental design. Further studies 
are now needed to refine and develop the model in order to improve 
understanding of the mechanisms underlying maternal-fetal cortisol transfer 























































































































































































































































































































































Appendix Table 6-2. Inter-assay precision and accuracy 
Concentrations of cortisol, cortisone, D4-Cortisol and D3-Cortisol were determined 
using calibration curves. Fourteen standards were prepared in 500 µL EBB (range of 
concentrations 0.1 ng – 400 ng) enriched with internal standards (10 ng) along with 
blank samples were diluted in 500 µL of water and processed using the same 
extraction method and analysis conditions as perfusate samples. Standard curves 
were plotted by calculating the peak area (analyte peak area / internal standard peak 
area). Weighting of 1/x and was applied to form standard curves of best fit with a 
regression coefficient above 0.99. The ion ratio (quantitative ion/qualitative ion) of 
the analytes was calculated using MultiQuant software and results were not 
considered acceptable if the ratio was greater than 20% of the ratio of the standards. 
Inter-assay fourteen point standard curve validation (n=6 different day respectively) 
  Concentration 
(ng/200 μL 








Low (0.2) 0.21 (0.02) 10.5 103 
 Mid (50) 46.7 (1.7) 3.6 93 
 High (400) 396.6 (43.4) 11.6 93 
 Tissue 
Sample* 
8.3 (0.6) 7.0  
D3-
Cortisol 
Low (0.1) 0.1 (0.02) 17.3 98 
 Mid (10) 10.4 (0.9) 8.8 104 
 High (20) 20.2 (2.0) 10.1 101 
 Tissue 
Sample* 
0.6 (0.04) 6.4   
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was used to assess the limits of quantification of accuracy and precision for each 
analyte. Precision was based on the percentage relative standard deviation (%RSD), 
which was calculated using peak area ratios. Tissue sample* is intra-assay (amount, 
ng for tissue replicates (n=6). Inter-assay was not performed for tissue samples, as all 
tissue samples were analysed on the same day. Low values are the limit of 
quantification for each analyte.  


































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.7 Chapter Conclusion 
The placental perfusion studies in Chapter 6 challenge the belief that maternal 
cortisol freely diffuses across the placenta, and confirm that 11β-HSD2 acts as a 
major ‘barrier’ to cortisol transfer from the mother to the fetus. Computational 
modeling suggested that at the highest concentration of maternal cortisol perfusion 
(with deuterated cortisol), only 3% of maternal cortisol input was transferred to the 
fetal circulation, while 26.5% of maternal cortisol was metabolised and the 70.5% 
remained in the maternal circulation. Inhibiting the activity of the 11β-HSD enzymes 
resulted in only a small increased in the proportion of maternal cortisol transferred to 
the fetal circulation.  
The model described in Chapter 6 could be used in further studies to examine the 







7.1 General Discussion / Summary of Results 
The work presented in this Thesis was based on the hypothesis that the HPA axis 
activity is dysregulated in maternal obesity, and that this may be associated with 
altered release, clearance and placental cortisol metabolism, and influence clinical 
outcomes related to fetal size and length of gestation. This was carried out by 
studying the relationship between maternal obesity, a number of measures of the 
HPA axis, associations within clinical outcomes, and investigating possible 
underlying mechanisms.   
The prevalence of obesity and therefore maternal obesity is increasing. As maternal 
obesity increases, the risks of the sequelae for offspring of obese who were fetuses in 
the obesogenic environment also increases. This may be a self perpetuating cyclical 
problem. With this increase in mind, and the links made to offspring health outcomes 
later in life, it is becoming increasingly important to be able to identify the 
mechanisms by which maternal obesity affects the mother and the baby, in the short 
term and in the long term. It will be important to identify therapeutic targets and 
agents, as well as biomarkers for disease risk in the increasing population at risk.  
This Thesis showed that there are significant effects of maternal obesity on the HPA 
axis hormones. Glucocorticoids are important for fetal-placental growth and 
maturation, and excess fetal exposure to glucocorticoids has been implicated in fetal 
programming, therefore this observation is of great importance.  
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In Chapter 3, it was shown that the activity of the HPA axis is decreased in maternal 
obesity, and that this associates with increased fetal size and longer gestation. 
Maternal cortisol, CRH, estrogens and progesterone were lower in obese pregnancy. 
Total urinary glucocorticoid metabolites increased significantly in lean pregnancy, 
but not in obese, suggesting that the lower levels of circulating cortisol in obese were 
not due to increased urinary clearance. Lower maternal cortisol in obese tended to be 
associated with increased birthweight. In obese, CRH at 28 weeks correlated 
inversely with gestational length, and independently predicted gestational length 
after adjustment for confounding factors.  
In Chapter 4, it was shown that active glucocorticoid hormones (cortisol and 
corticosterone) were significantly higher in maternal than cord blood. Inactive 
versions (cortisone and 11-dehydrocorticosterone, respectively) were significantly 
lower in cord than maternal blood. Increased maternal BMI was associated with 
lower maternal cortisol, corticosterone and 11-dehydrococrticosterone. Despite 
significant positive correlations between maternal and cord blood glucocorticoid 
levels, increased maternal BMI was not associated with lower cord blood 
glucocorticoid levels. This suggests that while the pattern of lower maternal cortisol 
described in Chapter 3 was maintained in maternal blood at the time of delivery, 
that conditions at delivery may overcome any potential negative effects of low 
maternal glucocorticoids on the fetus in the short-term. This may not preclude the 
longer-term effects of exposure of the fetus to lower glucocorticoid levels during 
obese pregnancy.  
In Chapter 5, the release of glucocorticoid hormones was studied. It was shown for 
the first time that cortisol is pulsatile in interstitial fluid during pregnancy, and that 
pulse frequency decreases with advancing gestation in obese pregnancy. Serum 
cortisol AUC, highest peak, and lowest trough increased with advancing gestation in 
lean and obese pregnant compared with non-pregnant controls. These findings 
suggest that changes in the ultradian profile of cortisol influence overall 
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glucocorticoid exposure, so they are important. This may be a mechanism to explain 
decreased HPA activity in obese pregnancy. This may be a novel pathway to obese 
related pregnancy outcomes such as adverse fetal growth.  
In Chapter 6, a deuterated cortisol tracer was used in the ex vivo placental perfusion 
model, in combination with computational modeling, to investigate the role of 
interconversion of cortisol and its inactive metabolite cortisone on transfer of cortisol 
from mother to fetus. It was shown that at the highest inlet perfusion concentration of 
D4-cortisol, that only 3% of maternal cortisol input was transferred to the fetal 
circulation, while 26.5% was metabolised and the remaining 70.5% exited via the 
maternal vein. Inhibiting 11β-HSD activity increased the transfer to the fetus to 7.3% 
of the maternal input, while 92.7% exited via the maternal vein. D3-cortisol was 
detected, suggesting for the first time that the placenta regenerates cortisol from 
cortisone. These findings challenge the concept that maternal cortisol diffuses freely 
across the placenta, confirm that 11β-HSD2 acts as a major ‘barrier’ to cortisol 
transfer to the fetus, and show preliminary evidence of local cortisol production 
within the placenta.  This is in keeping with other studies suggesting that the placenta 
acts as a barrier to prevent the developing fetus from overexposure to cortisol during 
pregnancy.  
 
7.2 Wider and Clinical Implications 
7.2.1 Dysregulation of the HPA Axis in Obese Pregnancy 
While it has long been recognized that obesity is associated with a dysregulated HPA 
axis, a recent systematic review (Incollingo Rodriguez et al., 2015) examining 
evidence for HPA axis dysregulation in obese individuals concluded that available 
evidence remains inconclusive. Evidence included multiple indices of HPA axis 
activity, including the cortisol awakening response, diurnal cortisol slope, total daily 
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output, reactivity, feedback sensitivity, and the long-term output. Inconsistencies in 
the data may relate to the different measures of obesity used (ie. generalized obesity 
or abdominal obesity), and variation in protocol. Although inconsistent, the evidence 
does support that obesity is linked to dysregulation of the HPA axis. It was proposed 
that the cumulative effect of increased cortisol reactivity, local regeneration of 
cortisol (Walker and Andrew, 2006) and increase clearance was postulated to 
contribute to lower levels of systemic cortisol (Putignano et al., 2001, Duclos et al., 
2001). This Thesis is one of a very few studies in humans investigating the effects of 
maternal obesity on the HPA axis. It found lower fasting morning cortisol levels in 
very severely obese women throughout pregnancy compared with a lean control 
group; a pattern similar to non-pregnant severe obesity (Champaneri et al., 2013). 
The lack of an increase in urinary clearance of glucocorticoids during pregnancy in 
obese women suggests that in contrast to non-pregnant obesity (Strain et al., 1980, 
Marin et al., 1992), the activation of the HPA axis which normally occurs during 
pregnancy (Duthie and Reynolds, 2013, Lindsay and Nieman, 2005) was blunted in 
these very severely obese pregnant women.  
 
7.2.2 Implications for Obese Related Pregnancy Outcomes 
Dysregulation of the HPA axis may underlie some obese related adverse pregnancy 
outcomes. As excess glucocorticoids are associated with fetal growth restriction 
(Goedhart et al., 2010, Bolten et al., 2011, Kivlighan et al., 2008) and preterm labour 
(Sandman et al., 2006), our finding of an association between lower cortisol and 
CRH with increased fetal size and longer length of gestation may explain the 
increased rates of macrosomia (Ehrenberg et al., 2004) and prolonged pregnancy 
(Denison et al., 2008, Heslehurst et al., 2017) reported in obese pregnancy. These 
findings also further support the hypothesis that CRH acts as a ‘placental clock’, by 
playing a role in governing the length of gestation and triggering the onset of labour 
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(Sandman et al., 2006).  
Glucocorticoids have been shown to down regulate placental glucose transporters 
(Hahn et al., 1999) and reduce lipid transport to the fetus (Magnusson-Olsson et al., 
2006). CRH has been shown to reduce amino acid transport (Giovannelli et al., 2011) 
and decrease mRNA expression of the GLUT3 amino acid transporter in the placenta 
(Gao et al., 2012). Estradiol, estriol and progesterone have also been shown to inhibit 
transport of monosaccharides in the placenta (Johnson and Smith, 1980). The lower 
levels of cortisol, CRH estradiol, estriol and progesterone in obese pregnancy 
observed in this work could be a mechanism for increased nutrient transport to the 
fetus in obese pregnancy, which could be a mechanism for increased fetal growth.  
 
7.2.3 Longer Term Offspring Outcomes 
Fetal exposure to excess glucocorticoids in utero has been linked to the development 
of cardio-metabolic risk factors and disease later in life (Reynolds, 2013). Offspring 
of obese are also more likely to develop obesity and cardio-metabolic risk factors 
(Drake and Reynolds, 2010). A recent data-linkage study has suggested that these 
associations may translate into increased risk of cardiovascular disease and death for 
offspring of obese mothers (Reynolds et al., 2013). 
The findings in this Thesis suggest that offspring of obese are exposed to 
comparatively lower levels of glucocorticoids in utero. The longer-term effects of 
this are not known, but may include cardio-metabolic risk factors and disease.  
A recent follow-up study of the offspring of the cohort in Chapter 3 found that first 
trimester maternal cortisol correlated with offspring salivary cortisol under basal and 
experimental conditions, and higher cortisol exposure in the third trimester was 
associated with offspring cortisol profile under basal conditions (Mina et al., 2017). 
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This finding is consistent with other studies that linked fetal cortisol exposure in late 
pregnancy to HPA responses in offspring (Yehuda et al., 2005).  
Another follow-up study (Mina et al., 2016) of these offspring reported that maternal 
obesity was a significant predictor of increased neuropsychiatric problems, 
externalizing behavior problems including symptoms of attention deficit 
hyperactivity disorder (ADHD) and aggressive behaviour, sleep problems and 
neurodevelopmental problems in their children. These findings were independent of 
maternal gestational diabetes (GDM), and the authors suggested that potential 
underlying causes could include maternal chronic inflammation (Bilbo and Schwarz, 
2012, Brown et al., 2014) and altered glucocorticoid exposure either directly through 
altered placental glucocorticoid barrier (Raikkonen et al., 2015) and / or epigenetic 
modification of glucocorticoid receptors (Heinrich et al., 2015, Parade et al., 2016). 
These studies provide further support for the hypothesis that exposure to maternal 
obesity and altered glucocorticoid exposure has longer-term consequences for the 
offspring. 
 
7.2.4 Possible Mechanisms – Altered Ultradian Rhythm 
To the best of our knowledge, the work in this Thesis is the first work to conduct 
dynamic tests of the ultradian rhythm in pregnancy, and in obese pregnancy. Altered 
pulsatility of glucocorticoid hormones may underlie the decreased HPA axis activity 
we observed in obese pregnancy. There has been increasing interest in the role of 
cortisol pulsatility in transcriptional regulation of glucocorticoid responsive genes. 
As disruptions in pulse characteristics have been reported in pathological states that 
relate to altered glucocorticoids such psychotic and depressive states (Young et al., 
1994, Young et al., 2004, Deuschle et al., 1997) and Cushing’s syndrome (van Aken 
et al., 2005, Boyar et al., 1979), it is possible that the decreased frequency of cortisol 
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pulses in interstitial fluid we observed in Chapter 5 could underlie the lower levels 
of maternal cortisol in obese reported in Chapters 3-4, and that these could be 
implicated in obese related adverse pregnancy outcomes that may relate to 
glucocorticoids. Animal studies have also suggested that it is the pulsatile pattern 
rather than the absolute concentrations of glucocorticoids exposure that determines 
subsequent responsiveness to stress, and this has obvious implications for 
understanding the pathogenesis of stress-related disease (Sarabdjitsingh et al., 2010a, 
Sarabdjitsingh et al., 2010b). 
There is an increasing body of evidence suggesting that fetal growth is influenced by 
both genetic and environmental factors, but the relevant molecular pathways are not 
well understood (Moore et al., 2015). Genetic factors influencing fetal growth are 
thought to include imprinted genes (Abu-Amero et al., 2006, Moore et al., 2015) and 
DNA methylation (Koukoura et al., 2012). Methylation of the GR gene exon 1F in 
the human placenta has been reported to be associated with large for gestational age 
(Filiberto et al., 2011) and increased placental 11β-HSD2 methylation has been 
reported in infants with lower birthweight (Marsit et al., 2012). Methylation of 11β-
HSD2 in peripheral blood cells in adulthood has also been linked to both neonatal 
anthropometric variables and risk factors for cardiovascular disease in adulthood 
(Drake et al., 2012). Given the links between genetic factors and fetal growth, we can 
speculate that altered ultradian rhythm of glucocorticoids (known to associate with 
other disease processes) could also be another mechanism influencing fetal growth. 
Identifying key genes and pathways that regulate fetal growth will allow for better 
monitoring of intrauterine growth, maximizing healthy outcomes.  
It has been suggested that more than 25% of the variation in length of gestation could 
be due to genetic factors (Clausson et al., 2000). Post term, prolonged pregnancy is 
thought to have a large heritability, which implicates genetic and or epigenetics as 
contributing factors on gestational age (Oberg et al., 2013, Laursen et al., 2004, 
Lunde et al., 2007, Kistka et al., 2007). However, no studies have found any specific 
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common genetic or epigenetic variants to be associated directly with prolonged 
gestation.  
With an increasing body of evidence suggesting that genetic factors are linked to 
fetal growth, the length of gestation, and cardiovascular health, and reports that 
disruptions in glucocorticoid pulse characteristics are associated with disease 
processes, we can speculate that an altered ultradian rhythm of cortisol may underlie 
these obese related pregnancy outcomes. 
 
7.2.5 Possible Mechanisms – Altered Placental Function 
Placental function may contribute to, or be influenced by altered HPA axis activity in 
obese pregnancy. A better understanding of placental cortisol metabolism and 
transport will facilitate studies of the effect of maternal obesity on placental function.  
The findings in Chapter 4 of significantly higher levels of active glucocorticoids 
(cortisol and corticosterone) in maternal blood, and significantly higher levels of 
inactive versions (cortisone and 11-dehydrocorticosterone) in cord blood, are in-
keeping with the hypothesis that the placenta acts as a barrier to cortisol transfer to 
the fetus. This finding was confirmed in Chapter 6, where the addition of 
carbenoxolone (11β-HSD inhibitor) to the maternal placental perfusion circulation, 
resulted in no further production of D3-cortisone.  
The findings in Chapter 6 challenged the concept that cortisol can freely cross the 
placenta from maternal to fetal compartments, suggesting that alternative 
mechanisms may protect the fetus from higher maternal cortisol. Potential 
mechanisms may include the ABC-transporters, which as discussed in Chapter 6, 
may be altered in obese pregnancy. A recent study (Mina et al., 2015) using 
placentas from the pregnancies in the cohort in Chapter 3 found significantly lower 
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levels of the ATP-binding cassette transport protein transporter encoded by ABCB1 
in obese, which actively pumps glucocorticoids from the fetal to the maternal 
circulation in rodents (Kalabis et al., 2005). The physiological relevance of this 
observation is not known, as placental ABCB1 levels are lowest at late stages of 
pregnancy (Sun et al., 2006). Mina TH et al. suggested that this may partly explain 
the lower circulating cortisol in this cohort of severely obese pregnancy women 
(Mina et al., 2015). Global deficiency of ABCB1 in rodents is thought to be 
associated with susceptibility to developing obesity (Foucaud-Vignault et al., 2011), 
and a polymorphism of ABCB1 in humans associated with obesity (Ichihara et al., 
2008). It is not known whether there is a genetic susceptibility of decreased ABCB1 
activity in this cohort of obese pregnant women, but this could be another 
mechanism underlying lower maternal cortisol.  
Regulation of 11β-HSD2 is tissue-specific, and may be altered in obese pregnancy. 
Placental 11β-HSD2 activity has been shown to be altered with some of the 
hormones studied in this Thesis, or with other parameters known to be altered in 
obesity, such as inflammation. Progesterone and estrogen inhibit placental 11β-
HSD2 activity in term human placenta in vitro (Sun et al., 1998), and glucocorticoids 
down-regulate placental 11β-HSD2 (Clarke et al., 2002, Kerzner et al., 2002). The 
lower circulating levels of glucocorticoids, estrogen and progesterone described in 
Chapter 3 may limit the down-regulatory effect of these hormones on 11β-HSD2 
activity in obese pregnancy and may underlie increased fetal size via a reduction in 
fetal cortisol exposure.  This may also be a potential mechanism contributing to the 
finding in Chapter 4, where increased BMI was associated with lower maternal 
cortisol, but not cord cortisol at delivery.  
While not studied in this Thesis, pro-inflammatory cytokines, which are raised in 
obesity, also have an effect on 11β-HSD2 regulation. Adipose tissue produces a 
significant amount of pro-inflammatory cytokines such as TNFα, and interleukin-6 
(Galic et al., 2010). Further, in obese pregnancy, the relative increase in adipose 
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hypertrophy and hyperplasia leads to a dysregulated release of inflammatory markers 
(Avram et al., 2007, de Ferranti and Mozaffarian, 2008). Placentas from obese 
pregnant women have increased infiltration of macrophages, and increased 
expression of inflammatory markers (Challier et al., 2008). Chisaka et al., reported 
that in placental trophoblasts, TNF-alpha and interleukin-1 down-regulate 11β-HSD2 
mRNA expression and activity in vitro and suggested that TNFα and IL-1 may 
increase transplacental passage of cortisol from the maternal to fetal circulation by 
attenuating 11β-HSD2 activity (Chisaka et al., 2005). 
 
7.3 Strengths and Limitations 
The strengths of this study are that a large sample size was used for characterizing 
the HPA axis hormones in Chapters 3-4, and initial studies examining possible 
mechanisms for these changes. Chapter 5 dynamic studies of cortisol were 
performed. While the sample size was smaller for this, this is not unusual in more 
intensive dynamic testing studies. This study also involved both obese and lean non-
pregnant controls, in order to study the relative contributions of pregnancy and 
obesity.   
 In Chapters 4-6, glucocorticoids were quantified using LC-MS/MS, which is the 
gold standard for measuring these analytes. Functional testing was also performed, 
with placental perfusion studies in Chapter 6.  
Due to the time involved in developing the placental perfusion model and optimizing 
the assay for sample analysis, it was not possible to study the transport in a bigger 
sample of both lean and obese placentas for comparison.  
The studies in this Thesis were limited by the absence of any longer-term follow-up 
studies. While significant progress has been made in understanding the effects of 
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maternal obesity on the HPA axis during pregnancy, longer-term programming 
effects are still being explored. 
 
7.4 Future Directions 
Targeted interventions for improving outcomes in pregnancies complicated by 
maternal obesity are limited. This is due to the combination of a lack of specific 
targets and also the unknown implications of interventions during pregnancy on the 
longer-term health of the offspring. Given the longer-term implications for offspring 
of obese, and the increasing support for the developmental original of disease 
hypothesis, there is an urgent need for therapeutic targets and agents in obese 
pregnancy.  
Two recent randomized controlled trials tested interventions aimed to reduce 
increased fetal size at birth in offspring of obese. The EMPOWaR study in 
Edinburgh tested whether administering metformin to obese pregnant women before 
any gestational diabetes was identified would affect offspring birthweight, but this 
study found no effect (Chiswick et al., 2015). The UPBEAT study tested a 
behavioural intervention in obese pregnant women, and concluded that lifestyle 
changes alone were insufficient to reduce the rates of gestational diabetes and large 
for gestational age infants (Poston et al., 2015).  
The work in this Thesis suggests that glucocorticoids may be a possible new target 
for intervention, and provides a basis for a number of avenues that can now be 
further explored and a more complete understanding may be established. With 
further work, mechanisms by which maternal obesity alters the HPA axis could be 
ascertained, and potential therapeutic targets identified. 
Further studies investigating impact of maternal obesity on HPA axis activity and 
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circulating cortisol levels could include analysis of the 11β-HSD enzymes in central 
and peripheral adipose tissue, and studies testing the effect of both abdominal and 
generalized obesity on HPA axis activity in pregnancy. The influence of the HPA 
axis on other obese related pregnancy outcomes such as dysfunctional labour and 
prolonged pregnancy could be studied.   
Placental cortisol metabolism studies could be extended by using the ex vivo 
placental perfusion model to investigate whether cortisol metabolism or transport is 
altered in obese compared with lean placentas. Infusion protocols could also be 
altered in order to study the transport from the fetal to the maternal compartment. 
Use of inhibitors of 11β-HSD1, and the ABC transporters may give more detailed 
information about cortisol transport in the maternal-fetal barrier.  
In vivo studies of placental cortisol metabolism in humans may be limited due the 
risk of potential harm to the developing fetus. Animal studies using a cortisol tracer 
could be used to study glucocorticoid transport between the maternal and fetal 
compartments during pregnancy. However, the major circulating glucocorticoid in 
rodents is corticosterone (as opposed to cortisol), so the translation of findings to 
human physiology may be limited.  
As the importance of glucocorticoid pulsatility is increasingly recognized, future 
studies involving the delivery of glucocorticoids in a pulsatile fashion could be 
utilized to study the effects of glucocorticoid pulsatility on fetal or placental tissues 
(eg. ex vivo placental perfusion, or in vivo studies in adrenalectomised animal).   
Longer-term offspring follow-up studies are needed to investigate whether altered 
glucocorticoid exposure in utero is associated with any change to the child’s HPA 
axis sensitivity or diurnal rhythm. Studies are needed to ascertain the role of sleep in 
regulating the HPA axis, and whether maternal sleep problems could program a 
child’s HPA axis or whether lower circulating cortisol could program a child’s 
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diurnal rhythm.  
While weight loss prior to pregnancy is encouraged, the effect of weight loss on the 
HPA axis is not well understood. Limited evidence from animal studies suggests that 
the HPA axis is activated in rats undergoing weight loss due to caloric restriction, but 
the equivalent weight loss by bariatric surgery prevents this (Grayson et al., 2014). In 
humans, calorie restriction has also been linked to increased total cortisol levels 
(Tomiyama et al., 2010). Further study in this area may inform best practice for 
optimizing pre-pregnancy weight loss and maternal cortisol levels. 
 
7.5 Concluding Remarks 
This Thesis found firstly that maternal obesity is associated with lower maternal 
cortisol levels and decreased HPA axis activity during pregnancy when compared to 
normal weight women. Secondly, these changes are maintained at the time of 
delivery in maternal, but not cord blood. Thirdly, altered glucocorticoid pulsatility 
may underlie these changes in obese pregnancy. Fourthly, the placenta does not 
appear to contribute significantly to maternal cortisol levels by the regeneration of 
cortisol from cortisone, and cortisol may not freely cross from the maternal to the 
fetal circulations.  
Future studies could include more detailed analysis of the effects of altered 
glucocorticoid pulsatility in pregnancy, further investigation of placental cortisol 
metabolism and transport, and longer term offspring follow-up studies.  
Altered glucocorticoid exposure in utero is likely to be one mode of programming a 
child’s own health. A better understanding of HPA axis dysregulation in obese 
pregnancy could potentially inform us which high-risk pregnancies should be 
targeted to improve the health of the developing baby, and the safety of the mother. 
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